fluorodeoxyglucose f18 has been researched along with Carcinoma, Non-Small Cell Lung in 1460 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 44 (3.01) | 18.2507 |
| 2000's | 445 (30.48) | 29.6817 |
| 2010's | 734 (50.27) | 24.3611 |
| 2020's | 237 (16.23) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, T; Huang, Q; Shen, J; Wen, L; Yao, L; Zhang, N; Zuo, M | 1 |
| Chen-Yoshikawa, TF; Fukui, T; Goto, M; Iwano, S; Kadomatsu, Y; Nakamura, S; Nakanishi, K; Ozeki, N; Sugiyama, T; Ueno, H | 1 |
| Aigner, C; Darwiche, K; Eberhardt, WEE; Gauler, T; Guberina, M; Guberina, N; Hautzel, H; Herrmann, K; Karpf-Wissel, R; Metzenmacher, M; Ploenes, T; Pöttgen, C; Schuler, M; Stuschke, M; Theegarten, D; Umutlu, L; Wiesweg, M | 1 |
| Durgun, B; Guney, IB; Kucuker, KA; Kucuker, M | 1 |
| Abdollahi, H; Amini, M; Arabi, H; Deevband, MR; Hajianfar, G; Nazari, M; Rahmim, A; Shiri, I; Zaidi, H | 1 |
| Chen, H; Feng, A; Huang, Y; Kong, Q; Shao, Y; Wang, H; Xu, Z | 1 |
| Cai, Q; Flores, R; Henschke, CI; Lee, DS; Taioli, E; Wang, Y; Yankelevitz, DF; Yip, R; You, N; Zhu, Y | 1 |
| Kagimoto, A; Mimae, T; Miyata, Y; Okada, M; Tsutani, Y | 1 |
| Gao, C; Liu, H; Zou, Q | 1 |
| Antonoff, MB; Blumenthaler, AN | 1 |
| Pak, K; Yoon, HJ | 1 |
| Buck, J; Dammak, S; Gee, H; Hanna, GG; Hau, E; Le, T; Lee, K; Lim, R; Ong, A; Palma, D; Vinod, S; Yeghiaian-Alvandi, R | 1 |
| Li, X; Piao, Y; Wen, W; Xu, D | 1 |
| Boellaard, R; Buvat, I; de Langen, AJ; Frings, V; García, DV; Kolinger, GD; Kramer, GM; Smit, EF; Zwezerijnen, GJC | 1 |
| Aksel, N; Anar, C; Erbaycu, AE; Gayaf, M; Koporal, H | 1 |
| Cao, Q; Fang, Y; Ge, D; Hou, Y; Jiang, D; Lin, D; Liu, G; Shen, Y; Shi, H; Tan, L; Wang, H; Wang, Q; Yin, J; Yu, Y; Zhang, S | 1 |
| Burchett, PF; De Cecco, CN; Martin, SS; Muscogiuri, E; Schoepf, UJ; Tessarin, G; van Assen, M; Vogl, TJ | 1 |
| Hashimoto, K; Imai, H; Kagamu, H; Kaira, K; Kobayashi, K; Kuji, I; Matsusaka, Y; Miura, Y; Mouri, A; Shiono, A; Yamaguchi, O | 1 |
| Chen, H; Meng, T; Pang, Y; Shang, Q; Zhao, L | 1 |
| Adam, JA; de Geus-Oei, LF; Delgado Bolton, RC; Dubray, B; Herrmann, K; Hicks, RJ; Lievens, Y; Santos, A; Schöder, H; Troost, EGC; van Elmpt, W; Vaz, SC; Vera, P; Visvikis, D | 1 |
| Decazes, P; Eude, F; Guisier, F; Pressat-Laffouilhere, T; Salaün, M; Thiberville, L; Vera, P | 1 |
| Andersen, FL; Barrington, SF; Dunn, JT; Fischer, BM; Kovacs, DG; Malaih, AA; Nygård, L | 1 |
| Fan, C; Guo, G; Liu, J; Shi, A; Wang, J; Wang, Y | 1 |
| Chen, N; Chu, C; Guo, J; He, H; Hu, N; Li, Q; Liu, F; Liu, H; Peng, K; Qiu, B; Wang, D; Xie, CM; Yin, S | 1 |
| Amo-Salas, M; Bosque, JJ; García Vicente, AM; Honguero-Martinez, AF; Jiménez Londoño, GA; Pérez-Beteta, J; Pérez-García, VM; Soriano Castrejón, ÁM | 1 |
| Ahn, SJ; Bom, HS; Cho, SG; Kim, J; Kim, YH; Park, H; Park, KS | 1 |
| Abd Elkareem, M; Abdelhafez, YG; Abdelsamie Kandeel, A; Mostafa, R; Nardo, L | 1 |
| Kim, SJ; Lee, SW | 1 |
| Diehn, M; Harris, JP; Hiniker, SM; Jiang, A; Lau, B; Loo, BW; Maxim, PG; Modlin, LA; Quon, A; Sodji, QH; Trakul, N | 1 |
| Cheng, J; Feng, P; Fu, F; Gao, H; Li, Z; Liu, H; Meng, N; Wang, M; Wei, W; Wu, Y; Yang, Y; Yuan, J; Zhang, J | 1 |
| Ay, MR; Bahadorzadeh, B; Ghafarian, P; Hajianfar, G; Hosseini, SA; Shiri, I; Zaidi, H | 1 |
| Hu, B; Li, L; Li, X; Liao, Y; Wang, X; Xiao, M; Yao, W; Zhang, F; Zhang, H | 1 |
| Du, R; Fang, H; Guo, F; Han, J; Kang, J; Lu, Z; Song, Q | 1 |
| Andraos, TY; Cheng, H; Halmos, B; Huntzinger, C; Ohri, N; Shirvani, SM | 1 |
| Bono, F; Cortinovis, D; Crivellaro, C; De Bernardi, E; Elisei, F; Guerra, L; L'Imperio, V; Landoni, C; Mathoux, G; Messa, C; Monaco, L; Musarra, M; Pagni, F; Turolla, EA | 1 |
| Castillo, E; Castillo, R; Chen, Y; Forghani-Arani, F; Guerrero, T; Miller, R; Rusthoven, C; Santangelo, T; Vinogradskiy, Y | 1 |
| Amrane, K; Campedel, L; Kharroubi, D; Le Meur, C | 1 |
| Fukui, M; Hattori, A; Matsunaga, T; Nomura, K; Suzuki, K; Takamochi, K | 1 |
| Jang, SJ; Jo, IY; Lee, JH; Lee, JW; Lee, SM | 1 |
| Al-Hammadi, N; Chandramouli, SH; Divakar, SR; Gurusamy, VM; Hammoud, RW; Usman, M | 1 |
| Iguchi, K; Nakamura, M; Suzuki, E; Tanahashi, M; Tsuchida, H; Uchiyama, S; Watanabe, T; Yobita, S; Yoshii, N | 1 |
| Li, TC; Liu, KF; Liu, YN; Wang, GL; Zhao, K; Zhao, X | 1 |
| Eren, G; Kupik, O | 1 |
| Hicks, RJ | 2 |
| Juneau, D; Léger, MA; Routy, B | 1 |
| Aras, F; Olmezoglu, A | 1 |
| Goksel, S; Karaman, E; Tuluce, K | 1 |
| Chen, M; Chen, WM; Lin, WC; Shia, BC; Wu, SY | 1 |
| Abdollahi, H; Ay, MR; Falahatpour, Z; Geramifar, P; Mahdavi, SR; Nikoofar, A; Salimi, Y | 1 |
| Laue, HOA; Persigehl, T | 1 |
| Atzinger, A; Förster, S; Hartmann, A; Hohenforst-Schmidt, W; Klink, T; Kuwert, T; Schmidkonz, C; Steppert, C; Sterlacci, W; Sziklavari, Z; Vieth, M; Zhang, R | 1 |
| Cao, M; Wang, Q; Wei, W; Zhang, X | 1 |
| Deng, S; Li, J; Sang, S; Xu, X; Yang, Y | 1 |
| Bai, M; Gao, Z; Li, J; Liu, J; Meng, X; Wang, S; Wu, L; Wu, M; Yu, J | 1 |
| Bai, F; Chen, Q; Gao, K; Huang, Y; Ling, L; Sun, L; Wang, Y; Wen, Y; Xiong, J; Yang, L; Yang, W; Zhai, R; Zhang, X; Zhou, Z | 1 |
| Andersen, MB; Drljevic-Nielsen, A; Hjorthaug, K; Kruis, MF; Nijkamp, JA; Rasmussen, F; Thygesen, J | 1 |
| Endo, M; Nakahashi, K; Nakatsuka, M; Shiono, S | 1 |
| Chen, Y; Fan, K; Zhang, D | 1 |
| Adler, S; Cai, Q; Chan, H; Flores, R; Henschke, CI; Kaufman, A; Taioli, E; Triphuridet, N; Yankelevitz, DF; Yip, R; Zhu, Y | 1 |
| Ajdari, A; Bortfeld, T; Liao, Z; Mohan, R; Wei, X | 1 |
| Li, J; Ma, R; Wang, YY; Zhao, Q; Zhao, R | 1 |
| Dong, A; Wang, Y; Zhang, J | 1 |
| Agüloğlu, N; Can, C; Gündoğan, C; Güzel, Y; Kaplan, İ; Karaoğlan, H; Kepenek, F; Kömek, H; Taşdemir, B | 1 |
| Agüloğlu, N; Aksu, A; Akyol, M; Doksöz, TÇ; Katgı, N | 1 |
| Hashimoto, K; Imai, H; Kagamu, H; Kaira, K; Kobayashi, K; Kuji, I; Miura, Y; Mouri, A; Shiono, A; Yamaguchi, O | 1 |
| Erol, M; Karanis, MIE; Kucukosmanoglu, I; Unlu, Y | 1 |
| Fei, W; Kong, H; Li, N; Meng, X; Yan, S; Yao, Y; Zhang, A; Zhang, Y; Zhou, N; Zhou, X | 1 |
| Gouel, P; Mallet, R; Modzelewski, R; Thureau, S; Vera, P | 1 |
| Gao, G; Huang, L; Quan, B; Zhang, P; Zheng, W | 1 |
| Cattaneo, M; Chirindel, A; Hojski, A; Kaumanns, A; König, D; Lardinois, D; Rothschild, SI; Tamm, M; Wiese, M | 1 |
| Annema, J; Crombag, L; Fielding, D; Hardcastle, N; Irving, LB; Jennings, BR; Kothari, G; Lee, P; Nguyen, P; Ost, DE; Rangamuwa, K; Siva, S; Steinfort, DP; Yasufuku, K; Yo, S | 1 |
| Iijima, Y; Ishikawa, M; Iwai, S; Mizoguchi, T; Motono, N; Uramoto, H | 3 |
| Cheng, G; Huang, Y; Jiang, X; Liu, LN; Shi, YH; Wu, HJ; Xia, YX; Xu, DK; Xu, H; Zhang, D | 1 |
| Cyran, C; Früh, M; Gatidis, S; Hepp, T; Küstner, T; La Fougère, C; Nikolaou, K; Pfannenberg, C; Rubin, D; Schölkopf, B | 1 |
| Chen, J; Jiang, H; Wang, J; Xu, C; Zhang, H; Zhang, L; Zhang, X | 1 |
| Huang, Y; Jiang, L; Li, Q; Li, Y; Song, X; Yang, F; Yuan, H | 1 |
| Gomi, T; Ito, K; Kajiyama, A; Kusumoto, M; Mizumura, S; Watanabe, H; Watanabe, SI; Yatabe, Y | 1 |
| Chen, BY; Clark, PM; Damoiseaux, R; Ghezzi, C; Perez, S; Ryan, K; Wong, A | 1 |
| Hsu, CX; Shiau, YC; Wang, SY | 1 |
| Chang, BS; Chen, YH; Chu, SC; Lin, CB; Lue, KH | 1 |
| Hwang, JH; Kim, KU; Lim, CH; Park, SB; Park, YW | 1 |
| Beyer, T; Hacker, M; Shiyam Sundar, LK | 1 |
| He, L; Jiang, L; Li, D; Sun, X; Tan, X; Yuan, H | 1 |
| Albano, D; Bellini, P; Bertagna, F; Cerudelli, E; Dondi, F; Treglia, G | 1 |
| Hama, Y; Tate, E | 1 |
| Dai, Q; Huang, G; Jin, M; Liu, L; Wang, M | 1 |
| Ahn, MJ; Choi, JY; Han, J; Im, Y; Kim, J; Kwon, OJ; Park, YJ; Um, SW | 1 |
| Keyhanian, K; Sekhon, HS | 1 |
| Belderbos, JSA; Cooke, SA; Damen, EMF; de Ruysscher, D; Dieleman, EMT; Faivre-Finn, C; Fredberg Persson, G; Lalezari, F; Lambrecht, M; Lewensohn, R; Reymen, B; Sikorska, K; Sonke, JJ; van Diessen, JNA; van Elmpt, W; Vogel, W | 1 |
| Abe, K; Aoki, K; Daimon, M; Iwahana, T; Kato, H; Kobayashi, Y; Ono, R | 1 |
| Nakahira, S; Oi, K; Saito, Y; Tamagawa, H; Taniguchi, E; Tsujimura, N | 1 |
| Kang, SR; Kim, MS; Oh, IJ; Oh, S | 1 |
| He, L; Jiang, L; Li, D; Sun, X; Tan, X; Yao, X; Yuan, H | 1 |
| Abuali, T; Amini, A; Du, D; Glaser, S; Ladbury, C; Liu, A; Liu, J; Massarelli, E; Salgia, R; Villaflor, V; Watkins, W; Williams, T | 1 |
| Byun, BH; Ju, HM; Kim, BC; Lim, I; Woo, SK | 1 |
| Amthauer, H; Baumgärtner, GL; Frost, N; Furth, C; Gerhold, M; Michaels, L; Neudecker, J; Ochsenreither, S; Penzkofer, T; Rogasch, JMM; Rückert, JC; Schmidt, B; Schneider, P | 1 |
| Chan, SC; Chang, BS; Chen, KC; Chen, YC; Chen, YH; Chu, SC; Lin, CB; Lue, KH | 1 |
| Chen, Y; Ding, H; Fu, S; Li, Y; Lin, S; Ren, P; Tang, S; Xu, Y; Ye, H; Zhang, Y | 1 |
| Hongwei, S; Huiqin, X; Jianzhong, C; Li, L; Ruonan, W; Shuqin, X; Sijin, L; Xinzhong, H | 1 |
| Bartenstein, P; Belka, C; Eze, C; Holzgreve, A; Käsmann, L; Kunz, WG; Li, M; Manapov, F; Müller, P; Nieto, AE; Reinmuth, N; Ricke, J; Taugner, J; Tufman, A; Unterrainer, LM; Unterrainer, M; Winkelmann, M | 1 |
| Ikeda, H; Koyama, H; Nagata, H; Ohno, Y; Ozawa, Y; Takenaka, D; Toyama, H; Ueda, T; Yamamoto, K; Yoshikawa, T; Yui, M | 1 |
| Fan, Y; Guo, C; Huang, W; Li, S; Liao, X; Liu, J; Liu, M; Wang, R; Xiong, Y; Zhang, J | 1 |
| Boo, SH; Moon, SW; Park, HL; Park, SY; Yoo, IR | 1 |
| Bakker, J; Borm, FJ; de Gruijl, TD; de Langen, AJ; Smit, EF; Smit, J; Wondergem, M | 1 |
| Barton, M; Carolan, M; Field, M; Harris, G; Holloway, L; Metcalfe, P; Nigam, R | 1 |
| Anselmo, P; Arcidiacono, F; Casale, M; Trippa, F | 1 |
| García Valiente, P; Sánchez Togneri, L | 1 |
| Brose, A; Eschmann, SM; König, J; Michalski, K; Miederer, M; Nestle, U; Ruf, J; Schreckenberger, M; Tosch, M | 1 |
| Bowen, SR; Gates, EDH; Hippe, DS; Vesselle, HJ; Zeng, J | 1 |
| Beheshti, M; Grambozov, B; Kalantari, F; Karner, J; Rinnerthaler, G; Ruznic, E; Sedlmayer, F; Stana, M; Zehentmayr, F; Zellinger, B | 1 |
| Beiki, D; Eftekhari, M; Emami-Ardekani, A; Fallahi, B; Geramifar, P; Manafi-Farid, R; Mirshahvalad, SA; Seifi, S | 1 |
| Li, J; Song, R; Sun, X; Tan, W; Wang, J; Xing, L; Zhang, Y; Zheng, Z | 1 |
| Aigner, C; Darwiche, K; Eberhard, W; Hautzel, H; Herrmann, K; Hockmann, J; Plönes, T; Stuschke, M | 1 |
| Dilber, I; Kelam, N; Kokeza, J; Ogorevc, M; Strikic, A; Vukoja, M; Zekic Tomas, S | 1 |
| Chen, C; Dai, C; Deng, J; E, H; Hou, L; Huang, J; Li, C; Li, Q; Luo, Q; Ma, M; Ren, Y; Wu, J; Yang, M; Zhang, L; Zhao, D | 1 |
| Chen, Y; Dai, W; Feng, Y; Wang, P | 1 |
| Basu, A; Biswas, J; Chakraborty, A; Chakraborty, I; Ghosh, D; Mandal, B; Manna, A; Mondal, J | 1 |
| Chen, ZY; Cheng, Y; Huang, JJ; Shao, D | 1 |
| Beer, L | 1 |
| Chang, C; Lei, B; Liu, L; Ruan, M; Sun, J; Wang, L; Wang, Y; Xie, W; Yan, H; Zhang, H | 1 |
| Chen, W; Li, T; Qiu, X; Song, Y; Sun, P; Wang, C; Zhang, P; Zhao, K; Zhu, X | 1 |
| Alduraibi, A; Balaji, N; Bin Essa, N; Bomanji, J; Fraioli, F; Groves, AM; Kaplar, Z; Lilburn, DML; Navani, N | 1 |
| Ajona, D; Calvo, A; Collantes, M; Ecay, M; Francisco-Cruz, A; Gil-Bazo, I; Iribarren, F; López, I; Peñuelas, I; Puyalto, A; Rodríguez-Remírez, M; Sandiego, S; Simón, JA; Solórzano, JL; Vilalta-Lacarra, A | 1 |
| Chung, J; Hanneman, K; Metser, U; Murad, V; Ortega, C | 1 |
| Bando, Y; Ikushima, H; Kondo, K; Kuwahara, K; Miyoshi, H; Otani, T; Otsuka, H; Yamashita, M | 1 |
| Amthauer, H; Apostolova, I; Blüthgen, N; Cegla, P; Cholewiński, W; Hofheinz, F; Klinger, B; Kreissl, MC; Kukuk, E; Strobel, H; van den Hoff, J; Zips, D; Zschaeck, S | 1 |
| Castello, A; Finocchiaro, G; Grizzi, F; Lopci, E; Mazziotti, E; Qehajaj, D; Rahal, D; Rossi, S; Toschi, L | 1 |
| Ahn, JS; Ahn, MJ; Choi, JY; Kim, BT; Lee, KH; Moon, SH; Park, K; Sun, JM | 1 |
| Honma, K; Misawa, M; Nomori, H; O'uchi, T; Oyama, Y; Shiraishi, A; Shoji, K; Sugimura, H | 1 |
| Gao, Y; Guo, HY; Huang, HH; Lin, JT; Sun, M; Xu, WP; Yan, HH; Yan, MR; Yang, XN; Zhong, WZ | 1 |
| Court, LE; Fuller, CD; Gay, S; Ger, RB; Howell, RM; Layman, RR; Li, H; Mawlawi, O; Meier, JG; Mumme, R; Pahlka, RB; Stafford, RJ; Zhou, S | 1 |
| Benson, J; Davidzon, GA; Horng, G; Leung, ANC; Mattonen, SA; Nair, VS; Napel, S; Shrager, JB; Vasanawala, M | 1 |
| Dubray, B; Ganem, J; Gouel, P; Salaun, M; Texte, E; Thureau, S; Vera, P | 1 |
| Damiano, V; De Placido, S; Del Vecchio, S; Fonti, R; Matano, E; Mazziotti, E; Mozzillo, E; Pellegrino, S; Piccin, L | 1 |
| Isoda, H; Koyasu, S; Nakamoto, Y; Nishio, M; Togashi, K | 1 |
| Mimae, T; Okada, M | 1 |
| Dai, M; Han, J; Wang, J; Wang, Y; Zhang, J; Zhang, Z; Zhao, X; Zhao, Y | 1 |
| Abraham, T; Brodin, NP; Ohri, N; Tomé, WA | 1 |
| Adam, J; Ammari, S; Berenbaum, A; Besse, B; Botticella, A; Caramella, C; Dercle, L; Deutsch, E; Grimaldi, S; Le Pechoux, C; Leboulleux, S; Mezquita, L; Planchard, D; Seban, RD | 1 |
| Higuchi, T; Hirasawa, H; Nakano, T; Ohno, T; Saitoh, JI; Shirai, K; Shrestha, S; Tokue, A; Tsushima, Y | 1 |
| Akiba, J; Azuma, K; Fujimoto, K; Ishibashi, M; Ishii, K; Kaida, H; Kawahara, A; Takamori, S | 1 |
| Choi, WH; Kang, JH; Kim, YS; Lee, HY; Park, JK; Sung, SW; Yoo, IR | 1 |
| Bauckneht, M; Biello, F; Bruzzi, P; Ceriani, V; Cittadini, G; Dal Bello, MG; Genova, C; Grossi, F; Lopci, E; Mennella, S; Morbelli, S; Piva, R; Rijavec, E; Rossi, G; Sambuceti, G | 1 |
| Gillies, RJ; Gray, JE; Mu, W; Qi, J; Schabath, MB; Tunali, I | 1 |
| Cai, L; Deberardinis, RJ; Do, QN; Faubert, B; Hensley, CT; Kernstine, KH; Lenkinski, RE; Malloy, CR; Oliver, D; Rogers, TJ; Torrealba, J; Wachsmann, JW | 1 |
| Arimura, H; Ninomiya, K | 1 |
| Farsad, M | 1 |
| Bao, YN; Cui, YT; Huang, CX; Lin, Y; Tian, Y; Wang, XC; Yu, ZL; Zhang, JH | 1 |
| Castello, A; Lopci, E; Rossi, S | 1 |
| Chang, C; Lei, B; Liu, L; Ruan, M; Shen, Y; Sun, X; Wang, L; Xie, W | 1 |
| Cao, Q; Cao, Y; Jin, H; Li, D; Lin, Z; Liu, Y; Lv, W; Xu, Z; Yang, M; Yang, S | 1 |
| Dejust, S; El Farsaoui, K; Morland, D; Moubtakir, A; Prevost, A | 1 |
| He, L; He, R; Li, G; Li, X; Qiao, Y; Ren, YW; Song, YQ; Wang, CY; Wang, N; Wang, RZ; Wang, TL; Yang, QK; Zhang, XF | 1 |
| Castello, A; Lopci, E; Mazziotti, E; Rossi, S; Toschi, L | 1 |
| Chankowsky, J; Hirsh, V; Khokhar, RA; Kovacina, B; McDougall, CC; Nair, JKR; Probst, S; Raidu, BVS; Sabri, A; Saeed, UA; Taylor, J; Van Kempen, LC | 1 |
| Bonardel, G; Dercle, L; Schwartz, LH; Seban, RD | 1 |
| Callahan, J; Everitt, S; Konert, T; La Fontaine, MD; MacManus, MP; Sonke, JJ; van de Kamer, JB; Vogel, WV | 1 |
| Altmayer, S; Basso Dias, A; de Souza Santos, F; Henz Concatto, N; Hochhegger, B; Hoefel Paes, J; Machado Medeiros, T; Mattiello, R; Mohammed, TL; Verma, N; Watte, G; Zanon, M | 1 |
| Chen, W; Cheng, D; Hu, B; Shi, H; Xiu, Y; Zhang, Y | 1 |
| Castello, A; Lopci, E | 1 |
| Faivre-Finn, C | 1 |
| Adebahr, S; Bultel, YP; Dieckmann, K; Eschmann, SM; Fleckenstein, J; Gkika, E; Grosu, AL; Hass, P; Hehr, T; Holl, G; König, J; Kremp, S; Küsters, A; Miederer, M; Mix, M; Nestle, U; Rischke, HC; Schaefer-Schuler, A; Schimek-Jasch, T; Stockinger, M; Thieme, A; Tosch, M | 1 |
| Casali, M; Ciammella, P; Filice, A; Fioroni, F; Galaverni, M; Iotti, C; Versari, A | 1 |
| Liu, B; Niu, R; Shao, XL; Shao, XN; Shi, YM; Wang, JF; Wang, XS; Wang, YT; Yu, WJ; Zhang, FF | 1 |
| Aoki, S; Araya, M; Komiyama, T; Kuriyama, K; Maehata, Y; Marino, K; Matsumoto, Y; Miyakawa, A; Miyawaki, D; Nishimura, Y; Nonaka, H; Onishi, H; Saito, M; Saito, R; Sano, N; Sasaki, R; Shibamoto, Y; Shioyama, Y; Suzuki, G; Tominaga, L; Yamada, S | 1 |
| Arena, V; Ceci, F; Ianniello, A; Pelosi, E; Penna, D; Poli, E; Polverari, G; Sandri, A | 1 |
| Amini, B; Behrens, C; Carter, BW; Cascone, T; Fujimoto, J; Gibbons, DL; Godoy, MCB; Heymach, JV; Hofstetter, WL; Hwu, P; Kadara, H; Lee, JJ; Mitchell, KG; Moran, CA; Parra, ER; Peng, W; Piwnica-Worms, D; Reuben, A; Sepesi, B; Swisher, SG; Vaporciyan, AA; Villalobos, P; Walsh, GL; Wang, J; Wang, Y; Weissferdt, A; William, WN; Wistuba, II | 1 |
| Al-Kadi, OS | 1 |
| Chen, H; Lin, Q; Zhao, L | 1 |
| Bengtsson, T; Carano, RAD; de Crespigny, A; Fredrickson, J; Jemaa, S; Nielsen, T | 1 |
| Guo-Qiang, S; Jian, W; Jun, Z; Long-Bao, X; Ming-Ya, P | 1 |
| Abdulla, DSY; Backes, H; Behringer, D; Buettner, R; Eichstaedt, M; Fischer, RN; Franklin, J; Frechen, S; Fuhr, U; Gardizi, M; Junge, L; Kaminsky, B; Kinzig, M; Kobe, C; Limburg, M; Mattonet, C; Merkelbach-Bruse, S; Michels, S; Nogova, L; Ouyang, D; Persigehl, T; Rokitta, D; Scheffler, M; Schnell, R; Sörgel, F; Sos, ML; Stelzer, C; Suleiman, AA; Taubert, M; Tian, Y; Wolf, J | 1 |
| Laffon, E; Marthan, R | 2 |
| Guo, Y; Qian, X; Zhai, X | 1 |
| Chen, J; Huang, J; Xia, J; Xu, R | 1 |
| Bernhardt, D; Combs, SE | 1 |
| Akatli, A; Akyol, H; Asik, M; Balci, TA; Comak, A; Elmali, F; Kekilli, E; Koroglu, R; Kuslu, D; Simsek, FS; Ulutas, H; Yalcin, NC | 1 |
| Flores, RM; Henschke, CI; Kaufman, A; Lee, DS; Wang, Y; Yankelevitz, DF; Yip, R; Zhu, Y | 1 |
| Bian, J; Liu, N; Xu, X; Yan, K | 1 |
| Geol Lee, C; Kim, JS; Kim, N | 1 |
| Bosque, JJ; García Vicente, AM; Honguero-Martinez, AF; Jiménez Londoño, GA; Pérez-Beteta, J | 1 |
| Hojo, M; Hotta, M; Minamimoto, R; Naka, G; Takeda, Y | 1 |
| Andersen, TL; Dahlsgaard-Wallenius, SE; Gerke, O; Hildebrandt, MG; Høilund-Carlsen, PF; Johansen, A; Morsing, A; Petersen, H; Vilstrup, MH | 1 |
| Ahac, V; Boc, N; Eickhoff, J; Jeraj, R; Simoncic, U; Skalic, K; Studen, A; Unk, M; Valentinuzzi, D; Vrankar, M; Zagar, I; Zupancic, Z | 1 |
| Liu, J; Shi, J; Wang, H; Zhao, L | 2 |
| Koong, SS; Lee, KH; Yoo, JY; Yoo, MY | 1 |
| Gill, S; Loh, N; Tan, D | 1 |
| Aragaki, M; Fujiwara-Kuroda, A; Hida, Y; Kaga, K; Kato, T; Wakasa, S | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Kawakita, N; Matsumoto, D; Otsuka, H; Takashima, M; Takizawa, H; Tangoku, A; Toba, H | 1 |
| Hashimoto, K; Kagamu, H; Kaira, K; Kobayashi, K; Kuji, I; Miura, Y; Mouri, A; Murayama, Y; Shiono, A; Yamaguchi, O | 1 |
| Kim, SJ; Kim, YS; Seol, HY | 2 |
| Bussink, J; de Geus-Oei, LF; Meijer, TWH; Noortman, WA; Slump, CH; van Velden, FHP; Vriens, D | 1 |
| Eba, S; Noda, M; Notsuda, H; Oishi, H; Okada, Y; Saito, R; Sakurada, A; Takanami, K; Tanaka, R | 1 |
| Cheng, Y; Jiang, BY; Shao, D; Wang, SX; Yuan, ZS | 1 |
| Bai, F; Bowen, SR; Chaovalitwongse, WA; Duan, C; Hippe, DS; Kinahan, PE; Liu, X; Miyaoka, RS; Pierce, LA; Rengan, R; Thammasorn, P; Vesselle, HJ; Wang, S; You, J; Zeng, J | 1 |
| Cheng, J; Qi, M; Ren, C; Song, S; Sun, Y; Zhang, J; Zhang, Y | 1 |
| Chang, C; Lei, B; Liu, L; Ruan, M; Sun, X; Wang, L; Xie, W; Yan, H | 1 |
| Yu, T | 1 |
| Assie, JB; Bonardel, G; Champion, L; Chouaid, C; Duchemann, B; Girard, N; Giroux-Leprieur, E; Goldfarb, L; Massiani, MA; Playe, M; Seban, RD; Soussan, M | 1 |
| Ball, D; Bressel, M; Bucknell, N; Campbell, BA; David, S; Haghighi, N; Hanna, GG; Kok, D; MacManus, M; Newman, S; Phillips, C; Plumridge, N; Shaw, M; Siva, S; Tran, P; Wheeler, G; Wirth, A | 1 |
| Antonorsi, N; Cheze Le Rest, C; Filali Razzouki, A; Hatt, M; Mondon, R; Pinto-Leite, T; Tankyevych, O; Tixier, F; Visvikis, D | 1 |
| Cheon, M; Choi, JY; Hyun, SH; Kim, BT; Lee, KH; Park, YJ; Um, SW; Won, HH; Yoo, J; Zo, JI | 1 |
| Adriaensens, P; Boellaard, R; Mesotten, L; Pfaehler, E; Pieplenbosch, S; Thomeer, M; Vanhove, K; Zhovannik, I | 1 |
| Henschke, CI; Siddique, M; Yankelevitz, DF; Yip, R | 1 |
| Cipriano, FEG; Correia, NSC; de Azevedo-Marques, PM; de Vita Graves, C; Fabro, AT; Ferreira Junior, JR; Koenigkam-Santos, M | 1 |
| Huang, Y; Li, M; Ma, L; Shi, F; Song, Y; Wang, C; Zhao, K | 1 |
| Chen, M; Liang, H; Qiu, X; Wang, M; Xu, Y; Zhao, J; Zhong, W; Zhu, Z | 1 |
| Araujo-Filho, JAB; Chang, J; Ginsberg, MS; Lobaugh, S; Mayoral, M; Perez-Johnston, R; Plodkowski, AJ; Rekhtman, N; Rusch, VW; Zheng, J | 1 |
| Aigner, C; Darwiche, K; Eberhardt, WEE; Guberina, M; Guberina, N; Hautzel, H; Herrmann, K; Karpf-Wissel, R; Ploenes, T; Pöttgen, C; Schuler, M; Stuschke, M; Theegarten, D; Umutlu, L; Wetter, A | 1 |
| Agrawal, A; Jiwnani, S; Karimundackal, G; Kumar, R; Mathew, B; Prabhash, K; Prakash Agarwal, J; Pramesh, CS; Purandare, NC; Puranik, A; Rangarajan, V; Shah, S; Tandon, S | 1 |
| Cong, Y; Honma, K; Machida, Y; Nomori, H; Otsuki, A; Oyama, Y; Sugimura, H; Yamazaki, I | 1 |
| Aggarwal, C; Berman, AT; Cengel, KA; Dorsey, JF; Fan, Y; Feigenberg, SJ; Frick, MA; Jean-Baptiste, S; Kao, GD; Lee, SH; Levin, WP; Uche, CZ; Xiao, Y | 1 |
| Bi, L; Dagan Feng, D; Fulham, M; Kim, J; Li, N; Liu, Q; Song, S | 1 |
| Belka, C; Dinkel, J; Eze, C; Käsmann, L; Kirchner, J; Kunz, WG; Manapov, F; Mittlmeier, LM; Ricke, J; Roengvoraphoj, O; Sawicki, LM; Schmidt-Hegemann, NS; Tufman, A; Unterrainer, M | 1 |
| Chang, H; Chen, YY; Chou, HP; Huang, HK; Huang, TW; Lee, SC; Lin, KH; Lin, LF; Wu, TH | 1 |
| Aigner, C; Christoph, DC; Eberhardt, W; Faehling, M; Fendler, WP; Ferdinandus, J; Grünwald, V; Herrmann, K; Karl, KO; Kessler, L; Metzenmacher, M; Umutlu, L | 1 |
| Almahariq, MF; Bissonnette, JP; Everitt, S; Geiger, G; Grills, IS; Manus, MM; Sonke, JJ; Sun, A; Vogel, W | 1 |
| Gage, KL; Gillies, RJ; Katsoulakis, E; Mu, W; Schabath, MB; Whelan, CJ | 1 |
| Ancın, B; Doğan, R; Köksal, D; Kumbasar, U; Tuncel, M; Uysal, S | 1 |
| Cao, Y; Fan, X; Li, X; Wang, Y; Xu, W; Zheng, X | 1 |
| Ambrosini, V; Ardizzoni, A; Argalia, G; Calabrò, D; Conci, N; Dall'Olio, FG; Fabbri, F; Fanti, S; Fragomeno, B; Marchese, PV; Ricci, D | 1 |
| Ke, L; Meng, X; Wu, L; Yu, J | 1 |
| Daly, ME; Dyer, BA; Moran, A; Wang, Y; Yamamoto, T; Yip, SSF | 1 |
| Amthauer, H; Bluemel, S; Böhmer, D; Frost, N; Furth, C; Michaels, L; Neudecker, J; Ochsenreither, S; Penzkofer, T; Rogasch, JMM; Rückert, JC; Temmesfeld-Wollbrück, B; von Laffert, M | 1 |
| Bruzzi, JF | 2 |
| Burchett, P; Costello, P; De Cecco, CN; Gordon, L; Martin, SS; Monti, CB; Ravenel, J; Rieter, WJ; Schoepf, UJ; van Assen, M; Vogl, TJ | 1 |
| Bonitta, G; Casagrande, S; Castellani, M; Cattoni, M; Cuzzocrea, M; De Palma, D; Dominioni, L; Franzi, S; Imperatori, A; Mendogni, P; Nosotti, M; Pieropan, S; Rotolo, N; Schiorlin, I; Tosi, D | 1 |
| Colandrea, M; Di Stasio, GD; Ferrari, ME; Galetta, D; Grana, CM; Maisonneuve, P; Sorbello, S; Spaggiari, L; Travaini, L; Travascio, L | 1 |
| Isaka, M; Konno, H; Mizuno, T; Nagata, T; Ohde, Y | 1 |
| Bowen, SR; Horn, KP; Kinahan, PE; Miyaoka, RS; Rengan, R; Thomas, HMT; Vesselle, HJ; Zeng, J | 1 |
| Johnson, A; Manners, D; Norman, R; Piccolo, F | 1 |
| Antonoff, MB; Blumenthaler, AN; Hofstetter, WL; Mehran, RJ; Rajaram, R; Rice, DC; Roth, JA; Sepesi, B; Strange, CD; Swisher, SG; Vaporciyan, AA; Walsh, GL | 1 |
| Chen, X; Hua, J; Li, L; Liu, L; Liu, Q; Liu, Y | 1 |
| Ito, K; Motoi, N; Muraoka, Y; Nakagawa, K; Narita, T; Watanabe, H; Watanabe, SI; Yatabe, Y; Yoshida, Y; Yotsukura, M | 1 |
| Assié, JB; Bonardel, G; Champion, L; Chouaid, C; Deleval, N; Girard, N; Giroux-Leprieur, E; Massiani, MA; Mezquita, L; Richard, C; Seban, RD | 1 |
| Besson, FL; Bulifon, S; Comtat, C; Durand, E; Fadel, E; Faure, S; Fernandez, B; Ghigna-Bellinzoni, MR; Jais, X; Lebon, V; Levy, A; Mercier, O; Mitilian, D; Montani, D; Mussot, S; Parent, F; Planchard, D; Seferian, A | 1 |
| Brinkmann, JK; Digumarthy, SR; Fintelmann, FJ; Jeck, WR; Mino-Kenudson, M; Shepard, JO; Troschel, FM | 1 |
| Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X | 1 |
| Bayarri-Lara, CI; Cueto Ladrón de Guevara, A; de Miguel Pérez, D; Delgado-Rodríguez, M; Expósito Ruiz, M; Giraldo Ospina, CF; Lorente, JA; Moyano Rodriguez, MJ; Puche, JL; Rodriguez Fernández, A; Ruiz Zafra, J; Sánchez-Palencia Ramos, A; Serrano, MJ | 1 |
| Denoux, T; Li, H; Lian, C; Ruan, S; Vera, P | 1 |
| Antunovic, L; Castiglioni, I; Chiti, A; Gallivanone, F; Kirienko, M; Leonardi, L; Sollini, M; Testanera, G; Veronesi, G; Voulaz, E | 1 |
| Baeza, JA; Barbeiro, AR; García-Gómez, FJ; Jiménez-Ortega, E; Leal, A; Ureba, A; Vargas, A; Wals-Zurita, A | 1 |
| Han, A; Huang, Y; Jin, F; Li, M; Liu, A; Ma, L; Yang, Q; Yu, J; Zhu, H | 1 |
| Dasu, A; Even, A; Lambin, P; Lindblom, E; Toma-Dasu, I; Uhrdin, J; van Elmpt, W; Wersäll, P | 1 |
| Chang, YC; Chen, JL; Chen, YC; Hsu, FM; Huang, JY; Huang, YS; Jaw, FS; Ko, WC; Yen, RF | 1 |
| Abe, H; Ahn, JM; Chen, M; Choe, JH; Choi, H; Endo, H; Goodwin, J; Helke, KL; Inoue, M; Jenkins, DMR; Jeong, JY; Kim, JW; Lee, SY; Minna, JD; Neugent, ML; Robinson, MW; Ruthenborg, RJ; Shackelford, DB; Singh, PK; Takeda, N; Wake, M; Xuan, Z; Yoo, H | 1 |
| Altorki, NK; Ghaly, G; Harrison, S; Kamel, MK; Lee, PC; Nasar, A; Nguyen, AB; Port, J; Rahouma, M; Stiles, BM | 1 |
| Bi, N; Cease, KB; Frey, KA; Gross, M; Hassan, KA; Hayman, J; Kalemkerian, GP; Kong, FM; Lawrence, TS; Matuszak, M; Orringer, M; Ramnath, N; Ritter, T; Schipper, M; Ten Haken, RK; Wang, W | 1 |
| Bornschlegl, S; Delivanis, DA; Dietz, AB; Gustafson, MP; Kottschade, L; Merten, MM; Ryder, M; Withers, S | 1 |
| Boellaard, R; Hoekstra, OS; Kramer, GM | 1 |
| Goldring, J; Lim, E; Mallorie, A; Patel, A; Wagner, T | 1 |
| Akhurst, T; Ashley Cox, R; Ball, D; Bressel, M; MacManus, M | 1 |
| Baroni, G; Botta, F; Ciardo, D; Cremonesi, M; Ferrari, ME; Garibaldi, C; Gilardi, L; Grana, CM; Jereczek-Fossa, BA; Orecchia, R; Piperno, G; Ronchi, S; Timmerman, R; Travaini, LL | 1 |
| Ayyıldız, O; İçer, S; Karacavus, S; Kaya, E; Kayaaltı, Ö; Tasdemir, A; Yılmaz, B | 1 |
| Appelt, AL; Borissova, S; Brink, C; Drøgemüller Lund, M; Hansen, O; Hoffmann, L; Josipovic, M; Khalil, AA; Knap, MM; Lutz, CM; Møller, DS; Nielsen, TB; Nyhus, CH; Ottosson, W; Persson, G; Schytte, T; Sibolt, P | 1 |
| Alavi, A; Duan, F; Houshmand, S; Khiewvan, B; Machtay, M; Opanowski, A; Salavati, A; Siegel, BA; Simone, CB; Snyder, BS; Wei, B | 1 |
| Bhure, U; Del Sol Pèrez-Lago, M; Gautschi, O; Keller, FA; Roos, JE; Strobel, K; Tornquist, K; Werner, L | 1 |
| Koparal, H; Korkmaz, E; Ozbilek, E; Yalcın, B; Yasar, Z; Yılmaz, U | 1 |
| Hadžihasanović, B; Kristić, S; Vegar Zubović, S | 1 |
| Bol, A; Clermont, C; Delor, A; Geets, X; Ghaye, B; Goossens, S; Hanin, FX; Janssens, G; Lee, JA; Remouchamps, V; Van Maanen, A; Wanet, M | 1 |
| Alves, FC; Costa, G; Costa, JMN; de Lima, JP; Isidoro, J; Lapa, P; Marques, M; Oliveiros, B | 1 |
| Bal, CS; Bhalla, AS; Kumar, R; Mohan, A; Pandey, AK; Sharma, A; Vishnubhatla, S | 1 |
| Chang-Halpenny, C; Diehn, M; Eclov, NCW; Gensheimer, MF; Graves, EE; Hara, WY; Hong, JC; Le, QT; Loo, BW; Maxim, PG; Murphy, JD; Neal, JW; Olson, MR; Quon, A; To, J; Wakelee, HA; Zhu, H | 1 |
| Hu, N; Li, DQ; Tan, YL; Wang, YH; Yang, XH | 1 |
| Belderbos, JSA; Das, M; De Ruysscher, D; Even, AJG; Jochems, A; La Fontaine, MD; Lambin, P; Mottaghy, FM; Reymen, B; van Elmpt, W | 1 |
| Abravan, A; Eide, HA; Helland, Å; Knudtsen, IS; Løndalen, AM; Malinen, E; van Luijk, P | 1 |
| Fukushima, T; Gomi, D; Katou, A; Kobayashi, T; Koizumi, T; Mamiya, K; Oguchi, K; Sekiguchi, N; Tateishi, K | 1 |
| Fujisawa, Y; Kishida, Y; Koyama, H; Ohno, Y; Seki, S; Sugihara, N; Yoshikawa, T | 2 |
| Ito, R; Ito, S; Iwano, S; Kato, K; Kawaguchi, K; Naganawa, S; Shimamoto, H; Umakoshi, H | 1 |
| Agarwal, KK; Bhalla, AS; Das, CJ; Kumar, R; Mohan, A; Pandey, AK; Patel, CD; Sekhar Bal, C; Sharma, A; Sharma, MC; Sharma, P; Vishnubhatla, S | 1 |
| Belka, C; Dantes, M; Eze, C; Huber, RM; Li, M; Manapov, F; Roengvoraphoj, O; Taugner, J; Tufman, A; Wijaya, C | 1 |
| Bettinardi, V; Coliva, A; Compierchio, A; Doglioni, C; Fallanca, F; Gianolli, L; Incerti, E; Mapelli, P; Negri, G; Picchio, M; Rossetti, F; Savi, A | 1 |
| Belderbos, JSA; Das, M; De Ruysscher, D; Even, AJG; La Fontaine, MD; Lambin, P; Mottaghy, FM; Reymen, B; van Elmpt, W | 1 |
| Cheng, G; Huang, H | 1 |
| Cheng, G | 2 |
| Fayad, H; Hatt, M; Jaouen, V; Laurent, B; Le Rest, CC; Visvikis, D | 1 |
| Bonomo, L; Calandriello, L; Congedo, MT; Del Ciello, A; Giordano, A; Infante, A; Larici, AR; Leccisotti, L; Poscia, A; Sica, G | 1 |
| Bowen, SR; Kinahan, PE; Samuel, JJE; Thomas, HM | 1 |
| Court, LE; Fried, DV; Gomez, DR; Jensen, GL; Mackin, DS; Yost, CM; Zhou, S | 1 |
| Ayadi, M; Claude, L; Douillard, JY; Dupuy, C; Goulon, D; Isnardi, V; Jouglar, E; Mahé, MA; Ségura-Ferlay, C | 1 |
| Downey, RJ; Dunphy, M; Gandelman, S; Goncalves, MD; Halpenny, DF; Jackson, J; Jones, LW; Lukose, A; Plodkowski, AJ; Schwitzer, E; Tan, KS; Taylor, S | 1 |
| Ge, D; Gu, J; He, J; Huang, Y; Jin, X; Lu, C; Shi, S; Xu, F; Ye, L; Zeng, Z | 1 |
| Bortfeld, T; Choi, N; Liao, Z; Liu, A; Mohan, R; Niemierko, A; Shusharina, N | 1 |
| Hyun, SH; Koh, YW; Lee, SJ; Park, SY | 1 |
| Coolen, J; De Leyn, P; De Ruysscher, D; De Wever, W; Decaluwé, H; Depypere, L; Deroose, C; Dooms, C; Fieuws, S; Lambrecht, M; Moons, J; Nackaerts, K; Stanzi, A; Van Raemdonck, D; Vansteenkiste, J; Verbeken, E | 1 |
| Cho, JS; Eom, JS; Kim, BS; Kim, IJ; Kim, K; Kim, MH; Kim, SJ; Kim, YS; Lee, MK; Pak, K | 1 |
| Bussink, J; Carvalho, S; de Geus-Oei, LF; Lambin, P; Leijenaar, RTH; Oberije, C; Troost, EGC; van Elmpt, W; van Timmeren, JE | 1 |
| Aigner, C | 1 |
| Carvalho, S; Dasu, A; Lambin, P; Lazzeroni, M; Toma-Dasu, I; Uhrdin, J; van Elmpt, W; Wersäll, P | 1 |
| Bires, P; Lederleitner, D; Masarykova, A; Pobijakova, M; Povinec, P; Scepanovic, D | 1 |
| Andreo, F; Centeno, C; López de Castro, P; Martínez-Barenys, C; Mendiluce, L; Ruiz-Manzano, J; Sanz-Santos, J; Serra, P; Torky, M | 1 |
| Cho, S; Jheon, S; Kang, YK; Kim, K; Kim, SE; Lee, WW; Song, YS | 1 |
| Laila, H; Leila, A; Mohamed, R; Mustapha, E; Soumia, F | 1 |
| Deasy, JO; Gelb, E; Humm, JL; Hunt, MA; Lee, SH; Rimner, A; Tyagi, N | 1 |
| Belderbos, J; De Ruysscher, D; La Fontaine, M; Persson, G; Reymen, B; Sonke, JJ; van Diessen, J; van Elmpt, W; Vogel, W; Westman, G | 1 |
| Chin, AL; Diehn, M; Gensheimer, MF; Guo, HH; Kumar, KA; Loo, BW; Maxim, PG; Neal, JW; Wakelee, H | 1 |
| Ayers, K; Bakr, S; Bouchard, G; Diehn, M; Gentles, AJ; Jamali, M; Nair, V; Napel, S; Plevritis, SK; Quon, A; Shafiq, M; Shrager, JB; van de Rijn, M; West, RB; Yu, A; Zhang, W | 1 |
| Bartenstein, P; Belka, C; Dantes, M; Eze, C; Huber, RM; Manapov, F; Roengvoraphoj, O; Taugner, J; Tufman, A; Wijaya, C | 1 |
| Appelbaum, D; Liu, H; Meng, J; Penney, BC; Pu, Y; Zhang, JX | 1 |
| Bezjak, A; Bissonnette, JP; Bratman, S; Le, L; Leighl, N; Palma, D; Raman, S; Schellenberg, D; Sun, A; Warner, A | 1 |
| Kina, S; Miura, K; Nagano, N; Nagasaka, S; Sato, T; Sugiyama, H; Takeda, Y; Tsujimoto, Y | 1 |
| Beer, DG; Brown, RKJ; Carrott, PW; Chang, AC; Chen, G; Heiden, BT; Hermann, M; Lin, J; Lynch, WR; Orringer, MB; Reddy, RM; Zhao, L | 1 |
| Baxa, J; Bejcek, J; Ferda, J; Flohr, T; Ludvik, J; Matouskova, T; Pesek, M; Schmidt, B; Sedlmair, M | 1 |
| Belderbos, J; Gilhuijs, K; Julyan, P; Mercieca, S; van Herk, M; van Loon, J | 1 |
| Chen, J; Huang, Y; Jia, X; Liu, N; Liu, W; Qi, Y; Sun, X; Yuan, S | 1 |
| Cui, H; Feng, D; Fu, Z; Gong, G; Gu, J; Wang, X; Yin, Y; Zhou, J | 1 |
| Chen, Y; He, C; Huang, X; Li, L; Li, T; Yang, L; Yuan, J | 1 |
| Cui, C; Feng, W; Guo, X; Huang, J; Li, X; Liang, Z; Liu, M; Ma, Y; Wu, Z; Zhang, F | 1 |
| Behzadi, B; Doroudinia, A; Karam, MB; Koma, AY; Mehrian, P | 1 |
| Kim, HJ; Kim, WC; Koom, WS; Lee, J; Lee, M | 1 |
| Chung, JH; Kim, S; Lee, SH; Pahk, K; Yi, E | 1 |
| Aboagye, EO; Arshad, MA; Barwick, TD; Chua, S; Cook, GJ; Dickson, J; Landau, D; Lu, H; McDermott, G; O'Connor, R; Power, DA; Rockall, A; Rodgers, N; Scarsbrook, A; Tam, H; Thornton, A; Wallitt, K | 1 |
| Aktas, GE; Balta, C; Karamustafaoğlu, YA; Sarikaya, A; Sarikaya, İ; Süt, N | 1 |
| Cho, JY; Cho, YJ; Kim, ES; Kim, Y; Lee, CT; Lee, JH; Lee, SH; Lee, YJ; Leem, CS; Park, JS; Yoon, HI | 1 |
| Ding, M; Ebeling, R; Heard, D; Posey, R; Zollinger, W | 1 |
| Aide, N; Desmonts, C; Do, P; Guizard, AV; Houdu, B; Lasnon, C; Licaj, I; Thomas, G | 1 |
| Motosugi, U; Omiya, Y; Onishi, H; Saito, A; Satoh, Y | 1 |
| Adli, M; Alan, O; Alkis, H; Babacan, NA; Dane, F; Ercelep, O; Kaya, S; Ones, T; Sahin, D; Salva, H; Telli, TA; Tuylu, TB; Yumuk, F | 1 |
| Alavi, A; Jahangiri, P; Pournazari, K; Simone, CB; Swisher-McClure, S; Torigian, DA; Werner, TJ | 1 |
| Ni, J; Sun, S; Tian, J; Wei, K; Zhang, Y | 1 |
| Chang, JH; Keam, B; Kim, DW; Kim, E; Kim, HJ; Kim, TM; Paeng, JC; Wu, HG | 1 |
| Boerner, B; Bruehlmeier, M; Frey, LD; Gambazzi, F; Graber, SM; Heuberger, J; Irani, S; Janthur, WD; Springer, OS; Tini, GM; Zweifel, R | 1 |
| Belderbos, J; Bjorkestrand, H; Damen, E; De Ruysscher, D; Dieleman, E; Faivre-Finn, C; Fredberg Persson, G; Reymen, B; Sikorska, K; Sonke, JJ; van Diessen, J; van Elmpt, W; Westman, G | 1 |
| Fujino, H; Kajiura, K; Kondo, K; Miyoshi, H; Otani, T; Otsuka, H; Takizawa, H | 1 |
| Bal, CS; Bhalla, AS; Gupta, P; Jain, D; Kumar, R; Mohan, A; Pandey, AK; Sharma, A; Sharma, MC; Thulkar, S; Vishnubhatla, S | 1 |
| Bashir, U; Bille, A; Cook, GJ; Foot, O; Goh, V; Mclean, E; Siddique, MM; Wise, O | 1 |
| Campbell, J; Cheng, M; Frey, KA; Gross, M; Huang, KC; Kong, FS; Lawrence, TS; Li, L; Owen, D; Piert, M; Stenmark, M; Ten Haken, RK; Waller, JL; Wang, W | 1 |
| Ganem, J; Gardin, I; Hapdey, S; Modzelewski, R; Thureau, S; Vera, P | 1 |
| Chen, F; Chen, L; Chen, T; Huang, Y; Jing, M; Sun, H; Tang, X; Tian, Y; Wang, C; Xie, R; Yang, C; Yang, J; Zhou, Y | 1 |
| Fan, Y; Galperin-Aizenberg, M; Li, H; Pryma, D; Simone, CB | 1 |
| Castello, A; Grizzi, F; Lopci, E; Qehajaj, D; Russo, C | 1 |
| Ahn, JS; Ahn, MJ; Choi, JY; Moon, SH; Park, K; Sun, JM | 1 |
| Deng, S; Li, J; Sang, S; Zhang, B; Zhang, W | 1 |
| Ho, KC; Lin, CY; Liu, CY; Su, TP; Wang, CW; Yang, CT; Yen, TC | 1 |
| Allen, AM; Aravot, D; Barac, YD; Flex, D; Kramer, MR; Krutzwald-Josefson, E; Peled, N; Peysakhovich, Y; Saute, M | 1 |
| Bauman, JE; Behnia, F; Eaton, KD; Goulart, BHL; Kell, E; Martins, RG; Mulligan, MS; Patel, SA; Romine, PE; Vesselle, HJ; Wallace, SG; Wood, DE | 1 |
| Kawamura, M; Matsutani, N; Suzuki, S; Takahashi, Y | 1 |
| Aigner, C; Eberhardt, W; Gauler, T; Guberina, M; Herrmann, K; Jentzen, W; Pöttgen, C; Schuler, M; Stamatis, G; Stuschke, M; Theegarten, D | 1 |
| Boo, SH; Moon, SW; Park, HL; Park, JK; Park, SY; Sung, SW; Yoo, IR | 1 |
| Adeni, AE; Alessandrino, F; Awad, MM; Nishino, M; Sahu, S; Shinagare, AB; Tirumani, SH | 1 |
| Casal, RF; Chen, M; Eapen, GA; Grosu, HB; Jimenez, CA; Li, L; Ost, DE; Sagar, AS; Sepesi, B; Sunny, J; Tschirren, J; Williams, J | 1 |
| Amtoft, AG; Dejanovic, D; Pøhl, M; Sørensen, JB | 1 |
| Bakr, S; Davidzon, GA; Echegaray, S; Horng, G; Leung, ANC; Mattonen, SA; Nair, VS; Napel, S; Vasanawala, M | 1 |
| Han, JH; Koh, YW; Lee, SJ; Park, SY | 1 |
| Fujisawa, Y; Kishida, Y; Koyama, H; Ohno, Y; Ohyu, S; Seki, S; Sugihara, N; Yoshikawa, T; Yui, M | 1 |
| Fukushima, T; Gomi, D; Kobayashi, T; Koizumi, T; Oguchi, K; Sekiguchi, N | 1 |
| Bao, X; Lu, S; Niu, X; Wang, M; Wang, Q; Wang, S; Wang, Y; Xu, L; Zhang, J | 1 |
| Ahn, HK; Hyun, SH; Kim, SG; Lee, H | 1 |
| Cho, YS; Choi, JY; Hyun, SH; Lee, KH; Lim, CH; Moon, SH | 1 |
| Wang, T; Wang, Z | 1 |
| Arslan, M; Dag, Y; Simsek, FS | 1 |
| Beer, L; Fabikan, H; Fazekas, A; Fuereder, T; Haug, AR; Herold, C; Hochmair, M; Kifjak, D; Mayerhoefer, ME; Prosch, H; Schwab, S; Schwabel, B; Wadsak, W | 1 |
| Diab, RH; Einstein, SA; Erasmus, LJ; Mawlawi, OR; Meier, JG; Xu, G | 1 |
| Bonanno, L; Cuppari, L; Evangelista, L; Frega, S; Menis, J; Pasello, G; Reccia, P | 1 |
| Fujisawa, Y; Koyama, H; Ohno, Y; Sugihara, N; Takenaka, D; Yoshikawa, T; Yui, M | 1 |
| Fujii, T; Hishizawa, M; Inagaki, N; Kawaguchi-Sakita, N; Kim, YH; Kitamura, M; Kitawaki, T; Matsumoto, S; Nomura, M; Otsuka, A; Saito, R; Sakamori, Y; Sone, M; Taura, D; Yamasaki, T; Yamauchi, I; Yasoda, A | 1 |
| Alavi, A; Goodman, CR; Houshmand, S; Kalbasi, A; Rice, SR; Saboury, B; Salavati, A; Simone, CB; Vujaskovic, Z; Werner, TJ | 1 |
| Bootsma, G; de Booij, M; De Ruysscher, D; Dingemans, AM; Hendriks, LEL; Hofman, P; Houben, R; Schoenmaekers, J; Schreurs, W; Westenend, M | 1 |
| Carvalho, S; de Ruysscher, D; Denis, F; Jochems, A; Lambin, P; Leijenaar, RTH; Muratet, JP; Nestle, U; Oberije, C; Schimek-Jasch, T; Troost, EGC; van Elmpt, W; van Timmeren, JE; Woodruff, HC | 1 |
| Huang, Y; Jiang, L; Li, Y; Wang, H; Wang, Q; Wu, X | 1 |
| Pahk, K | 1 |
| Li, Y; Wen, G; Zhang, J; Zhong, K | 1 |
| Akhurst, T; Ball, DL; Bressel, M; Callahan, JW; Everitt, SJ; Hicks, RJ; Hofman, MS; Iravani, A; Mac Manus, MP; Siva, S; Turgeon, GA | 1 |
| Stirling, RG; Zalcberg, J | 1 |
| Chen, D; Fu, L; Guo, D; Jiang, G; Jin, F; Jing, W; Kong, L; Li, M; Wu, J; Yu, J; Yue, J; Zhu, H; Zou, B | 1 |
| Aerts, J; Biesma, B; Dingemans, AC; Groen, HJM; Hoekstra, O; Klinkenberg, TJ; Kloosterziel, C; Pieterman, R; Schramel, FMNH; Smit, EF; Smit, HJM; van den Borne, B; van der Heijden, EHFM; van der Noort, V; van Tinteren, H; Verhagen, A | 1 |
| Li, R; Lin, J; Tang, K; Wang, L; Zheng, X | 1 |
| Abubaker, S; Al-Ibraheem, A; Altuhhova, D; Belderbos, JSA; Bieu, BQ; Canh, NX; Carvalho, H; Duarte, PS; Fidarova, E; Ha, LN; Hanna, GG; Kapoor, R; Karusoo, L; Khader, J; Konert, T; Kütük, T; Le, TA; MacManus, MP; Numair, Y; Paez, D; Polo, A; Santos, AO; Sood, A; Soydal, C; Thorwarth, D; Vogel, WV; Zuliani, AC | 1 |
| Choi, JY; Hwang, HS; Kim, BT; Kim, H; Kim, S; Kwon, OJ; Lee, HY; Lee, KS; Shim, YM; Yi, CA | 1 |
| Cho, A; Choi, BW; Hong, YJ; Hur, J; Kim, HY; Kim, YJ; Lee, HJ; Lee, JW; Shim, HS | 1 |
| Bootsma, GP; Brans, BT; de Ruysscher, DK; Dingemans, AM; Hendriks, LE; Hofman, PA; Scheppers, NA | 1 |
| Calcagni, ML; Del Ciello, A; Fadda, G; Treglia, G | 1 |
| Baumann, M; Bütof, R | 1 |
| Brocken, P; de Geus-Oei, LF; Dekhuijzen, PN; Peters-Bax, L; van der Heijden, HF | 1 |
| Ahn, JS; Ahn, MJ; Cho, SH; Choi, JY; Ji, JH; Moon, SH; Park, K; Park, LC; Sun, JM | 1 |
| Banzo, I; Carril, JM; Del Castillo-Matos, R; Ibáñez-Bravo, S; Jiménez-Bonilla, JF; Martínez-Amador, N; Martínez-Rodríguez, I; Ortega-Nava, F; Quirce, R; Rubio-Vassallo, AS | 1 |
| Agarwal, KK; Bal, C; Kumar, R; Sharma, P; Singla, S; Suman Kc, S | 1 |
| Alafate, A; Fujiwara, T; Gobara, H; Hiraki, T; Ishii, H; Kaji, M; Kanazawa, S; Kato, K; Miyoshi, S; Okumura, Y; Sato, S; Shinya, T | 1 |
| Carozzi, FM; Carrozzi, L; Comin, C; Deliperi, A; Falaschi, F; Falchini, M; Grazzini, M; Innocenti, F; Lopes Pegna, A; Maddau, C; Mascalchi, M; Paci, E; Picozzi, G; Pistelli, F; Vaggelli, L; Vella, A | 1 |
| Bohle, RM; Bohnenberger, H; Fleckenstein, J; Grgic, A; Kim, YJ; Kirsch, CM; Kremp, S; Kuhnigk, JM; Mai, S; Rübe, C; Schaefer, A; Schäfers, HJ | 1 |
| Chen, HH; Chen, HY; Chiu, NT; Guo, HR; Lai, YH; Lee, BF; Su, WC; Yao, WJ | 1 |
| Bollineni, VR; de Groot, EH; Groen, HJ; Kerner, GS; Koole, MJ; Langendijk, JA; Luurtsema, G; Pruim, J; Steenbakkers, RJ; Widder, J; Wiegman, EM; Willemsen, AT | 1 |
| Fu, L; Fu, Z; Han, DL; Kong, L; Li, J; Yu, JM; Yu, YH; Zhang, Y; Zhu, SH | 1 |
| Balci, TA; Cengiz, E; Karyagar, S; Karyagar, SS; Koc, ZP; Öztürk, I; Sayc, Y | 1 |
| Buchbender, C; Gauler, T; Hartung, V; Heusch, P; Heusner, TA; Köhler, J; Lanzman, RS; Nensa, F; Poeppel, TD; Wetter, A; Wittsack, HJ | 1 |
| Chen, L; Chen, M; Li, X; Ma, H; Sun, X; Xie, P; Xing, L; Xu, W; Xu, X; Yu, J; Zhang, H; Zhang, L | 1 |
| Ball, DL; Callahan, J; Hicks, RJ; MacManus, MP; Martin, O; Siva, S | 1 |
| Antoch, G; Beiderwellen, K; Bockisch, A; Buchbender, C; Forsting, M; Gauler, T; Gomez, B; Heusch, P; Heusner, TA; Köhler, J; Kühl, H; Lanzman, RS; Nensa, F; Schuler, M; Wittsack, HJ | 1 |
| Bazhenova, L; Bethel, K; Gambhir, SS; Hoh, C; Iagaru, AH; Keu, KV; Kolatkar, A; Kuhn, P; Kuschner, W; Loo, BW; Luttgen, MS; Nair, VS; Nieva, J; Shrager, JB; Vasanawala, M | 1 |
| Bussink, J; de Geus-Oei, LF; Kaanders, JH; Oyen, WJ; Peters-Bax, L; Schuurbiers, OC; Troost, EG; Usmanij, EA; van der Heijden, EH | 1 |
| Aide, N; Berriolo-Riedinger, A; Blagosklonov, O; Brenot-Rossi, I; Bridji, B; Cachin, F; Caignon, JM; Chaumet-Riffaud, P; Collombier, L; Courbon, F; Devillers, A; Doyeux, K; Dubray, B; Fernandez, P; Gremillet, E; Houzard, C; Kolesnikov-Gauthier, H; Modzelewski, R; Olivier, P; Roux, J; Tessonnier, L; Thureau, S; Vera, P; Vervueren, L | 1 |
| Bilfinger, TV; Franceschi, D; Kim, B; Matthews, R; Moore, WH; Vu, CC | 1 |
| Canales, BK; Stone, WZ; Wymer, DC | 1 |
| Farjah, F; Lou, F; Rizk, NP; Rusch, VW; Sima, C | 1 |
| Bandiera, A; Gajate, AM; Gallivanone, F; Gianolli, L; Landoni, C; Melloni, G; Muriana, P; Sestini, S; Zannini, P | 1 |
| Ahn, HK; Ahn, MJ; Ahn, YC; Choi, JY; Hyun, SH; Kim, H; Kim, J; Park, K; Shim, YM | 1 |
| Feldmann, HJ; Nestle, U; Schanne, D | 1 |
| Araki, T; Nambu, A; Onishi, H; Satoh, Y | 1 |
| Alavi, A; Bradley, JD; Cho, KH; DeNittis, A; Duan, F; Gorelick, JJ; Johnson, DW; Kim, SK; Komaki, R; Macapinlac, H; Machtay, M; Munden, R; Neumann, DR; Reddin, JS; Sherwin, N; Siegel, BA; Snyder, BS; Videtic, G; Wilf, LH | 1 |
| Das, M; De Ruysscher, D; Hüllner, M; Lambin, P; Reymen, B; Sharifi, H; Troost, EGC; van Elmpt, W; Veit-Haibach, P; Wildberger, JE; Zegers, K | 1 |
| Aerts, HJ; Boellaard, R; Carvalho, S; Dekker, AL; Gillies, RJ; Hoekstra, CJ; Hoekstra, OS; Lambin, P; Leijenaar, RT; Parmar, C; van Elmpt, WJ; Velazquez, ER | 1 |
| Aerts, HJ; Carvalho, S; Dekker, A; Gillies, R; Lambin, P; Leijenaar, RT; Oberije, C; Oellers, M; Parmar, C; Reymen, B; Troost, EG; van Elmpt, W; Velazquez, ER | 1 |
| Toney, LK; Vesselle, HJ | 1 |
| Chen, GH; Fan, XW; Gao, HQ; Jiang, GL; Qian, W; Wu, KL; Yao, ZF; Zhang, YJ | 1 |
| Booth, K; Hanna, GG; Lynch, T; McAleese, J; McGonigle, N; McGuigan, J; McManus, KG; O'Sullivan, J | 1 |
| Abdulla, S; Alavi, A; Basu, S; Saboury, B; Salavati, A; Torigian, DA | 1 |
| Endo, M; Kaira, K; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Ohde, Y; Ono, A; Takahashi, T; Yamamoto, N | 1 |
| Hayashi, S; Hoshi, H; Tanaka, H | 1 |
| Feng, Y; Li, S; Ma, Y; Wang, Y; Yang, Y; Zhao, B; Zheng, Q | 1 |
| Fushiki, H; Jitsuoka, M; Matsunari, I; Mitsuoka, K; Miyoshi, S; Murakami, Y; Nishimura, S; Noda, A; Sasaki, H | 1 |
| Hida, Y; Hirano, S; Kaga, K; Matsui, Y; Muto, J; Nakada-Kubota, R; Ohtaka, K; Okamoto, S; Shiga, T; Tamaki, N | 1 |
| Feng, DD; Fulham, MJ | 1 |
| Duan, XY; Gao, JG; Guo, YM; Shang, J; Wang, JS; Wang, W | 1 |
| Geiger, GA; Grover, S; Kim, MB; Langer, CJ; Plastaras, JP; Pryma, DA; Rengan, R; Simone, CB; Xanthopoulos, EP | 1 |
| Alfieri, RR; Ardizzoni, A; Bartolotti, M; Bordonaro, R; Bortesi, B; Bruzzi, P; Caffarra, C; Cavazzoni, A; Cosentino, S; Fumarola, C; Ippolito, M; Latteri, F; Petronini, PG; Ruffini, L; Scarlattei, M; Soto Parra, HJ; Spadaro, P; Tiseo, M | 1 |
| Chander, A; Fielding, P; Huang, C; Kelly, M; Mehta, G | 1 |
| Gong, H; Han, SR; Tong, AN; Wang, YM; Yan, P; Yao, H; Zhao, H | 1 |
| De Ruysscher, D | 2 |
| Aoki, Y; Fujii, H; Kunieda, E; Nishimura, S; Oku, Y; Ozawa, Y; Sanuki, N; Takeda, A; Yokosuka, N | 1 |
| Davidzon, G; Gevaert, O; Nair, VS; Plevritis, SK; West, R | 1 |
| Aguiló, R; Arriola, E; Belda-Sanchis, J; Curull, V; Pijuan, L; Rodríguez de Dios, N; Rodríguez-Fuster, A; Sánchez-Font, A; Suárez-Piñera, M; Taus, Á; Vollmer, I; Zuccarino, F | 1 |
| Huang, G; Li, Q; Liu, J; Xie, W; Zhang, J; Zhang, Y; Zhao, X; Zhou, X | 1 |
| Endo, M; Hanaoka, H; Kaira, K; Koh, Y; Nakajima, T; Ohde, Y; Oriuchi, N; Serizawa, M; Takahashi, T; Yamaguchi, A; Yamamoto, N | 1 |
| Li, XM; Liang, Y; Liu, Y; Wu, N; Zhang, H; Zhang, WJ; Zhao, SJ; Zheng, R | 1 |
| MacRae, R; Nair, VJ; Pantarotto, JR; Sirisegaram, A | 1 |
| Inubushi, M; Koizumi, M; Koyama, M; Miwa, K; Murata, T; Nagao, M; Sasaki, M; Wagatsuma, K | 1 |
| Amler, L; Eaton, K; Fine, BM; Gitlitz, B; Hicks, R; Hughes, B; Loecke, D; Mileshkin, L; Mitchell, P; Pirzkall, A; Townley, P; Wood, K | 1 |
| Brown, RK; Cease, KB; Gross, M; Kong, FM; Schipper, M; Stanton, P; ten Haken, RK; Yu, J; Yuan, ST; Zhao, L | 1 |
| Avci, E; Cengiz, HH; Cengiz, M; Cetin, E; Demirci, NY; Eroglu, FN; Tatci, E; Tunc, M; Ulger, S; Yilmaz, U | 1 |
| Beriwal, S; Burton, SA; Christie, NA; Clump, DA; Heron, DE; Horne, ZD; Landreneau, RJ; Luketich, JD; Quinn, AE; Schuchert, MJ; Shah, S; Vargo, JA | 1 |
| Couturier, O; Fosse, P; Hachemi, M; Hureaux, J; Lacœuille, F; Urban, T; Vervueren, L | 1 |
| Hida, Y; Hirano, S; Kaga, K; Matsui, Y; Muto, J; Nakada-Kubota, R; Ohtaka, K; Okamoto, S; Tamaki, N | 1 |
| Ball, DL; Binns, DS; Brennan, S; Campeau, MP; Fisher, RJ; Hicks, RJ; Lin, MY; MacManus, M; Solomon, B; Wu, M | 1 |
| Ando, M; Asami, K; Atagi, S; Ishii, M; Kanazu, M; Kawaguchi, T; Kubo, A; Kusunoki, Y; Maruyama, K; Matsuda, Y; Minomo, S; Ogawa, Y; Takada, M; Uehira, K | 1 |
| Cheng, MH; Duan, XB; Fan, W; Xie, LJ; Xu, ZQ | 1 |
| Bardet, S; Brenot-Rossi, I; Dubray, B; Edet-Sanson, A; Faure, G; Gomez, P; Houzard, C; Jalali, K; Lerouge, D; Mahé, MA; Ménard, JF; Meyer, ME; Mezzani-Saillard, S; Modzelewski, R; Mornex, F; Olivier, P; Rousseau, C; Salem, N; Thureau, S; Vera, P | 1 |
| Aldrich, MC; Andrade, GM; Ballman, KV; Cerfolio, RJ; Chen, CL; D'Amico, TA; Decker, PA; Deppen, SA; Grogan, EL; Harpole, DH; Jones, DR; Keenan, RJ; Meyers, BF; Putnam, JB; Shrager, JB; Verdial, FC | 1 |
| Gordon, LL; Greer, TJ; Koch, NC; Pastis, NJ; Sharma, AK; Silvestri, GA; Tanner, NT; Wahlquist, AE | 1 |
| Burke, L; Henry, MT; Hinchion, J; Kennedy, MP; Maher, MM; McCarthy, J; McCarthy, L; McSweeney, S; Moloney, F; O'Regan, K; Ryan, D | 1 |
| Bansal, P; Behera, D; Gupta, A; Gupta, N; Maturu, VN; Rai Mittal, B; Singh, N | 1 |
| Fujino, H; Kajiura, K; Kawakami, Y; Kondo, K; Kubo, H; Mokhtar, M; Nakagawa, Y; Ohtani, T; Otsuka, H; Sakiyama, S; Takizawa, H; Tangoku, A; Yoshida, M | 1 |
| Chakraborty, PS; Dhull, VS; Karunanithi, S; Kumar, R; Nadarajah, J; Salunkhe, NR | 1 |
| De Ruysscher, D; Doll, C; Duncker-Rohr, V; Eriksen, JG; Grosu, AL; MacManus, M; Mix, M; Nestle, U; Oyen, W; Rücker, G; Vogel, W; Weber, W | 1 |
| Ansari, S; Castillo, E; Castillo, R; Castillo, S; Guerrero, T; Hobbs, B; Li, M; Meshkov, D; Olanrewaju, A; Pham, N | 1 |
| Endo, M; Kaira, K; Kenmotsu, H; Murakami, H; Naito, T; Ono, A; Takahashi, T; Yamamoto, N | 1 |
| Drescher, R; Freesmeyer, M; Winkens, T | 1 |
| Chan, WW; Choy, TS; Ho, PP; Khong, PL; Kwong, DL; Lam, KO; Lee, EY; Lee, VH; Leung, DK; Leung, TW | 1 |
| Cho, J; Choi, NC; Sharp, GC; Shusharina, N | 1 |
| Hyun, IY; Ryu, JS | 1 |
| Duan, F; Machtay, M; Siegel, BA; Snyder, BS | 1 |
| Berman, AT; Ellenberg, SS; Simone, CB | 1 |
| Buvat, I; Chouahnia, K; Cyrta, J; Eder, V; Martinod, E; Morère, JF; Orlhac, F; Pouliquen, C; Soussan, M | 1 |
| Aboagye, EO; Faber, C; Griffiths, J; Heinzmann, K; Hermann, S; Honess, DJ; Jacobs, AH; Kopka, K; Kuhlmann, MT; Müller-Tidow, C; Schäfers, M; Schelhaas, S; Schneider, R; Schober, O; Smith, DM; Viel, T; Wachsmuth, L; Wagner, S | 1 |
| Chen, CY; Hsiao, YC; Hsieh, BT; Huang, WS; Ooi, H | 2 |
| Ahn, SJ; Ban, HJ; Bom, HS; Chung, WK; Jeong, JU; Kim, KS; Kim, YC; Kwon, SY; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Li, F; Li, L; Li, Y; Su, M; Tian, R | 1 |
| Deng, L; Li, C; Lu, Y; Na, F; Wang, J; Xue, J | 1 |
| Aukema, TS; Burgers, SA; Klomp, HM; Rijna, H; Schaake, EE; Valdés Olmos, RA; van Gool, MH; van Pel, R; van Tinteren, H | 1 |
| Berstad, AE; Bugge, AS; Johnsrud, K; Kongerud, J; Lund, MB; Naalsund, A | 1 |
| Ball, DL; Binns, D; Callahan, J; Collins, M; Everitt, SJ; Herschtal, A; Hicks, RJ; Kron, T; MacManus, M; Plumridge, N; Schneider, M | 1 |
| Aukema, TS; Burgers, SA; Codrington, HE; Klomp, HM; Rijna, H; Schaake, EE; Teertstra, HJ; Valdés Olmos, RA; van Gool, MH; van Pel, R; van Tinteren, H | 1 |
| Bahce, I; Boellaard, R; Dahele, M; Dickhoff, C; Hartemink, KJ; Hoekstra, OS; Smit, EF; Thunnissen, E; Vos, CG | 1 |
| Ball, DL; Chabrot, M; Everitt, SJ; Hicks, RJ; Leimgruber, A; MacManus, M; Möller, A; Solomon, B | 1 |
| Li, S; Lv, C; Wang, X; Yan, S; Yang, Y; Yu, J; Zhao, B | 1 |
| Ezzouhri, S; Fleury, V; Hatt, M; Ingrand, P; Lamour, C; Le Rest, CC; Perdrisot, R; Tixier, F; Valla, C; Visvikis, D | 1 |
| Deng, H; Hu, S; Jia, Z; Shen, G | 1 |
| Bucchi, L; Burgio, MA; Crociani, L; Gavelli, G; Genestreti, G; Gurioli, C; Matteucci, F; Monti, M; Parisi, E; Piciucchi, S; Poletti, V; Scarpi, E | 1 |
| Abele, J; Allegretto, M; Bedard, E; Hunt, I; Maquire, C; Patel, A; Perry, T | 1 |
| Freesmeyer, M; Reissig, A; Tauhardt, E; Winkens, T | 1 |
| Ahn, BC; Hong, CM; Jeong, SY; Kim, DH; Lee, J; Lee, SW; Song, BI | 1 |
| Caicedo, C; Garcia-Velloso, MJ; Gurpide, A; Labiano, T; Lopez-Picazo, JM; Lozano, MD; Perez Gracia, JL; Richter Echevarria, JA; Vigil Diaz, C; Zulueta, J; Zulueta, JJ | 1 |
| Akgun, M; Araz, O; Calik, M; Daloglu, F; Demirci, E; Durur-Subasi, I; Karaman, A; Orsal, E; Subasi, M; Ucar, EY | 1 |
| Gotoh, M; Higuchi, M; Muto, S; Ohsugi, J; Okabe, N; Sakuma, H; Suzuki, H; Teranishi, Y; Yonechi, A | 1 |
| Barnes, A; Bomanji, JB; Fraioli, F; Groves, AM; Janes, SM; Kayani, I; Menezes, L; O'Meara, C; Punwani, S; Screaton, NJ; Syed, R; Win, T; Zaccagna, F | 1 |
| Duan, YL; Guo, YL; Li, FX; Li, JB; Shang, DP; Sun, XR; Wang, W; Zhang, YJ | 1 |
| Bazhenova, L; Bethel, K; Carlsson, A; Gambhir, SS; Hoh, CK; Horng, G; Iagaru, AH; Jamali, M; Keu, KV; Kolatkar, A; Kuhn, P; Kuschner, W; Loo, BW; Luttgen, MS; Nair, VS; Nieva, J; Shrager, JB; Vasanawala, M | 1 |
| Allgäuer, M; Andratschke, N; Appold, S; Dieckmann, U; Ernst, I; Ganswindt, U; Grosu, AL; Guckenberger, M; Holy, R; Molls, M; Nestle, U; Nevinny-Stickel, M; Schanne, DH; Semrau, S; Sterzing, F; Wittig, A | 1 |
| Hiraoka, M; Iizuka, Y; Matsuo, Y; Mizowaki, T; Nakamoto, Y; Togashi, K; Ueki, N; Umeoka, S | 1 |
| Di Perri, D; Geets, X; Lee, J; Sterpin, E; Wanet, M | 1 |
| Cheon, GJ; Chung, JK; Im, HJ; Kang, KW; Kim, EE; Kim, IJ; Kim, SJ; Lee, DS; Pak, K | 1 |
| Créhange, G; Feutray, S; Humbert, O; Maingon, P; Martin, E; Peignaux-Casasnovas, K; Truc, G; Vulquin, N | 1 |
| Das, M; Fontanarosa, D; Spijkerman, J; Van Elmpt, W | 1 |
| Fan, M; Fu, Z; Gong, H; Huang, W; Li, B; Liu, B; Zhang, Z; Zhou, T | 1 |
| Frechen, S; Fuhr, U; Kahraman, D; Kobe, C; Nogova, L; Scheffler, M; Suleiman, AA; Wolf, J; Zander, T | 1 |
| Choi, WH; Chung, SK; Kim, YK; Lee, KY; Park, HL; Wang, YP; Yoo, IeR | 1 |
| García Vicente, AM; Honguero Martínez, AF; Jiménez Londoño, GA; León Atance, P; Soriano Castrejón, AM; Udias, JM; van Gómez López, O | 2 |
| Burger, IA; Dinkelborg, L; Friebe, M; Graham, K; Haerle, SK; Hany, TF; Horn-Tutic, M; Kowal, K; Luurtsema, G; Maas, B; Pruim, J; Schaefer, NG; Schibli, R; Stephens, A; von Schulthess, GK; Wiegers, J; Zitzmann-Kolbe, S | 1 |
| Bal, C; Gupta, RK; Kumar, K; Kumar, R; Singh, H | 1 |
| De Ruysscher, D; Eriksson, J; Even, AJ; Hoebers, FJ; Houben, RM; Lambin, P; Mottaghy, FM; Ollers, MC; Reymen, B; Troost, EG; van Elmpt, W; Windhorst, AD; Zegers, CM | 1 |
| Acksteiner, C; Steinke, K | 1 |
| Czyżewski, D; Gabryś, J; Kuś, E | 1 |
| Knudtsen, IS; Malinen, E; Ollers, M; van Elmpt, W | 1 |
| Achenbach, HJ; Amthauer, H; Apostolova, I; Buchert, R; Furth, C; Hofheinz, F; Lougovski, A; Riedel, S; Rogasch, J; Schramm, G; Schreiber, J; Steffen, IG; Wertzel, H | 1 |
| Bussink, J; de Geus-Oei, LF; Usmanij, EA | 1 |
| Buvat, I; Doyeux, K; Edet-Sanson, A; Gardin, I; Hapdey, S; Michel, C; Vauclin, S; Vera, P | 1 |
| Fang, Y; Han, Y; Wu, H; Xiao, H; Yuan, M; Zeng, Y; Zhou, Z | 1 |
| Bodner, WR; Garg, MK; Gucalp, R; Guha, C; Keller, SM; Ohri, N; Perez-Soler, R; Piperdi, B | 1 |
| Calcagni, ML; Di Franco, D; Galli, G; Giordano, A; Indovina, L; Leccisotti, L; Rufini, V | 1 |
| Kang, WJ; Kim, BS; Lee, JD | 1 |
| Correa, AM; Erasmus, JJ; Hofstetter, W; Kim, MP; Mehran, R; Rice, DC; Roth, JA; Swisher, SG; Vaporciyan, AA; Walsh, GL | 1 |
| Aerts, HJ; Aristophanous, M; Berbeco, R; Chen, AB; McCall, K; Yip, S | 1 |
| Cho, A; Chung, KY; Kim, DJ; Lee, CY; Lee, JG; Park, SY; Yu, WS | 1 |
| Fan, M; Fu, Z; Huang, W; Li, B; Li, H; Liu, B; Zhang, Z; Zhou, T | 1 |
| Antoine, M; de Figueiredo, BH; Fernandez, P; Hatt, M; Lagarde, P; Lamare, F; Petit, A; Trouette, R | 1 |
| Campion, L; Denis, F; Krhili, S; Muratet, JP; Septans, AL; Yossi, S | 1 |
| Aliyev, A; Asa, S; Atahan, E; Halaç, M; Özhan, M; Sağer, MS; Sönmezoğlu, K; Vatankulu, B; Yilmaz Aksoy, S | 1 |
| Calais, J; Dubray, B; Gardin, I; Modzelewski, R; Thiberville, L; Thureau, S; Vera, P | 1 |
| Buchbender, C; Gomez, B; Grueneien, J; Grueneisen, J; Heusch, P; Köhler, J; Nensa, F; Reis, H; Ruhlmann, V; Schaarschmidt, BM; Umutlu, L | 1 |
| Aoyagi, K; Koyama, H; Matsumoto, S; Ohno, Y; Seki, S; Sugimura, K; Takenaka, D; Yamagata, H; Yoshikawa, T; Yui, M | 1 |
| Appelbaum, DE; Liao, C; Penney, BC; Pu, Y; Simon, CA; Zhang, C | 1 |
| Hugo, G; Saraiya, S; Weiss, E | 1 |
| Choi, NC; Sharp, GC; Shusharina, N | 1 |
| Arveschoug, AK; Hager, H; Harders, SW; Hjorthaug, K; Hoejbjerg, JA; Madsen, HH; Meldgaard, P; Pilegaard, HK; Rasmussen, F; Rasmussen, TR; Rehling, M | 1 |
| Doğan, D; Karahatay, S; Karatas, O; Kavakli, K; Okuyucu, K; Ozaydın, S | 1 |
| Chang, WC; Chen, JH; Cheng, CY; Chu, CM; Gao, HW; Hsu, HH; Hsu, YC; Huang, TW; Ko, KH; Lee, SC | 1 |
| Groen, HJM; Klinkenberg, TJ; van den Berg, LL; Widder, J | 1 |
| Carvalho, S; Dasu, A; Lambin, P; Lazzeroni, M; Toma-Dasu, I; Uhrdin, J; van Elmpt, W | 1 |
| Akosman, C; Altunok, EC; Eren, OO; Ordu, C; Oyan, B; Selcuk, NA; Toklu, T | 1 |
| Duan, XY; Guo, YM; Li, M; Li, Y; Wang, W | 1 |
| Fernandez, P; Lamare, F; Merlin, T; Visvikis, D | 1 |
| Auffermann, WF; Bechara, R; Behera, M; Chen, Z; Deng, X; Force, SD; Fu, H; Fu, RW; Gal, AA; Harvey, RD; Khuri, FR; Kim, S; Mendel, J; Miller, DL; Owonikoko, TK; Pickens, A; Ramalingam, SS; Rogatko, A; Rossi, MR; Saba, NF; Sica, GL; Sun, SY; Tighiouart, M; Torres, WE | 1 |
| Fulham, MJ; Gnaneswaran, S; Tandy, B | 1 |
| Abe, M; Cong, Y; Kato, Y; Nomori, H; Sugimura, H | 1 |
| Alavi, A; Bradley, JD; DeNittis, A; Duan, F; Gorelick, JJ; Johnson, DW; Machtay, M; Ohri, N; Siegel, BA; Snyder, BS; Werner-Wasik, M | 1 |
| Dong, X; Li, W; Sun, X; Wan, H; Wu, P; Xing, L; Yu, J | 1 |
| Duan, X; Li, J; Li, XF; Ma, Y; Postel, GC; Wang, F; Wang, X; Yin, X; Zhang, G; Zheng, H | 1 |
| Ding, G; Fu, Z; Huang, W; Kong, L; Li, M; Yang, G; Yu, J; Zhang, Y; Zhao, F | 1 |
| Aygün, MS; Bakdik, S; Bekci, TT; Burnik, C; Çayci, M; Düzgün, N; Esme, H; Kurtipek, E; Terzi, Y; Unlü, Y | 1 |
| Duan, Y; Fan, T; Guo, Y; Li, J; Shang, D; Shao, Q; Sun, X; Wang, W; Xu, M; Zhang, Y | 1 |
| Everitt, S; Hicks, RJ; MacManus, M | 1 |
| Chen, M; Li, Y; Shao, T; Yu, L | 1 |
| Herndon, JE; Howard, BA; Kwon, W; Patz, EF | 2 |
| Antoch, G; Buchbender, C; Gomez, B; Grueneisen, J; Heusch, P; Hild, F; Köhler, J; Quick, HH; Reis, H; Rubbert, C; Ruhlmann, V; Schaarschmidt, B; Wetter, A | 1 |
| Dong, M; Liu, K; Ma, S; Wang, Y; Yao, Y; Zhou, J | 1 |
| Bassett, P; Chicklore, S; Chua, S; Cook, GJ; Goh, V; Loi, HY; O'Brien, ME; Punwani, R; Sharma, B; Siddique, M | 1 |
| Andratschke, N; Bundschuh, RA; Essler, M; Mayer, B; Papp, L; Pyka, T; Specht, HM; Zsótér, N | 1 |
| Hoshikawa, M; Kimura, H; Kurimoto, N; Marushima, H; Nakamura, H; Saji, H; Tagaya, R; Takagi, M | 1 |
| Aberle, DR; Gatsonis, CA; Govindan, R; Halvorsen, RA; Hanna, LG; Karp, JS; Mozley, PD; Shields, AF; Siegel, BA; Subramaniam, RM; Torigian, DA; Weber, WA; Yu, JQ | 1 |
| Fu, Z; Hu, M; Li, C; Liu, J; Lu, J; Meng, X; Shi, X; Sun, X; Xing, L; Yu, J | 1 |
| Bernstine, H; Domachevsky, L; Galili, R; Groshar, D; Saute, M | 1 |
| Bilfinger, T; Franceschi, D; LoGiurato, B; Matthews, R; Moore, W; Relan, N; Safaie, E | 1 |
| Bussink, J; de Geus-Oei, LF; Oyen, WJ; Usmanij, EA | 1 |
| Ishino, S; Miyake, H; Mori, I; Vincent, P | 1 |
| Abe, K; Ishikawa, Y; Jingu, K; Kadoya, N; Kaneta, T; Koto, M; Kubozono, M; Matsushita, H; Shirata, Y; Sugawara, T; Takeda, K; Umezawa, R; Yamamoto, T | 1 |
| Steinke, K; Thomas, PA; Whitley, JM; Zaheer, SN | 1 |
| Torigian, DA; Vilstrup, MH | 1 |
| Din, SU; Downey, R; Foster, A; Kohutek, ZA; Rimner, A; Rosenzweig, KE; Weber, WA; Wu, AJ; Yorke, ED; Zhang, Z | 1 |
| Alama, A; Barletta, G; Biello, F; Boccardo, S; Bottoni, G; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Sambuceti, G; Truini, A; Vanni, I | 1 |
| Kinahan, PE; Linden, HM; Mankoff, DA | 1 |
| Chen, S; Fu, YL; Hu, B; Li, H; Yang, MF; Zhang, WQ | 1 |
| Cho, DG; Jeong, S; Kim, HK; Kim, SH; Kwak, YK; Lee, GJ; Lee, JH; Park, YH; Yoon, SC; Yu, M | 1 |
| Ahn, BC; Hong, CM; Jeong, SY; Jung, JH; Kim, CY; Kim, DH; Lee, J; Lee, SW; Oh, JR; Son, SH | 1 |
| Hofheinz, F; van den Hoff, J | 1 |
| Guckenberger, M | 1 |
| Ahsanuddin, S; Ashamalla, H; Foster, A; Mattes, MD; Moshchinsky, AB; Rimner, A; Rizk, NP; Weber, WA; Wu, AJ | 1 |
| Court, LE; Fave, X; Fried, DV; Ibbott, G; Liao, Z; Mawlawi, O; Zhang, L; Zhou, S | 2 |
| Beer, AJ; Ganter, C; Herrmann, K; Holzapfel, K; Lorenzen, S; Metz, S; Nekolla, SG; Rummeny, EJ; Schwaiger, M; van Marwick, S; Wester, HJ | 1 |
| Chung, DH; Chung, JK; Heo, DS; Jeon, YK; Kang, KW; Keam, B; Kim, DW; Kim, TM; Lee, SH; Lee, SJ; Paeng, JC | 1 |
| Marquez-Medina, D; Martin-Marco, A; Popat, S | 1 |
| Aide, N; Binns, D; Bourhis, D; Callahan, J; Desmonts, C; Hicks, RJ; Hofman, MS; Le Roux, PY; Quak, E; Robin, P; Salaun, PY | 1 |
| Kassai, Y; Koyama, H; Matsumoto, S; Ohno, Y; Sugimura, K; Takenaka, D; Yoshikawa, T; Yui, M | 1 |
| Bengtsson, T; Binns, DS; de Crespigny, AJ; Hicks, RJ; McCarthy, TJ; Sanabria-Bohorquez, SM | 1 |
| Gatsonis, C; Siegel, B; Weber, WA | 1 |
| Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K; Yukawa, T | 1 |
| Hong, SH; Jang, HS; Kang, JH; Kim, SJ; Kim, YK; Kim, YS; Lee, DS; Lee, KY; Na, SJ; Park, KR; Yoo, IR | 1 |
| Bosari, S; Castellani, M; Del Gobbo, A; Ferrero, S; Franco, R; Gaudioso, G; Nosotti, M; Palleschi, A; Pellegrinelli, A; Vaira, V; Zito Marino, F | 1 |
| Duncker-Rohr, V; Eschmann, SM; Essler, M; Grosu, AL; Holl, G; König, J; Leifert, A; Miederer, M; Mix, M; Nestle, U; Plotkin, M; Puskas, C; Rischke, HC; Rühl, F; Schimek-Jasch, T; Tosch, M; Vach, W | 1 |
| Ahn, BC; Jeong, SY; Jung, JH; Kim, CY; Kim, DH; Lee, J; Lee, SW; Son, SH | 1 |
| Horiike, A; Inubushi, M; Koizumi, M; Nishio, M; Ohyanagi, F; Saga, T; Tanimoto, K; Yanagitani, N; Yoshikawa, K; Zhang, MR | 1 |
| Ahn, HK; Ahn, MJ; Ahn, YC; Choi, JY; Hyun, SH; Kim, J; Shim, YM | 1 |
| Damhuis, RA; Derks, JL; Dingemans, AM; Hendriks, LE; Hochstenbag, MM; Houben, RM; Postmus, PE; Smit, EF; Troost, EG | 1 |
| Das, M; Dingemans, AC; Even, AJG; Lambin, P; Mottaghy, FM; Oellers, M; Reymen, B; Troost, EGC; van Elmpt, W; Wildberger, JE; Zegers, CML | 1 |
| Ito, R; Ito, S; Iwano, S; Kato, K; Kishimoto, M; Naganawa, S | 1 |
| Da, J; Di, J; Guo, Y; Liang, C; Liu, D; Liu, J; Qiang, G; Shi, B; Xu, R; Xu, Y; Yan, J | 1 |
| Bae, SK; Jung, SJ; Kim, CK; Lee, SM | 1 |
| Arslan, N; Aydin, E; Dadali, Y; Gokcek, A; Okuyucu, K; Ozmen, O; Tatci, E; Yilmaz, U | 1 |
| Choi, WH; Han, EJ; Kim, SH; Park, JC; Park, SY; Yang, YJ | 1 |
| Furukawa, T; Kushitani, K; Mimae, T; Miyata, Y; Okada, M; Takeshima, Y; Tsutani, Y | 1 |
| Girard, P | 1 |
| Altorki, NK; Ameye, L; Berghmans, T; Borst, GR; de Jong, WK; Eschmann, S; Flamen, P; Garcia, C; Govindan, R; Higashi, K; Komaki, R; Lafitte, JJ; Meert, AP; Paesmans, M; Patz, EF; Rami-Porta, R; Sculier, JP; Van Baardwijk, A; Vansteenkiste, J; Wong, CY | 1 |
| Anouan, KJ; Edet-Sanson, A; Gardin, I; Hapdey, S; Lelandais, B; Ruan, S; Vera, P | 1 |
| Choi, WH; Kim, TJ; Kim, YK; Lee, KY; O, JH; Yoo, IeR | 1 |
| Chen, K; Hai, W; Huang, Q; Peng, J; Xu, Y; Yang, Z; Zan, Y; Zheng, X | 1 |
| Chen, P; Hou, P; Jiang, Y; Liu, H; Pu, Y; Wroblewski, K; Zhang, CP | 1 |
| Akdemir, ÜÖ; Özkaya, S; Öztürk, C; Yıldırım, F; Yurdakul, AS | 1 |
| Fleckenstein, J; Kremp, K; Kremp, S; Palm, J; Rübe, C | 1 |
| Bussink, J; de Geus-Oei, LF; Grootjans, W; Troost, EG; van der Heijden, EH; Visser, EP; Wijsman, R | 1 |
| Bradley, JD; Duan, F; Machtay, M; Markovina, S; Siegel, BA; Snyder, BS | 1 |
| Corbusier, F; Gevenois, PA; Goldman, S; Keyzer, C; Kyratzi, E; Sokolow, Y | 1 |
| Brink, C; Hansen, O; Pan, Y; Petersen, H; Schytte, T; Wu, YL | 1 |
| Behera, D; Garg, K; Jaiswal, A; Kumar, R; Mathur, S; Mohan, A; Mohanti, BK; Pathy, S; Raina, V; Roy, S; Taywade, S; Thulkar, S | 1 |
| Achenbach, HJ; Amthauer, H; Apostolova, I; Furth, C; Kalinski, T; Riedel, S; Rogasch, JM; Schreiber, J; Schultz, M; Steffen, IG; Steinkrüger, FL; Wertzel, H | 1 |
| Higashi, M; Jinguji, M; Nakabeppu, Y; Nakajo, M; Nakamura, Y; Nakayama, H; Sato, M; Yoshiura, T | 1 |
| Chang, S; Kim, SJ | 1 |
| Bar-Shalom, R; Dan, LF; Guralnik, L; Kagna, O; Kremer, R; Nir, RR; Peysakhovich, Y | 1 |
| Chotipanich, C; Iamsa-art, C; Kunawudhi, A; Phadungrerk, R; Promteangtrong, C | 1 |
| Buvat, I; Chouahnia, K; Martinod, E; Orlhac, F; Soussan, M | 1 |
| Fledelius, J; Frøkiaer, J; Hjorthaug, K; Khalil, AA | 1 |
| Ahn, HK; Choi, JY; Hyun, SH; Kim, BT; Kim, H; Kim, J; Kwon, OJ; Lee, KH; Zo, JI | 1 |
| Lee, SJ; Park, KJ; Park, SY; Yoon, JK | 1 |
| Asamura, H; Fujii, H; Hayashi, Y; Kamiyama, I; Kinoshita, T; Ohtsuka, T | 1 |
| Becker, N; Bezjak, A; Bissonnette, JP; Clarke, K; Ford, V; Higgins, J; Le, LW; Marshall, A; McCloskey, P; Mehmood, Q; Sun, A; Vines, DC; Yap, M | 1 |
| Kang, F; Li, G; Li, X; Liu, C; Tian, F; Wang, J; Wang, S; Wang, Z; Yang, W; Zhang, M; Zhao, M | 1 |
| Azzoli, CG; Chaft, JE; Downey, R; Dunphy, M; Ginsberg, MS; Hellmann, M; Kris, MG; Naidoo, J; Rusch, V; Travis, WD; Woo, K | 1 |
| Dong, M; Li, W; Liu, J; Sun, X; Xing, L; Yu, J | 1 |
| Ahmad, R; Demaerel, P; Deroose, CM; Gheysens, O; Goffin, KE; Ooms, D; Van Laere, K; Van Paesschen, W; Vansteenkiste, J | 1 |
| Bauersachs, J; Bengel, FM; Derlin, T; Jonigk, D | 1 |
| Ciunci, CA; Epstein, AJ; Paulson, EC; Vachani, A; Veenstra, CM; Zafar, HM | 1 |
| Alaerts, H; Beels, L; D'hulst, L; Gheysens, O; Maes, A; Nicolaij, D; Van de Wiele, C | 1 |
| Igai, H; Kaira, K; Kakegawa, S; Kamiyoshihara, M; Nagashima, T; Nakazawa, S; Nishiyama, M; Obayashi, K; Ohtaki, Y; Shimizu, K; Takeyoshi, I | 1 |
| Bentzen, SM; Fischer, BM; Klausen, TL; Langer, SW; Lonsdale, MN; Nygård, L; Persson, GF; Vogelius, IR | 1 |
| Burger, IA; Casanova, R; Curioni, A; Hillinger, S; Huellner, MW; Husmann, L; Schmidtlein, CR; Soltermann, A; Steiger, S; Stolzmann, P | 1 |
| Cho, A; Lee, JW; Lee, SM; Yun, M | 1 |
| Bernard, C; Coucke, P; Duysinx, B; Hatt, M; Hustinx, R; Jansen, N; Janvary, ZL; Jodogne, S; Lovinfosse, P; Visvikis, D | 1 |
| Choi, JY; Han, J; Heo, JH; Jang, SJ; Kim, BT; Kim, J; Kim, K; Lee, JY; Shim, YM | 1 |
| Cheon, GJ; Goo, JM; Kim, YT; Lee, SM; Paeng, JC; Park, CM; Park, YS; Yoon, SH | 1 |
| Bauer, TT; Förster, GJ; Kaiser, D; Kollmeier, J; Pfannschmidt, J; Tönnies, M; Tönnies, S; Wernecke, KD | 1 |
| Belderbos, JS; Chen, C; Sonke, JJ; van den Heuvel, MM; van Diessen, JN | 1 |
| Chan, I; Etemad-Rezai, R; Johnson, C; Landis, M; Louie, AV; Mattonen, SA; Palma, DA; Rodrigues, G; Senan, S; Ward, AD; Yeung, TP | 1 |
| Alavi, A; Bradley, JD; DeNittis, A; Duan, F; El Naqa, I; Johnson, DW; Machtay, M; Ohri, N; Siegel, BA; Snyder, BS; Wei, B; Werner-Wasik, M | 1 |
| Belcher, E; Black, E; Bradley, KM; Gleeson, FV; McGowan, DR; Moore, A; Sykes, A; Teoh, EJ | 1 |
| Abid, A; Biyi, A; Elouazzani, H; Oukabli, M; Raoufi, M; Rhorfi, IA | 1 |
| Boellaard, R; de Langen, AJ; Frings, V; Hoekstra, OS; Kramer, GM; Mulder, ER; Nissen, IA; Smit, EF; van Velden, FH | 1 |
| Aukema, TS; Bard, MP; Klomp, HM; Konings, R; Rijna, H; Sikorska, K; Titulaer, BM; Valdés Olmos, RA; van Gool, MH; Zwijnenburg, A | 1 |
| Cheze-Le Rest, C; de Geus-Oei, LF; Disselhorst, JA; Hatt, M; Oyen, WJ; Tixier, F; Visser, EP; Visvikis, D; Vriens, D | 1 |
| Fledelius, J; Meldgaard, P; Sorensen, BS; Winther-Larsen, A | 1 |
| Cho, A; Choi, BW; Hong, SR; Hong, YJ; Hur, J; Im, DJ; Kim, JH; Kim, YJ; Lee, HJ; Lee, JS; Moon, YW; Shim, HS; Suh, YJ | 1 |
| Matsunaga, N; Shigemoto, Y; Suga, K | 1 |
| Aldelaijan, S; De Blois, F; Devic, S; Faria, S; Lehnert, S; Mohammed, H; Seuntjens, J; Tomic, N | 1 |
| Barbolosi, D; Bardia, F; Baret, A; Barlesi, F; Ciccolini, J; Muracciole, X; Padovani, L; Taieb, D; Teissonnier, L | 1 |
| Aguilera, T; Diehn, M; Gudur, M; Li, R; Loo, BW; Rubin, DL; Shultz, D; Wu, J | 1 |
| Burnette, BL; Du, L; Huang, D; Jamshidi, N; Korn, RL; Kuo, MD; Yamamoto, S | 1 |
| Boellaard, R; de Langen, AJ; Frings, V; Hoekstra, OS; Hoetjes, N; Kramer, GM; Smit, EF | 1 |
| Bussink, J; de Geus-Oei, LF; Grootjans, W; Hatt, M; Oyen, WJ; Usmanij, EA; van der Heijden, EH; Visser, EP; Visvikis, D | 1 |
| Cheng, Y; Gong, J; Guo, B; Huang, L; Ling, X; Shang, J; Tang, Y; Xiao, Z; Xu, H; Zhang, L | 1 |
| Bellendorf, A; Bockisch, A; Cordes, S; Darwiche, K; Eberhardt, W; Friedel, G; Gauler, T; Guberina, M; Heinzelmann, F; Jöckel, KH; Pöttgen, C; Schuler, MH; Schwenzer, N; Stamatis, G; Stuschke, M; Welter, S | 1 |
| Allavena, P; Alloisio, M; Castino, GF; Chiti, A; Cortese, N; Grizzi, F; Lopci, E; Marchesi, F; Marchetti, S; Olivari, L; Pistillo, D; Qehajaj, D; Rahal, D; Roncalli, M; Santoro, A; Toschi, L | 1 |
| Arai, Y; Gobara, H; Inaba, Y; Kanazawa, S; Kobayashi, T; Kodama, Y; Kurihara, H; Okumura, Y; Shinya, T; Sone, M; Watanabe, H; Yamagami, T; Yamakado, K | 1 |
| De Leyn, P; De Ruysscher, D; De Wever, W; Decaluwé, H; Deroose, CM; Dingemans, AM; Dooms, C; Martinussen, H; Nackaerts, K; Peeters, ST; Van Baardwijk, A; Vansteenkiste, J; Yserbyt, J | 1 |
| Filice, A; Franceschetto, A; Lococo, F; Paci, M; Rapicetta, C; Ricchetti, T; Rossi, G; Stefani, A; Treglia, G | 1 |
| Chang, S; Kim, SJ; Koo, PJ; Pak, K | 1 |
| Dong, X; Huang, Y; Li, W; Maxim, PG; Sun, L; Sun, X; Wan, H; Xing, L; Yu, J; Zhao, X | 1 |
| Cease, K; Chen, G; Chopra, V; Gross, M; Raghunathan, R; Ramnath, N; Troeschel, S; Zhao, L | 1 |
| Achenbach, HJ; Amthauer, H; Apostolova, I; Furth, C; Genseke, P; Kalinski, T; Riedel, S; Rogasch, JM; Schreiber, J; Schultz, M; Steffen, IG; Steinkrüger, FL; Wertzel, H | 1 |
| Asakura, K; Kaseda, K; Kazama, A; Ozawa, Y | 1 |
| Achenbach, HJ; Amthauer, H; Apostolova, I; Buchert, R; Derlin, T; Ego, K; Furth, C; Hofheinz, F; Kalinski, T; Riedel, S; Schreiber, J; Schultz, M; Steffen, IG; Wertzel, H | 1 |
| Chen, LH; Chen, M; Dai, YM; Guan, J; Li, L; Li, QY; Li, XZ; Liu, LY; Wang, S; Wu, HB; Xiao, NJ; Yang, M; Zhang, Y; Zhang, YW; Zhou, WL | 1 |
| Harada, M; Hayashi, T; Hirata, K; Ichimura, W; Kitao, T; Kondo, K; Sekizawa, M; Shima, K; Takei, T; Tamaki, N | 1 |
| Kang, DY; Lee, JW; Lee, SM; Lee, SY; Na, JO | 1 |
| Djuran, B; Erak, MDj; Mitrić, M; Tesanović, D; Vasiljev, S | 1 |
| Bai, L; Guo, Y; Li, X; Ning, N; Niu, G; Yang, J; Zhang, W | 1 |
| Descallar, J; Ho Shon, I; Koh, ES; Pramana, A; Vinod, SK; Wang, D | 1 |
| Aboagye, EO; Beckley, A; Carroll, L; Kaliszczak, MA; Nguyen, QD; Pisaneschi, F; Slade, RL; Smith, G | 1 |
| Kim, ES; Lee, JW; Lee, SM; Seo, KH | 1 |
| Fukuhara, M; Hasegawa, T; Higuchi, M; Inoue, T; Owada, Y; Suzuki, H; Watanabe, Y; Yamaura, T | 1 |
| Hida, T; Horio, Y; Inaba, Y; Iwata, H; Kuroda, H; Sakao, Y; Shimizu, J; Tanaka, H; Yatabe, Y; Yoshida, T | 1 |
| Boellaard, R; de Jong, EE; Dingemans, AC; Groen, HJ; Hoekstra, OS; Lambin, P; Leijenaar, RT; Smit, EF; Troost, EG; van der Noort, V; van Elmpt, W | 1 |
| Dejust, S; Fabre, G; Morland, D; Papathanassiou, D; Prevost, A | 1 |
| Becker, N; Bezjak, A; Bissonnette, JP; Clarke, K; Higgins, J; Le, LW; Marshall, A; Sun, A; Vines, DC; Yap, ML | 1 |
| Bazan, JG; Duan, F; Graves, EE; Horng, D; Loo, BW; Machtay, M; Siegel, BA; Snyder, BS | 1 |
| Briere, TM; Court, LE; Gomez, DR; Liao, Z; Martel, MK; Mohan, R; Niedzielski, JS; Stingo, F; Yang, J | 1 |
| Bertolini, G; Moresco, RM; Moro, M; Pastorino, U; Prisinzano, G; Raccagni, I; Roz, L; Sozzi, G; Tortoreto, M; Valtorta, S | 1 |
| Alstrup, AK; Bender, D; Borghammer, P; Breining, P; Dagnæs-Hansen, F; Gormsen, LC; Jakobsen, S; Jørgensen, NP; Knudsen, K; Madsen, LB; Mortensen, FV; Petersen, MS; Schleimann, MH | 1 |
| Chen, D; Guan, W; Han, Y; Shi, Z; Zang, Z; Zhou, J | 1 |
| Anile, G; Banna, GL; Calcara, G; Castaing, M; Fraggetta, F; Gieri, S; Ippolito, M; Marletta, F; Nicolosi, M; Patanè, D; Russo, G; Spina, R; Stefano, A; Strano, S; Vigneri, P | 1 |
| Ferguson, MK; Li, F; Liao, C; Liu, H; Penney, BC; Pu, Y; Simon, CA; Wu, T; Zhu, X | 1 |
| Berna, L; Botana, MI; Cases, E; Cordovilla, R; Fernández-Villar, A; Gallego, M; García-Luján, R; Masdeu, MJ; Monsó, E; Montón, C; Serra Fortuny, M; Vigil, L | 1 |
| Hattori, A; Matsunaga, T; Oh, S; Suzuki, K; Takamochi, K | 1 |
| Galeone, C; Lococo, F; Patricelli, G; Rapicetta, C | 1 |
| Calcagni, ML; Castelluccia, A; Mantini, G; Massaccesi, M; Mattoli, MV; Scolozzi, V | 1 |
| Bodner, WR; Cheng, H; Garg, M; Halmos, B; Kalnicki, S; Keller, SM; Ohri, N; Perez-Soler, R | 1 |
| Bailey, ST; Braas, D; Christofk, HR; Czernin, J; Demo, S; Dubinett, SM; Emberley, E; Fishbein, MC; Garon, E; Graeber, T; Gross, M; Jackson, NJ; Janes, J; Krysan, K; Lee, JT; Mackinnon, A; Magyar, C; Momcilovic, M; Pan, A; Parlati, F; Rodriguez, M; Sadeghi, S; Shackelford, DB; Walser, TC; Works, M; Zhang, W | 1 |
| Kurian, EM | 1 |
| Thie, JA | 2 |
| Cho, YS; Hyun, SH; Jeong, E; Kim, BT; Lee, KH; Moon, SH | 1 |
| Koh, YW; Lee, SJ; Park, SY | 1 |
| Jia, Z; Lan, Y; Ren, P; Shen, G; Zhang, K | 1 |
| Deuschl, C; Forsting, M; Gramsch, C; Grueneisen, J; Heusch, P; Mönninghoff, C; Nensa, F; Poeppel, TD; Quick, HH; Sawicki, LM; Schlamann, M; Umutlu, L | 1 |
| Ishikawa, S; Kimura, N; Nishiyama, Y; Ohkawa, M; Sasakawa, Y; Yamamoto, Y | 1 |
| Chung, JK; Jeong, JM; Jung, HW; Kim, DG; Lee, DS; Lee, HY; Lee, MC | 1 |
| Kotani, Y; Koyama, H; Matsumoto, S; Nogami, M; Ohno, Y; Onishi, Y; Sugimura, K; Takenaka, D; Yoshikawa, T | 1 |
| Choi, JY; Chung, MJ; Kim, BT; Kim, H; Kwon, OJ; Lee, KS; Shin, KM; Yi, CA | 1 |
| Law, I; Louring-Andersen, J | 1 |
| Fu, Z; Hu, M; Li, M; Liu, N; Shi, F; Yang, G; Yu, J; Yuan, S; Zhang, P | 1 |
| Hou, M; Li, XN; Liu, J; Liu, YF; Yu, HM; Yu, JM | 1 |
| Hellwig, D; Kirsch, CM; Kremp, S; Nestle, U; Rübe, C; Schaefer, A | 1 |
| Kitamura, H; Nakamura, H; Nishikawa, J; Taguchi, M | 1 |
| Chong, CF | 1 |
| Carrozzi, L; Comin, C; Falaschi, F; Grazzini, M; Innocenti, F; Lopes Pegna, A; Maria Carozzi, F; Mascalchi, M; Paci, E; Picozzi, G; Ronchi, C; Spinelli, C | 1 |
| Akashi, T; Chiba, T; Ito, H; Ito, K; Kubota, K; Mochizuki, M; Morita, T; Morooka, M; Murata, Y; Nomura, T; Shibuya, H | 1 |
| Jordan, CD; Salskov, A; Schmidt, R; Turcotte, E; Vallières, E; Vesselle, H; Wiens, L; Wood, DE | 1 |
| Guo, HB; Hu, M; Liu, LP; Liu, NB; Xu, XQ; Yang, GR; Yu, JM; Zhang, PL | 1 |
| Weder, W | 1 |
| Bar-Shalom, R; Gorenberg, M; Israel, O | 1 |
| Bepler, G; Boulware, D; Eikman, EA; Robinson, L; Sommers, E; Tanvetyanon, T | 1 |
| Hofman, MS; Nunan, T; O'Doherty, MJ; Rankin, SC; Smeeton, NC | 1 |
| Behr, TM; Gratz, S; Höffken, H; Kaiser, W; Kempke, B; Pfestroff, A | 1 |
| Bury, T; Corhay, JL; Duysinx, B; Hustinx, R; Larock, MP; Louis, R; Nguyen, D | 1 |
| Fu, Z; Han, A; Li, K; Sun, X; Xu, X; Yang, G; Yu, J; Zheng, J | 1 |
| De Marinis, F; Miele, E; Pasciuti, G; Rossi, L; Spinelli, GP; Tomao, F; Tomao, S; Zoratto, F; Zullo, A | 1 |
| Baarslag, HJ; de Haas, MJ; de Jong, JA; de Klerk, JM; Oud, K; Quarles van Ufford, HM | 1 |
| Coffey, JP; Hill, JC | 1 |
| Arnold, JF; Flentje, M; Jakob, PM; Kotas, M; Pracht, ED; Pyzalski, RW | 1 |
| Hicks, RJ; Mac Manus, M | 1 |
| Hong, TS; Killoran, JH; Mamede, M; Mamon, HJ | 1 |
| Dua, SG; Pramesh, CS; Purandare, NC; Rajnish, A; Rangarajan, V; Shah, S | 1 |
| Boersma, L; Bootsma, G; De Ruysscher, D; Dingemans, AM; Fatah, SA; Geraedts, W; Grutters, J; Hochstenbag, M; Lambin, P; Oellers, M; Pitz, C; Simons, J; Snoep, G; van Loon, J; Wanders, R | 1 |
| Cheng, NM; Ho, KC; Liu, YC; Wang, CW; Wu, YC; Yen, TC; Yu, CT | 1 |
| Goya, T; Honda, Y; Horio, H; Iyama, K; Kaji, M; Koizumi, K; Nakashima, R; Nomori, H; Sakaguchi, K; Shibata, H; Suzuki, T; Takanami, I; Uno, K | 1 |
| Arena, V; Douroukas, A; Pelosi, E | 1 |
| De Neve, W; De Ruysscher, D; Dehing-Oberije, C; Lambin, P; Lievens, Y; Meersschout, S; Rao, B; Van Beek, K; van der Weide, H; Van Meerbeeck, J; Yu, S | 1 |
| Endo, K; Endou, H; Higuchi, T; Hisada, T; Imai, H; Ishikita, T; Ishizuka, T; Kaira, K; Kanai, Y; Mori, M; Nakajima, T; Oriuchi, N; Shimizu, K; Sunaga, N; Yanagitani, N | 1 |
| Choi, CM; Kim, WS; Oh, YM; Ryu, JS; Shim, TS; Song, JW | 1 |
| Brix, WK; Jones, DR; Kozower, BD; Lau, CL; Smith, PW; Swenson, BR; Taylor, MD; Theodosakis, N; Wick, MR | 1 |
| Bandiera, A; Carretta, A; Casiraghi, M; Ciriaco, P; Libretti, L; Melloni, G; Zannini, P | 1 |
| Larson, SM; Schwartz, LH; Zhao, B | 1 |
| Abolmaali, N; Abramyuk, A; Gillham, C; Herrmann, T; Koch, A; Szluha Lazanyi, K; Tokalov, S; Zöphel, K | 1 |
| Duan, Y; Lu, PO; Wang, WZ; Yu, LJ | 1 |
| Aerts, HJ; Boersma, L; Borger, J; De Ruysscher, D; Dehing, C; Dekker, A; Dingemans, AM; Hochstenbag, M; Houben, A; Lambin, P; Ollers, M; Wanders, R | 1 |
| Hwang, SC; Lee, KB; Park, KJ; Sheen, SS; Sun, JS; Yoon, JK; Yoon, SN | 1 |
| Ghesani, N; Maldjian, PD | 1 |
| Chakraborty, PK; Chugani, DC; Jahania, MS; Juhász, C; Khalaf, M; Lu, X; Mangner, TJ; Muzik, O; Peng, F; Soubani, AO | 1 |
| Araki, T; Ichikawa, T; Kato, S; Matsumoto, K; Motosugi, U; Nambu, A; Nishikawa, K; Okuwaki, H; Saito, A | 1 |
| Eslamy, HK; Krupitskaya, Y; Kumar, A; Nguyen, DD; Wakelee, HA | 1 |
| Feng, M; Fernando, S; Gross, M; Hayman, JA; Kong, FM; Ten Haken, RK | 1 |
| Abdulkader, I; Gude, F; León, L; Ruibal, A | 1 |
| Fu, Z; Hu, M; Li, M; Liu, N; Ma, L; Pang, Q; Shi, F; Yang, G; Yu, J; Zhou, W | 1 |
| Fujiwara, K; Kanazawa, S; Kawai, H; Matsuo, K; Okumura, Y; Rai, K; Sato, S; Sato, T; Shinya, T; Watanabe, K; Yonei, T | 1 |
| Borbély, K; Fekésházy, A; Lengyel, Z; Magyar, M; Markóczy, Z; Zsiray, M | 1 |
| Aerts, HJ; De Ruysscher, D; Dekker, AL; Houben, R; Lambin, P; Offermann, C; Ollers, MC; Petit, SF; van Loon, JG; Winkens, B | 1 |
| Aerts, HJ; Boersma, L; Bootsma, G; Borger, J; Bosmans, G; De Ruysscher, D; Dekker, AL; Dingemans, AM; Geraedts, W; Houben, R; Lambin, P; Loon, Jv; Oellers, M; Offermann, C; Petit, SF; Pitz, C; Simons, J; van Baardwijk, AA; Wanders, R; Wouters, BG | 1 |
| Carson, KJ; Cosgrove, VP; Hounsell, AR; Jarritt, PH; Young, VA | 1 |
| Erasmus, JJ; Rohren, E; Swisher, SG | 1 |
| Absher, K; Conrad, GR; Lee, J; Sinha, P | 1 |
| Minoshima, S; Yeatman, CF | 1 |
| Allen-Auerbach, M; Weber, WA | 1 |
| Harada, T; Isowa, N; Kawasaki, Y; Maeda, R; Miura, H; Onuma, H; Tokuyasu, H; Touge, H | 1 |
| Bral, S; De Ridder, M; Duchateau, M; Everaert, H; Schallier, D; Storme, G; Tournel, K; Verellen, D | 1 |
| Baek, H; Byun, BH; Cheon, GJ; Choe, du H; Kim, CH; Kim, KM; Koh, JS; Lee, DY; Lee, JC; Lim, SM; Na, II; Ryoo, BY; Yang, SH | 1 |
| Ball, D; Binns, D; Everitt, S; Hicks, RJ; Kron, T; Mac Manus, M; Schneider-Kolsky, M; Walter, T | 1 |
| Koyama, H; Matsumoto, K; Matsumoto, S; Nogami, M; Ohno, Y; Onishi, Y; Sugimura, K; Takenaka, D; Yoshikawa, T | 1 |
| Han, SK; Kim, YW; Min, JW; Shim, YS; Um, SW; Yim, JJ; Yoo, CG | 1 |
| D'Hoore, I; De Leyn, P; Dooms, C; Nackaerts, K; Stroobants, S; Vansteenkiste, J; Wauters, I | 1 |
| de Geus-Oei, LF; Krabbe, PF; Oyen, WJ; Timmer-Bonte, JN; van Laarhoven, HW; Visser, EP; Vriens, D | 1 |
| Chung, JK; Kang, WJ; Kim, BS; Kim, S; Lee, DS; Lee, JW; Lee, MC | 1 |
| Hiyama, A; Kawakami, Y; Matsumoto, T; Matsunaga, N; Okabe, K; Suga, K; Sugi, K; Tanaka, N; Ueda, K | 2 |
| Horikoshi, T; Ito, H; Kasai, T; Kuniyasu, Y; Motoori, K; Takahashi, F; Takiguchi, Y; Uchiyama, K; Yasufuku, K | 1 |
| Fu, Z; Li, X; Ling, CC; Mu, D; Sun, X; Xing, L; Yang, G; Yu, J; Zhang, B | 1 |
| Ardissone, F; Arena, V; Billé, A; Borasio, P; Errico, L; Mancini, M; Pelosi, E; Skanjeti, A | 1 |
| Ichiguchi, O; Yoshioka, M | 1 |
| Fakiris, AJ; Fletcher, JW; Henderson, MA; Hoopes, DJ; Lin, PF; McGarry, RC; Tann, M; Timmerman, RD; Williams, MD; Yiannoutsos, CT | 1 |
| Han, JY; Kang, KW; Kim, HT; Kim, HY; Kim, SK; Lee, DH; Lee, HY; Lee, JS; Lee, SY; Park, SH | 1 |
| De Ruysscher, D; Dooms, C; Stroobants, S; van Baardwijk, A; van Suylen, RJ; Vansteenkiste, J; Verbeken, E | 1 |
| Carrère, MO; Giammarile, F; Morelle, M; Pommier, P; Remonnay, R | 2 |
| Behzadi, A; Deschamps, C; Lowe, V; Ung, Y | 1 |
| Buck, AK; Hasenkamp, E; Hombach, V; Krüger, S; Merk, T; Mottaghy, FM; Pauls, S; Reske, SN; Schumann, C; Wibmer, T | 1 |
| Diederich, S; Engeser, P; Junker, K; Passlick, B; Pfluger, T; Pottgen, C; Reck, M | 1 |
| Coquia, S; Tulchinsky, M; Wagner, H | 1 |
| Cline, KJ; Darling, GE; Driedger, AA; Evans, WK; Gu, CS; Gulenchyn, KY; Inculet, RI; Levine, MN; Maziak, DE; Miller, JD; Ung, YC | 1 |
| Guo, WH; Jia, P; Zhang, Y | 1 |
| Li, M; Liang, Y; Liu, Y; Wu, N; Zhang, WJ; Zhao, P; Zheng, R | 1 |
| Ikeda, K; Katahira, K; Kobayashi, H; Mori, T; Nomori, H; Ohba, Y; Shibata, H; Shiraishi, S | 1 |
| Aoyama, N; Koyama, H; Matsumoto, K; Matsumoto, S; Nogami, M; Ohno, Y; Onishi, Y; Sugimura, K; Takenaka, D; Yoshikawa, T | 1 |
| Baron, O; Bridji, B; Despins, P; Duveau, D; Mugniot, A; Perigaud, C; Roussel, JC; Sagan, C | 1 |
| Dooms, C; Stroobants, S; Vansteenkiste, J; Verbeken, E | 1 |
| Carson, KJ; Cosgrove, VP; Eakin, RL; Hanna, GG; Hounsell, AR; Jarritt, PH; Lynch, T; McAleese, J; O'Sullivan, JM; Stewart, DP; Young, VA; Zatari, A | 1 |
| Aukema, TS; Baas, P; Belderbos, JS; Burgers, SA; Klomp, HM; Teertstra, HJ; Valdés Olmos, RA; van den Heuvel, MM; Vogel, WV | 1 |
| Feng, R; Ma, L; Meng, X; Yu, JM; Yue, JB; Zhang, HQ | 2 |
| DeCamp, MM; Gangadharan, SP; Kent, MS; Nicotera, SP; Okereke, IC; Shen, C | 1 |
| Choi, JY; Chung, MP; Han, J; Kim, H; Kim, J; Koh, WJ; Kwon, OJ; Lee, KS; Suh, GY; Um, SW | 1 |
| Abe, K; Honda, H; Ito, K; Kawano, D; Maehara, Y; Miura, N; Morodomi, Y; Shoji, F; Takenaka, T; Yano, T | 1 |
| Han, B; Lin, S; Wang, RZ; Wang, YY; Yu, LJ | 1 |
| Cao, YX; Dong, JC; Duan, XH; Guan, YH; Le, JJ; Liu, BJ; Wu, JF; Xu, CQ; Zhao, J; Zuo, CT | 1 |
| Chang, H; Chen, JC; Cheng, YL; Huang, TW; Huang, WS; Lee, SC; Tzao, C | 1 |
| Amdur, RJ; Liu, C; Lu, B; Newlin, HE; Olivier, KR; Shi, W; Yeung, A | 1 |
| Bangard, C; Boellaard, R; Dietlein, M; Dimitrijevic, S; Eschner, W; Giaccone, G; Gross, SH; Hayes, W; Hoekstra, OS; Hoetjes, N; Kobe, C; Lammertsma, AA; Nogová, L; Pellas, T; Schmidt, K; Thomas, RK; Wolf, J; Zander, T | 1 |
| Endo, K; Ishizuka, T; Kaira, K; Kanai, Y; Mori, M; Oriuchi, N; Shimizu, K; Sunaga, N; Tominaga, H; Yanagitani, N | 1 |
| Alavi, A; Cengel, KA; Dubroff, JG; Friedberg, JS | 1 |
| Antoch, G; Bockisch, A; Forsting, M; Hahn, S; Hamami, M; Heusner, T; Peng, Z; Zhan, Y; Zhou, X | 1 |
| Erasmus, JJ | 1 |
| Christodoulou, M; Letovanec, I; Prior, JO; Stupp, R | 1 |
| Gould, MK; Krupitskaya, Y; Nair, VS | 1 |
| Hirata, T; Kitamura, H; Nakamura, H; Nishikawa, J | 1 |
| Ballek, E; Fleckenstein, J; Grgic, A; Hellwig, D; Kirsch, CM; Kremp, S; Nestle, U; Rübe, C; Schaefer-Schuler, A | 1 |
| Agarwal, M; Bajaj, SK; Brahmanday, G; Ravikrishnan, KP; Wong, CY | 1 |
| Bagni, B; Barbieri, F; Casali, C; Cucca, M; Iacuzio, L; Rossi, G; Uliano, M | 1 |
| Boersma, L; Bootsma, G; Brans, B; De Ruysscher, D; Dingemans, AM; Geraedts, W; Grutters, JP; Hochstenbag, M; Lambin, P; Pitz, C; Simons, J; Snoep, G; van Loon, J; Wanders, R | 1 |
| Antoch, G; Bockisch, A; Eberhardt, W; Esser, S; Forsting, M; Gölitz, P; Hamami, M; Heusner, T | 1 |
| Bruna-Muraille, C; Cuif-Job, A; Domange-Testard, A; Jovenin, N; Liehn, JC; Menéroux, B; Papathanassiou, D; Prévost, A | 1 |
| Ak, I; Entok, E; Sivrikoz, MC; Vardareli, E | 1 |
| Cong, CS; Fu, Z; Guo, SF; He, W; Liu, XJ; Yu, JM; Yu, YH; Zhang, Y | 1 |
| Ananth, L; Barnett, PG; Gould, MK; Nair, VS | 1 |
| Beyer, F; Buerke, B; Gerss, J; Heindel, W; Puesken, M; Scheffe, K; Schober, O; Weckesser, M; Wessling, J | 1 |
| Arguis, P; Garcia, S; Gimferrer, JM; Gómez-Caro, A; Lomeña, F; Marrades, R; Reguart, N; Sanchez, M | 1 |
| Abedalthagafi, M; Anderson, ED; Banovac, F; Chang, T; Collins, BT; Collins, SP; Debrito, P; Esposito, G; Gutierrez, CJ; Oermann, EK; Suy, S; Vahdat, S; Yousefi, S; Yu, X | 1 |
| Algara, M; Foro, P; Lacruz, M; Lozano, J; Membrive, I; Quera, J; Reig, A; Rodríguez, N; Sanz, X; Trampal, C | 1 |
| Fu, Z; Tan, GZ; Yang, WF; Yu, JM | 1 |
| Chung, DH; Goo, JM; Jang, BG; Kang, CH; Kang, KW; Kim, YT; Lee, CH; Lee, HJ; Lee, HY; Park, CM | 1 |
| Hasegawa, Y; Higashiyama, M; Hosoki, T; Kanzaki, R; Kodama, K; Maeda, J; Okami, J; Takami, M | 1 |
| Cook, GJ; Llamas Elvira, JM; Ramos-Font, C; Rebollo-Aguirre, AC; Romero Tabares, A; Villegas Portero, R | 1 |
| Nwogu, C | 1 |
| Berghmans, T; Dusart, M; Garcia, C; Hossein-Foucher, C; Lafitte, JJ; Mascaux, C; Meert, AP; Paesmans, M; Roelandts, M; Scherpereel, A; Sculier, JP; Terrones Munoz, V | 1 |
| Csiki, I; Delbeke, D; Diaz, R; Duggan, D; Lu, B; McElmurray, J; Spratt, DE | 1 |
| Han, J; Shim, SS | 1 |
| Fu, Z; Han, A; Mu, D; Sun, X; Yang, W; Yu, J; Zhang, Y | 1 |
| Carson, KJ; Cosgrove, VP; Eakin, RL; Hanna, GG; Hounsell, AR; Lynch, T; McAleese, J; O'Sullivan, JM; Stewart, DP; Zatari, A | 1 |
| Jo, WS; Kim, IJ; Kim, SJ; Kim, YK; Kim, YS; Lee, MK; Park, SK | 1 |
| Abolmaali, N; Abramyuk, A; Appold, S; Baumann, M; Herrmann, T; Lazanyi, KS; Tokalov, S; Wolf, G; Zöphel, K | 1 |
| Aristei, C; Falcinelli, L; Palumbo, B; Tarducci, R | 1 |
| Chen, L; Chen, W; Dai, YM; Huang, XQ; Jian, W; Li, C; Li, HT; Lin, Y; Lu, M; Xie, B; Xu, CX; Zhang, YK; Zhou, DQ | 1 |
| De Ruysscher, D; den Holder, L; Lambin, P; Ollers, M; van Elmpt, W; van Herwijnen, H; Vercoulen, L; Wouters, M | 1 |
| Dooms, C; Vansteenkiste, J | 1 |
| Dierckx, R; Mees, G; Pauwels, P; Van de Wiele, C; Van Meerbeeck, J; Vangestel, C | 1 |
| Aizawa, H; Azuma, K; Hattori, S; Imamura, Y; Ishibashi, M; Kaida, H; Kawayama, T; Kinoshita, T; Kurata, S; Okamoto, M; Sasada, T | 1 |
| Burke, C; Howlett, DC; Maxwell, D; Sharma, N; Thomas, R | 1 |
| Burdick, MJ; Djemil, T; Reddy, CA; Srinivas, SM; Stephans, KL; Videtic, GM | 1 |
| Allen, P; Dong, L; Erasmus, J; Ikushima, H; Komaki, R; McAleer, MF; Sasaki, R; Zhuang, Y | 1 |
| Carrasquillo, JA; Larson, SM; Nehmeh, SA; Schoellnast, H; Solomon, SB; Thornton, RH | 1 |
| Holloway, LC; Kumar, S; Shafiq, J; Vinod, SK | 1 |
| Christensen, JD; Colby, TV; Patz, EF | 1 |
| Hwang, SH; Kim, IJ; Kim, SJ; Lee, CH; Lee, EY; Lee, MK; Lee, SY | 1 |
| Koyama, H; Maniwa, Y; Matsumoto, K; Matsumoto, S; Nishimura, Y; Nogami, M; Ohno, Y; Onishi, Y; Sugimura, K; Takenaka, D; Yoshikawa, T | 1 |
| Chung, MP; Han, J; Jeon, K; Kim, H; Koh, WJ; Kwon, OJ; Lee, KS; Park, HK; Shim, YM; Suh, GY; Um, SW | 1 |
| Han, SK; Heo, EY; Kim, YW; Shim, YS; Yang, SC; Yoo, CG | 1 |
| Barnett, S; Baste, JM; Berlangieri, S; Knight, S; Murugappan, K; Scott, A; Seevanayagam, S; Tog, C | 1 |
| Fowler, A; Gabriel, G; Holloway, LC; Lin, M; Shon, IA; Vinod, SK; Yap, ML | 1 |
| Abaleke, S; Chatwin, CR; Ganeshan, B; Miles, KA; Young, RC | 1 |
| Ball, D; Bayne, M; Everitt, S; Fimmell, N; Hicks, RJ; Lau, E; MacManus, M; Pitman, A; Reynolds, J; Ware, R | 1 |
| Fujiwara, A; Hasegawa, Y; Higashiyama, M; Hosoki, T; Kanzaki, R; Kodama, K; Kozuka, T; Maeda, J; Okami, J; Takami, M; Tokunaga, T; Tomita, Y | 1 |
| Ball, D; Binns, D; Callahan, J; Everitt, S; Herschtal, A; Hicks, RJ; Kron, T; MacManus, M; Plumridge, N; Schneider-Kolsky, M | 1 |
| Hong, HS; Jeong, HT; Kim, KW; Lee, JD; Yun, M | 1 |
| Abe, M; Endo, M; Hayashi, I; Kaira, K; Kondo, H; Murakami, H; Naito, T; Nakagawa, K; Nakajima, T; Nakamura, Y; Ohde, Y; Okumura, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Devic, S; Faria, S; Lehnert, S; Lisbona, R; Menard, S; Tomic, N | 1 |
| Carrie, C; Chabaud, S; Dussart, S; Giammarile, F; Le Pechoux, C; Pommier, P; Touboul, E | 1 |
| Giesel, FL; Haberkorn, U; Kratochwil, C | 1 |
| Bujko, K; Dziuk, M; Gizewska, A; Kepka, L; Kolodziejczyk, M; Szalus, N; Zawadzka, A | 1 |
| Han, B; Pan, H; Wang, R; Yu, L | 1 |
| Ball, DL; Binns, D; Ding, Z; Herschtal, A; Hicks, RJ; Hogg, A; Mac Manus, MP | 1 |
| Alvfors, C; Bergman, A; Bergqvist, M; Bergström, S; Dahg, P; Ekman, S; Frödin, JE; Harmenberg, J; Hedlund, A; Ståhl, B | 1 |
| Aukema, TS; Codrington, HE; Kappers, I; Klomp, HM; Olmos, RA; van Pel, R; van Tinteren, H | 1 |
| Baumert, BG; Borger, J; De Ruysscher, D; Lambin, P; Lammering, G; Lutgens, L; Ollers, M; van Baardwijk, A; van den Ende, P | 1 |
| Asakura, K; Endo, M; Kaira, K; Murakami, H; Naito, T; Nakamura, Y; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Aerts, HJ; De Ruysscher, D; Lambin, P; Oberije, C; Velazquez, ER | 1 |
| Hu, M; Li, L; Yang, G; Yu, J; Zhao, W; Zhu, H | 1 |
| Darling, G; Hwang, D; Mah, K; Maziak, DE; Tirona, R; Tsao, MS; Ung, YC; Wong, CS; Wu, K | 1 |
| Conron, M; Hutchinson, AF; Irving, LB; Liew, D; Steinfort, DP | 1 |
| Ito, M; Murashima, S; Qiao, S; Suzawa, N; Takao, M; Takeda, K; Uchida, K; Yamada, T | 1 |
| De Ruysscher, D; Dekker, AL; Dingemans, AM; Lambin, P; Oberije, CJ; Petit, SF; van Elmpt, WJ; Vegt, E | 1 |
| Klarhöfer, M; Lenz, C; Scheffler, K; Sommer, G; Winter, L | 1 |
| Badran, K; Bykowski, J; Hayeri, MR; Hoh, CK; Obrzut, S | 1 |
| Jin, GH; Kweon, DC; Lee, JD; Lee, SB; Oh, KB; Park, DS; Park, HH | 1 |
| Bertin, F; Bonnaud, F; Dalmay, F; Gaillard, S; Melloni, B; Monteil, J; Vergnenègre, A | 1 |
| Blauwgeers, H; Boersma, L; Burgers, S; Gilhuijs, K; Klomp, H; Knegjens, J; Rossi, M; Siedschlag, C; Stroom, J; van Baardwijk, A; van Loon, J; van Suylen, RJ; Vogel, W | 1 |
| Bohn, P; Dubray, B; Edet-Sanson, A; Gardin, I; Hapdey, S; Ménard, JF; Modzelewski, R; Salles, A; Thiberville, L; Vera, P | 1 |
| Miyashita, T | 1 |
| Coche, E; De Bast, M; Geets, X; Grégoire, V; Lacroix, V; Lee, JA; Poncelet, A; Wanet, M; Weynand, B | 1 |
| Boellaard, R; de Langen, AJ; Frings, V; Hoekstra, OS; Smit, EF; van Tinteren, H; van Velden, FH | 1 |
| Abiko, M; Sato, T; Shiono, S | 1 |
| Bonardel, G; Carette, MF; de Labriolle-Vaylet, C; Grahek, D; Housset, B; Lebeau, B; Mangiapan, G; Margery, J; Meignan, M; Milleron, B; Talbot, JN; Vaylet, F | 1 |
| Hatt, M; Visvikis, D | 1 |
| De Ruysscher, D; Lambin, P; Öllers, M; van Elmpt, W | 1 |
| Kim, SK; Lee, HS; Lee, JW; Park, JW | 1 |
| Hamakawa, H; Katakami, N; Kokubo, M; Neri, S; Takahashi, Y; Terashi, T; Tomii, K | 1 |
| Akamatsu, H; Endo, M; Kaira, K; Murakami, H; Naito, T; Nakamura, Y; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Backes, WH; Brans, B; de Langen, AJ; Dingemans, AM; Groen, HJ; Hoekstra, OS; Leffers, P; Lubberink, M; Marcus, JT; Pruim, J; Smit, EF; van den Boogaart, V; van Tinteren, H | 1 |
| Kim, IJ; Kim, SJ; Kim, YD; Kim, YK; Lee, MK | 2 |
| Bhattacharjee, S; Longano, A; Powell, A; Yap, K | 1 |
| Bezjak, A; Bissonnette, JP; Brade, A; Cho, BC; Dahele, M; Franks, K; Freeman, M; Hope, A; Jaffray, DA; Pearson, S; Purdie, T; Sun, A | 1 |
| Binns, DS; Callahan, J; Conti, P; Fine, BM; Hicks, RJ; Macfarlane, D; Mileshkin, L; Pirzkall, A; Scott, AM; Yu, W | 1 |
| Alauddin, MM; Balatoni, J; Flores, L; Gelovani, JG; Gonzalez-Lepera, C; Krasnykh, V; Mukhapadhyay, U; Najjar, AM; Ogawa, K; Pal, A; Shavrin, A; Soghomonyan, S; Tong, W; Volgin, AY; Yeh, HH; Young, D | 1 |
| Carson, KJ; Hanna, GG; Hounsell, AR; O'Sullivan, JM; Senan, S; Van Sörnsen De Koste, JR | 1 |
| Agoglia, BG; Brambilla, D; Casiraghi, M; Guarize, J; Maisonneuve, P; Spaggiari, L; Tessitore, A; Travaini, LL | 1 |
| Kaushik, A; Nguyen, NC; Osman, MM; Wolverson, MK | 1 |
| Baek, HJ; Cheon, GJ; Choe, DH; Kim, KM; Koh, JS; Lee, JC; Na, II; Park, JY | 1 |
| Hamamoto, Y; Inoue, T; Kataoka, M; Ochi, T; Sakai, S; Sugawara, Y; Takahashi, T | 1 |
| Avila, EK; Gutin, PH; Lassman, AB; Morris, PG; Rosenblum, MK | 1 |
| Kaji, M; Mori, T; Nomori, H; Ohba, Y; Oya, N; Sasaki, J; Shibata, H; Shiraishi, K | 1 |
| Boersma, L; De Ruysscher, D; Lambin, P; Ollers, M; van Baardwijk, A; van Loon, J | 1 |
| Steinert, HC | 2 |
| Choi, NC; Digumarthy, SR; Engelman, JA; Mak, RH; Muzikansky, A; Sequist, LV; Shepard, JA | 1 |
| Amler, LC; Charu, V; Fine, BM; Gitlitz, BJ; Hicks, RJ; Hughes, BG; Macfarlane, D; Mileshkin, L; Mitchell, PL; Pirzkall, A; Solomon, B; Yu, W | 1 |
| Allen, AM; Aristophanous, M; Berbeco, RI; Chen, AB; Killoran, JH; Larson, E; Sher, DJ; Yap, JT | 1 |
| Bezjak, A; Bissonnette, JP; Brade, A; Cho, J; Dahele, M; Fung, S; Hope, A; Pearson, S; Purdie, T; Sun, A; Taremi, M | 1 |
| Gokce, M; Kilicgun, A; Saydam, O; Tanriverdi, O | 1 |
| Kim, IJ; Kim, SJ; Kim, YD; Kim, YK; Kim, YS; Lee, MK | 1 |
| Hatt, M; Le Rest, CC; Visvikis, D | 1 |
| Boellaard, R; Buettner, R; Dietlein, M; Draube, A; Engel-Riedel, W; Hallek, M; Hellmich, M; Heukamp, L; Jacobs, AH; Ko, YD; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Schlesinger, A; Schulte, K; Smit, E; Stoelben, E; Thomas, RK; Toepelt, K; Ullrich, RT; Wolf, J; Zander, T | 1 |
| Kong, FM; Ma, L; Meng, X; Mu, D; Sun, X; Xing, L; Yang, G; Yu, J; Zhang, B; Zhao, S | 1 |
| Atasalihi, A; Iskender, I; Kadioglu, SZ; Kir, A; Kosar, A | 1 |
| Bilici, A; Cinaral, F; Dogusoy, I; Kefeli, U; Oven Ustaalioglu, BB; Seker, M; Ustaalioglu, R | 1 |
| Fleckenstein, J; Grgic, A; Gröschel, A; Hellwig, D; Kirsch, CM; Kremp, S; Nestle, U; Rübe, C | 1 |
| Feng, R; Jiang, S; Wang, R; Yan, H; Zhao, F; Zhao, W; Zhu, K | 1 |
| Erasmus, JJ; Truong, MT; Viswanathan, C | 1 |
| Li, M; Liang, Y; Liu, Y; Wu, N; Zhang, W; Zhao, P; Zheng, R | 1 |
| Gobara, H; Hiraki, T; Kanazawa, S; Matsui, Y; Mimura, H; Toyooka, S | 1 |
| El-Deiry, WS; Ferrara, TA; Katz, SI; Mayes, PA; Smith, CD; Wang, W; Zhou, L | 1 |
| Alkhawaldeh, K; Biersack, HJ; Ezziddin, S; Henke, A | 1 |
| Fu, Z; Han, A; Hu, M; Huang, C; Kong, L; Xing, L; Yang, W; Yu, J; Zhang, P | 1 |
| Bücker, A; Grgic, A; Hellwig, D; Khreish, F; Kirsch, CM; Mathews, J | 1 |
| Au, DH; Ghaus, SJ; Gould, MK; Provenzale, D; Schultz, EM; Wagner, TH; Wallace, RB; Xu, X | 1 |
| Cline, KJ; Darling, GE; Driedger, AA; Evans, WK; Gu, CS; Gulenchyn, KY; Inculet, RI; Julian, JA; Kuruvilla, MS; Levine, MN; Maziak, DE; Ung, YC | 1 |
| Albert, M; Allen, AM; Caglar, HB; Killoran, J; Soto, R; Sun, Y; Zygmanski, P | 1 |
| Andrade, G; Deppen, S; Grogan, EL; Lambright, ES; Massion, PP; Nesbitt, JC; Putnam, JB; Speroff, T; Walker, R | 1 |
| Boellaard, R; Cheebsumon, P; Hoekstra, OS; Lammertsma, AA; Smit, EF; van Velden, FH; Yaqub, M | 1 |
| Gong, H; Huang, W; Li, B; Ma, L; Sun, H; Wang, J; Yu, J; Zhou, T | 1 |
| Dahele, M; Lagerwaard, F; Palma, D; Senan, S; Slotman, B | 1 |
| Kim, BS; Kim, IJ; Kim, K; Kim, SJ; Pak, K | 1 |
| Lv, YL; Miao, XH; Qian, Q; Song, Y; Wang, K; Wei, SZ; Yuan, DM; Zhu, XX | 1 |
| Berghmans, T; Flamen, P; Garcia, C; Meert, AP; Paesmans, M; Sculier, JP; van Ruychevelt, V | 1 |
| Bertolaccini, L; Bianchi, A; Rizzardi, G; Terzi, A | 1 |
| Durand, M | 1 |
| Baek, S; Choi, CM; Kim, SW; Lee, DH; Lee, JS; Moon, DH; Ryu, JS; Suh, C; Yoon, DH | 1 |
| Cantos, B; Gasent, JM; Ibeas, P; Provencio, M; Rodríguez, B | 1 |
| Ak, I; Döner, E; Dündar, E; Simsek, FS; Sivrikoz, CM | 1 |
| Bazan, JG; Graves, EE; Lavori, PW; Le, QT; Lee, P; Loo, BW; Quon, A; Wakelee, HA; Weerasuriya, DK | 1 |
| Citak, N; Gurses, A; Kök, A; Melek, H; Metin, M; Pekcolaklar, A; Sayar, A | 1 |
| Barth, T; Muehling, B; Oberhuber, A; Orend, KH; Schelzig, H; Wehrmann, C | 1 |
| Brustugun, OT; Helland, Å; Knudtsen, IS; Malinen, E; Rødal, J; Skretting, A | 1 |
| Bazan, J; Diehn, M; Donington, JS; Graves, EE; Hara, WY; Hoang, CD; Kozak, MM; Le, QT; Loo, BW; Maxim, PG; Murphy, JD; Quon, A; Schipper, ML; Shrager, JB; Wakelee, HA; Whyte, RI; Zhou, L | 1 |
| Ho-Shon, I; Koh, ES; Lin, M; Lin, P; Som, S; Vinod, SK; Yap, J | 1 |
| Aerts, HJ; Bussink, J; De Ruysscher, D; Emans, D; Folgering, AM; Lambin, P; Oyen, WJ; van Elmpt, W; Velders, M | 1 |
| Dupuy, DE; Fernando, HC; Hillman, SL; Rilling, WS; Shepard, JA; Siegel, BA; Yoo, DC | 1 |
| Matsumoto, I; Oda, M; Tamura, M; Waseda, R; Watanabe, G | 1 |
| Bandiera, A; Bolognesi, A; Carretta, A; Ciriaco, P; Franzin, A; Gregorc, V; Melloni, G; Picozzi, P; Viganò, M; Zannini, P | 1 |
| Allen, TL; Kendi, AT; Maddaus, MA; Mitiek, MO | 1 |
| Chen, RC; Chiu, WK; Fried, DV; Higginson, DS; Jagtap, MR; Khandani, AH; Lawrence, MV; Marks, LB; Qaqish, BF; Saynak, M; Veeramachaneni, NK; Xie, L | 1 |
| Apfaltrer, P; Chu, TQ; Dinter, DJ; Fink, C; Henzler, T; Krissak, R; Manegold, C; Meyer, M; Nance, JW; Schmid-Bindert, G; Schoenberg, SO; Schoepf, UJ | 1 |
| Boellaard, R; Cheebsumon, P; de Langen, AJ; Frings, V; Hoekstra, OS; Lammertsma, AA; van Velden, FH; Yaqub, M | 1 |
| Colomer, R; Quintela-Fandino, M | 1 |
| Chiu, CH; Chou, TY; Lee, YC; Lin, KH; Tsai, CM; Wu, YC; Yeh, YC | 1 |
| Mornex, F; Roelandts, M; Van Houtte, P | 1 |
| de Koning, HJ; Groen, HJ; Lammers, JW; Mali, W; Nackaerts, K; Oudkerk, M; Thunnissen, FB; van Klaveren, RJ; van't Westeinde, SC; Vernhout, R; Weenink, C | 1 |
| Dubray, B; Edet-Sanson, A; Mezzani-Saillard, S; Modzelewski, R; Thureau, S; Vera, P | 1 |
| Furukawa, M; Kiura, K; Miyoshi, S; Oto, T; Toyooka, S; Yamane, M | 1 |
| Back, A; Bohn, P; Doyeux, K; Dubray, B; Edet-Sanson, A; Gardin, I; Hapdey, S; Modzelewski, R; Vera, P | 1 |
| Aoki, Y; Fujii, H; Koike, N; Kunieda, E; Ohashi, T; Ozawa, Y; Sanuki, N; Takeda, A; Yokosuka, N | 1 |
| Hatazawa, J; Inoue, T; Itoh, H; Kubota, K; Murakami, K; Saga, T; Shiomi, S | 1 |
| Antoch, G; Forsting, M; Geiger, B; Hartung, V; Herbrik, M; Heusner, TA; Riegger, C; Rosenbaum-Krumme, SJ; Treffert, J | 1 |
| Aoyama, N; Itoh, T; Koyama, H; Maniwa, Y; Matsumoto, S; Nishimura, Y; Nishio, M; Nishio, W; Ohno, Y; Onishi, Y; Sugimura, K; Takenaka, D; Yoshikawa, T | 1 |
| Wang, SX; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhong, WZ | 1 |
| Appelbaum, DE; Chen, CT; Chen, S; Kampalath, R; Liao, S; Penney, BC; Pu, Y; Salgia, R; Shih, MC; Shimada, N; Simon, CA; Suzuki, K; Wroblewski, K; Zhang, H | 1 |
| Bal, M; De Jaeger, K; Meijer, G; Schuring, D; Steenhuijsen, J; Theuws, J | 1 |
| Endo, M; Kaira, K; Kondo, H; Murakami, H; Naito, T; Nakagawa, K; Nakajima, T; Ohde, Y; Okumura, T; Takahashi, T; Yamamoto, N | 1 |
| Cheze-le Rest, C; Hatt, M; Lambin, P; Pradier, O; van Baardwijk, A; Visvikis, D | 1 |
| Aerts, JG; Baas, J; Hoogsteden, HC; Smit, EF; van der Leest, C; van Walree, N; Versteijlen, RJ | 1 |
| Eshuis, SA; Gemmel, F; Gemmel, P; van Vollenhoven, F | 1 |
| Allen-Auerbach, MS; Benz, MR; Czernin, J; Figlin, R; Garon, EB; Herrmann, K; Phelps, ME; Reckamp, KL; Walter, F; Weber, WA | 1 |
| Chang, CF; Gould, MK; Rashtian, A | 1 |
| Kong, FM; Wang, J; Wang, L; Welch, K | 1 |
| Haasbeek, CJ; Lagerwaard, FJ; Senan, S; Slotman, BJ; Verstegen, NE | 1 |
| Giaj Levra, M; Novello, S; Vavalà, T | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Ullrich, RT; Wolf, J; Zander, T | 2 |
| Feng, J; Jia, HL; Li, HM; Li, XD; Zhang, JY | 1 |
| Chen, L; Chen, M; Hu, X; Li, X; Ma, H; Sun, X; Xie, P; Xing, L; Xu, W; Xu, X; Yu, J; Yue, J; Zhang, H; Zhang, L | 1 |
| Bootsma, G; Borger, J; Bosmans, G; Botterweck, A; De Ruysscher, D; Dekker, A; Dingemans, AM; Geraedts, W; Lambin, P; Lunde, R; Oellers, M; Pitz, C; Reymen, B; Steevens, J; van Baardwijk, A; Wanders, R | 1 |
| Evans, T; Fernandes, AT; Kucharczuk, JC; Langer, C; Lin, L; Mitra, N; Rengan, R; Stevenson, J; Xanthopoulos, E | 1 |
| Ashley, S; Chua, S; Cook, G; Coward, JI; Gunapala, R; Myerson, JS; O'Brien, ME; Popat, S; Puglisi, M; Sharma, B; Trani, L; Wotherspoon, A | 1 |
| Emmering, J; Stokkel, MP; Vogel, WV | 1 |
| Bellyei, S; Farkas, R; Hideghéty, K; Kovács, P; Lõcsei, Z; Mangel, L; Sárosi, V; Sebestyén, K; Sebestyén, Z | 1 |
| Gurel, D; Kargi, A; Onen, A; Ozdogan, O; Sevinc, C; Turan, O | 1 |
| Datseris, IE; Oikonomopoulos, G; Platis, I; Skoura, E; Syrigos, KN | 1 |
| Liao, S; Penney, BC; Pu, Y; Suzuki, K; Zhang, H | 1 |
| Aoki, S; Araki, T; Araya, M; Komiyama, T; Kuriyama, K; Maehata, Y; Marino, K; Nambu, A; Oguri, M; Onishi, H; Saito, R; Satoh, Y; Sawada, E; Tominaga, L | 1 |
| Aoyama, N; Koyama, H; Matsumoto, K; Ohno, Y; Onishi, Y; Sugimura, K; Yoshikawa, T | 1 |
| Cui, ML; He, ZY; Zhao, L; Zhong, XN | 1 |
| Adam, G; Buhk, JH; Derlin, T; Groth, M; Henes, FO; Kooijman, H; Laqmani, A; Regier, M; Schwarz, D | 1 |
| Ambati, C; Lin, M | 1 |
| Collaud, S; Lardinois, D; Stahel, R; Steinert, HC; Tischler, V; Weder, W | 1 |
| Chang, H; Cheng, YL; Hsieh, CM; Huang, TW; Huang, WS; Lee, SC; Tzao, C | 1 |
| Gladish, G; Gomez, D; Komaki, R; Liao, Z; Lopez Guerra, JL; Zhuang, Y | 1 |
| Allen, AM; Aristophanous, M; Berbeco, RI; Chen, AB; Killoran, JH; Yap, JT; Yong, Y | 1 |
| Ahn, MJ; Ahn, YC; Han, J; Kim, BT; Kim, J; Kwon, OJ; Lee, HY; Lee, KS; Park, J; Park, K; Shim, YM | 1 |
| Fig, LM; Komissarova, M; Wong, KK | 1 |
| Abele, JT; Bédard, EL; Gill, RS; Perry, T; Schiller, D | 1 |
| Inoue, M; Kadota, Y; Minami, M; Okumura, M; Ose, N; Sawabata, N; Shintani, Y | 1 |
| Arguis, P; Boada, M; Cabañas, M; Gómez-Caro, A; Lomeña, F; Molins, L; Ramirez, J; Sanchez, M | 1 |
| de Bruin, WI; Siepel, FJ; Slump, CH; Steenvoorde, P; van Dalen, JA; van Duyn, EB; Wagenaar, NR | 1 |
| Albert, DH; Day, M; Fox, GB; Hickson, JA; Luo, Y; Mudd, SR; Refici-Buhr, M; Reuter, DR; Tapang, P; Voorbach, MJ | 1 |
| de Geus-Oei, LF; Disselhorst, JA; Oyen, WJ; Visser, EP; Vriens, D | 1 |
| Bom, HS; Choi, S; Chong, A; Jung, MY; Kim, JW; Kim, YH; Seon, HJ; Shin, SS | 1 |
| Goo, JM; Im, HJ; Kang, CH; Kim, JI; Kim, YW; Lee, HJ; Lee, SM; Paeng, JC; Park, CM | 1 |
| Barlesi, F; Bonardel, G; Cammilleri, S; Colavolpe, C; Guedj, E; Mundler, O | 1 |
| Kim, H; Kim, IJ; Kim, K; Kim, SJ; Kim, YS; Pak, K | 1 |
| Bengtsson, T; Hicks, RJ; Peterson, A; Port, RE | 1 |
| Claussen, CD; Hann von Weyhern, C; Hetzel, J; Horger, MS; Klotz, E; Mueller, M; Pfannenberg, C; Sauter, AW; Schulze, M; Spira, D; Winterstein, S | 1 |
| Bollineni, VR; Langendijk, JA; Pruim, J; Widder, J; Wiegman, EM | 1 |
| Chen, JH; Kao, CH; Liang, JA; Liao, CY; Yeh, JJ | 1 |
| Carson, KJ; Dahele, MR; Haasbeek, CJ; Hanna, GG; Hounsell, AR; Migchielsen, R; Senan, S; van Sörnsen de Koste, JR | 1 |
| Chang, CJ; Chiu, PH; Ho, KC; Kuo, WH; Lin, C; Wang, CW; Wu, CY; Wu, YC; Yen, TC; Yu, CT | 1 |
| Bauer, TT; Bittner, RC; Blum, T; Boch, C; Förster, GJ; Kollmeier, J; Misch, D; Tönnies, S | 1 |
| Ding, XP; Li, BS; Li, HS; Sun, HF; Wang, DQ; Wang, ZT; Yi, Y; Zhang, J | 1 |
| Bolton, WD; Geraldson, CT; Greene, RA; Lagrew, JP; Schammel, CM; Schammel, DP; Stephenson, JE | 1 |
| Chen, J; Gu, HY; Haacke, EM; Hu, J; Hua, J; Wu, LM; Xu, JR; Zhang, W | 1 |
| Gill, BS; Hoh, CK; Jensen, LG; Nobiensky, PD; Rivandi, AH; Sandhu, AP; Sandhu, SP | 1 |
| Allen, PK; Balter, P; Chang, JY; Chuang, HH; Komaki, R; Liu, H; Pan, T; Zhang, X | 1 |
| Mason, DP | 1 |
| Appelbaum, D; Pu, Y; Wroblewski, K; Zhang, H | 1 |
| Pu, Y; Wroblewski, K; Zhang, H | 1 |
| Nakajima, J | 1 |
| Ball, DL; Binns, DS; Gregory, DL; Hicks, RJ; Hogg, A; Link, E; Mac Manus, MP; Milner, A; Shum, PL | 1 |
| Ardissone, F; Arena, V; Billè, A; Errico, L; Okiror, L; Pelosi, E; Penna, D; Skanjeti, A | 1 |
| Bezjak, A; Brade, A; Cho, J; Clarke, K; Dahele, M; Franks, K; Freeman, M; Fung, S; Hope, A; Sun, A; Taremi, M | 1 |
| Chen, HH; Chiu, NT; Guo, HR; Lee, BF; Su, WC | 1 |
| Huang, G; Wang, YT | 1 |
| Antoch, G; Bockisch, A; Buchbender, C; Forsting, M; Herbrik, M; Heusner, TA; Treffert, J | 1 |
| Davidzon, G; Gevaert, O; Graves, EE; Hoang, CD; Nair, VS; Napel, S; Plevritis, SK; Quon, A; Rubin, DL; Shrager, JB | 1 |
| Civelek, AC; Huang, T; Jiang, H; Li, J; Li, XF; Ng, CK; Postel, GC; Shen, B | 1 |
| Gevaert, O; Hoang, CD; Leung, AN; Napel, S; Plevritis, SK; Quon, A; Rubin, DL; Xu, J; Xu, Y | 1 |
| Haasbeek, CJ; Lagerwaard, FJ; Senan, S; Senthi, S; Slotman, BJ | 1 |
| Bremerich, J; Forrer, F; Klarhöfer, M; Lardinois, D; Lenz, C; Sommer, G; Wiese, M; Winter, L | 1 |
| Bonomo, L; Calcagni, ML; Cocciolillo, F; Giordano, A; Massaccesi, M; Pelligrò, F; Spitilli, MG; Valentini, V | 1 |
| Fujii, K; Ichiyasu, H; Kohrogi, H; Saeki, S; Saita, N; Sakata, S; Sasaki, J; Sato, R | 1 |
| Kong, FM; Mahasittiwat, P; Quint, LE; Wang, J; Wong, KK | 1 |
| Abe, K; Baba, S; Honda, H; Ito, K; Kawano, D; Maehara, Y; Miura, N; Morodomi, Y; Shoji, F; Takenaka, T; Yano, T | 1 |
| De Ruysscher, D; Dingemans, AM; Lambin, P; Ollers, M; van Elmpt, W | 1 |
| Azuma, K; Hattori, S; Hoshino, T; Imamura, Y; Ishibashi, M; Kaida, H; Kawahara, A; Kinoshita, T; Kurata, S; Sadashima, E; Sasada, T; Zaizen, Y | 1 |
| Li, C; Li, P; Qian, Y; Shi, Y; Wu, H; Wu, Y; Yang, J; Zhang, H; Zhang, J | 1 |
| Ayabe, T; Onitsuka, T; Shimizu, T; Tomita, M | 1 |
| Aide, N; Bardet, S; Beauregard, JM; Gervais, R; Guizard, AV; Hicks, RJ; Lasnon, C; Lemoel, G; Milner, A; Paciencia, M; Zalcman, G | 1 |
| Kawakami, Y; Kenzaki, K; Kondo, K; Otsuka, H; Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H | 1 |
| Abolmaali, N; Abramyuk, A; Appold, S; Baumann, M; Hietschold, V; Zöphel, K | 1 |
| Chang, JY; Cox, JD; Erasmus, J; Komaki, R; Xiang, ZL | 1 |
| Giammarile, F; Houzard, C; Jegou, C; Moussallem, M; Traverse-Glehen, A; Valette, PJ | 1 |
| Choi, JY; Hyun, SH; Kim, BT; Kim, H; Kim, J; Kim, K; Lee, KH; Shim, YM; Um, SW | 1 |
| James, J; McWilliam, L; Prescott, M; Shawgi, M | 1 |
| Dickson, J; Ghosh-Ray, S; Sanghera, B; Sonoda, LI; Wong, WL | 1 |
| Kampalath, R; Liao, S; Penney, BC; Pu, Y; Wroblewski, K; Zhang, H; Zhang, Y | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Wolf, J; Zander, T | 1 |
| Abakay, A; Erdem, V; Kaya, H; Kömek, H; Selimoğlu Şen, H; Senyiğit, A; Sezgi, C; Tanrikulu, AC | 1 |
| Kara Gedik, G; Kaya, B; Ozcan Kara, P; Sari, O; Varoglu, E | 1 |
| Huang, G; Liu, J; Song, S; Sun, X; Tong, J; Zhang, C | 1 |
| Manych, M | 1 |
| Kucharczuk, J; Pryma, DA; Rengan, R; Sterman, D; Trister, AD; Xanthopoulos, E | 1 |
| Basaran, G; Dane, F; Demir, G; Korkmaz, T; Madenci, OC; Okutur, K; Ones, T; Polat, O; Seber, S; Turhal, NS; Yumuk, F | 1 |
| Ballangan, C; Eberl, S; Feng, DD; Fulham, M; Wang, X | 1 |
| Ahmad, S; Chicklore, S; Cook, GJ; Goh, V; Landau, D; Marsden, P; Roy, A; Siddique, M; Yip, C | 1 |
| Belderbos, J; Kwint, M; Lebesque, J; Nijkamp, J; Rossi, M; Sonke, JJ; Uyterlinde, W; van den Heuvel, M; Vogel, W | 1 |
| Matsunaga, T; Miyasaka, Y; Oh, S; Suzuki, K; Takamochi, K | 1 |
| Cueto, A; Rodríguez-Fernández, A; Ruiz-Zafra, J; Sánchez-Palencia, A | 1 |
| Al-Harbi, AS; Al-Jahdali, H; Khan, AN; Loutfi, S | 1 |
| Aoki, Y; Fujii, H; Kunieda, E; Mizuno, T; Ohashi, T; Oku, Y; Oooka, Y; Ozawa, Y; Sanuki, N; Takeda, A; Yokosuka, N | 1 |
| Li, L; Su, M | 1 |
| Levra, MG; Novello, S; Pelosi, E; Scagliotti, GV; Solitro, F; Vavalà, T; Veltri, A | 1 |
| Ding, X; Huang, W; Li, B; Li, H; Sun, H; Wang, Z; Yi, Y; Zang, R | 1 |
| Hwang, SH; Jeon, TJ; Kim, SJ; Kim, TH; Park, CH; Yoo, MR | 1 |
| Claussen, CD; Hetzel, J; Horger, MS; Klotz, E; Pfannenberg, C; Reimold, M; Sauter, AW; Schulze, M; Spira, D | 1 |
| Boubaya, M; Buvat, I; Chouahnia, K; Eder, V; Maisonobe, JA; Morère, JF; Soussan, M | 1 |
| Boellaard, R; Büttner, R; Dietlein, M; Engel-Riedel, W; Heukamp, L; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Stoelben, E; Wolf, J; Zander, T | 1 |
| Lee, P; Singhvi, M | 1 |
| Baschnagel, AM; Grills, IS; Kestin, LL; Mangona, VS; Robertson, JM; Welsh, RJ | 1 |
| Al-Nabhani, K; Almukhailed, O; Bomanji, J; Haroon, A; Syed, R | 1 |
| Bianco, A; Brunese, L; De Rimini, M; De Rosa, N; Grassi, R; Greco, B; Guarracino, MR; Lassandro, F; Muto, P; Muto, R; Piccolo, S; Rotondo, A; Setola, FR | 1 |
| Li, M; Li, N; Liang, Y; Liu, Y; Wu, N; Zhang, W; Zhao, P; Zheng, R | 1 |
| Hoekstra, CJ; Hoekstra, OS; Lammertsma, AA; Smit, EF; Stroobants, SG; Vansteenkiste, JF | 1 |
| Ichihara, K; Kobayashi, H; Kosuda, S; Kusano, S; Watanabe, M | 3 |
| Coleman, RE; Hagge, RJ | 1 |
| Peschina, W | 1 |
| Chung, JK; Han, SK; Jeong, HJ; Jeong, JM; Kim, BT; Lee, DS; Lee, MC; Min, JJ; Park, JM; Shim, YS | 1 |
| Pugsley, JM; Vallières, E; Vesselle, H; Wood, DE | 1 |
| Bartsch, P; Belhocine, T; Green, A; Hustinx, R; Jerusalem, G; Rigo, P; Seidel, L; Steinmetz, N | 1 |
| Boers, M; Hoekstra, CJ; Hoekstra, OS; Lammertsma, AA; Nuyts, J; Smit, EF; Stroobants, SG; Twisk, JW; Vansteenkiste, J | 1 |
| Agoston, P; Esik, O; Fekésházy, A; Galuska, L; Kálvin, B; Lengyel, E; Lengyel, Z; Szakáll, S; Székely, J; Trón, L | 1 |
| Scott, WJ | 1 |
| Changlai, SP; Hsia, TC; Kao, CH; Shen, YY; Yen, RF | 1 |
| Grijseels, EW; Herder, GJ; Hoekstra, OS; Smit, EF; van den Bergh, JH; van Velthoven, PC; Verboom, P | 1 |
| Buck, A; Goerres, GW; Hany, TF; Steinert, HC; von Schulthess, GK | 1 |
| Kirsch, CM; Licht, N; Nestle, U; Schmidt, S; Schnabel, K; Ukena, D; Walter, K | 1 |
| Choi, NC; Fidias, P; Fischman, AJ; Lynch, T; Mathisen, D; Niemierko, A; Ryu, JS; Wain, J; Wright, C | 1 |
| Stroobants, S; Vansteenkiste, J; Verschakelen, J | 1 |
| Bares, R; Eschmann, SM; Friedel, G | 1 |
| Bangard, M; Bender, H; Biersack, HJ; Gallkowski, U; Guhlke, S; Reichmann, K; Sartor, J; Willkomm, P | 1 |
| Comans, EF; Herder, GJ; Hoekstra, OS; Joshi, U; Postmus, PE; Smit, EF; Teule, GJ; Van Tinteren, H | 1 |
| Maisey, MN; O'doherty, MJ; Shon, IH | 1 |
| Goldsmith, SJ; Kostakoglu, L | 1 |
| Biesma, B; Hoekstra, CJ; Hoekstra, OS; Schramel, FJ; Smit, EF; Stroobants, SG; van Tinteren, H; van Zandwijk, N; Vansteenkiste, J | 1 |
| Constable, CJ; Fulham, MJ; McCaughan, BC; Wilkinson, MD | 2 |
| Bakker, PF; de Klerk, JM; Schlösser, NJ; Stevens, H; van Rijk, PP | 1 |
| Ball, DL; Hicks, RJ; Mac Manus, MP; Matthews, JP; McKenzie, A; Rischin, D; Salminen, EK | 1 |
| Ball, DL; Fisher, R; Hicks, R; MacManus, MR; Michael, M; Rischin, D; Wirth, A | 1 |
| Bass, CS; Cerfolio, RJ; Katholi, CR; Mukherjee, S; Ojha, B; Pask, AH | 1 |
| Eubank, W; Haynor, DR; Lewellen, TK; Mattes, D; Vesselle, H | 1 |
| Cook, GJ; Husband, JE; Koh, DM | 1 |
| Hany, TF; Kamel, EM; Korom, S; Lardinois, D; Seifert, B; Steinert, HC; von Schulthess, GK; Weder, W | 1 |
| Link, T; Peschel, C; Petersen, V; Schmidt, B; Schwaiger, M; Tyndale-Hines, L; Weber, WA | 1 |
| Dietlein, M; Hellwig, D; Kirsch, CM; Schicha, H; Schwaiger, M; Weber, WA | 1 |
| Bartalucci, AA; Bass, CS; Bryant, AS; Cerfolio, RJ; Mountz, JM; Ojha, B | 1 |
| Alavi, A; Bhargava, P; Reich, P; Zhuang, H | 1 |
| Antoch, G; Beyer, T; Bockisch, A; Debatin, JF; Freudenberg, LS; Kuehl, H; Marnitz, S; Nemat, AT; Stattaus, J | 1 |
| Conrad, GR; Sinha, P | 1 |
| Boers, M; Comans, EF; Diepenhorst, FW; Grijseels, EW; Hoekstra, OS; Postmus, PE; Schreurs, AJ; Smit, EF; Stallaert, RA; Teule, GJ; Uyl-de Groot, CA; van den Bergh, JH; van Mourik, JC; van Tinteren, H; van Velthoven, PC; Verboom, P | 1 |
| Delahaye, N; Gardin, I; Gutman, F; Hitzel, A; Le Guludec, D; Manrique, A; Rakotonirina, H; Véra, P | 1 |
| Aubier, M; Charpentier, E; Crestani, B; Delahaye, N; Fery-Lemonnier, E; Girard, P; Le Guludec, D; Lebtahi, R; Rakotonirina, H; Sarda, L; Syrota, A | 1 |
| Chan, JK; Demas, AN; Gould, MK; Kuschner, WG; Maclean, CC; Owens, DK; Rydzak, CE; Shigemitsu, H | 1 |
| Haynor, D; Turcotte, E; Vesselle, H; Wiens, L | 1 |
| Kernstine, KH | 1 |
| Coleman, RE; D'Amico, TA; Gonzalez-Stawinski, GV; Harpole, DH; Lemaire, A; Merchant, F; O'Halloran, E | 1 |
| Downey, RJ; Harpole, DH; Heelan, RT; Jung, SH; MacApinlac, HA; Meyers, BF; Posther, KE; Reed, CE; Rusch, VW; Siegel, BA; Silvestri, GA; Woolson, SL | 1 |
| Line, BR; White, CS | 1 |
| Berbaum, K; Bushnell, D; Kahn, D; Kernstine, K; McLaughlin, K; Menda, Y; Miller, S | 1 |
| Abe, K; Kosuda, S; Kusano, S | 1 |
| Dong, JC; Guan, YH; He, SL | 1 |
| Ichinari, H; Iiboshi, H; Kisanuki, A; Mine, K; Shibata, K; Tomita, M; Tomita, Y | 1 |
| Stroobants, SG; Vansteenkiste, JF | 2 |
| Annema, JT; Hoekstra, OS; Rabe, KF; Smit, EF; Versteegh, MI; Veseliç, M | 1 |
| Buck, AK; Glatting, G; Halter, G; Hetzel, M; Liewald, F; Neumaier, B; Reske, SN; Schirrmeister, H; Sunder-Plassmann, L; Wurziger, I | 1 |
| Chung, JK; Jeong, JM; Kim, SK; Lee, DS; Lee, MC; Lee, YJ | 1 |
| Holmstrom, A; Kelly, RF; Murar, J; Segurola, RJ; Tran, T | 1 |
| Bootsma, GP; Brouwer, MH; Corstens, FH; Cox, AL; Oyen, WJ; Tjan-Heijnen, VC; van der Wilt, GJ; Verhagen, AF | 1 |
| Johnstone, PA; Paulino, AC | 1 |
| Bertrand, RJ; Bosch, W; Bradley, J; Dehdashti, F; Miller, TR; Mutic, S; Siegel, BA; Thorstad, WL | 1 |
| Ho Shon, IA; Maisey, MN | 1 |
| Aksoy, E; Buck, AK; Glatting, G; Halter, G; Hetzel, M; Liewald, F; Mühling, B; Neumaier, B; Nüssle-Kügele, K; Reske, SN; Schirrmeister, H; Sunder-Plassmann, L | 1 |
| Aigner, RM; Fasching, G; Groell, R; Maier, A; Nicoletti, R; Schaffler, GJ; Schoellnast, H; Smolle-Jüttner, FM; Wolf, G; Woltsche, M | 1 |
| Cheran, SK; Herndon, JE; Patz, EF | 1 |
| Constable, CJ; Fulham, MJ; Gradinscak, DJ; Mohamed, A | 1 |
| Avril, N | 1 |
| Baek, HJ; Cheon, GJ; Cho, KJ; Choi, CW; Chung, JH; Lee, SS; Lim, SM; Park, JH | 1 |
| Naruke, T; Nomori, H; Ohtsuka, T; Suemasu, K; Uno, K; Watanabe, K | 1 |
| Lalani, T; Schmidt, R; Takasugi, JE; Turcotte, E; Vallières, E; Vesselle, H; Wiens, L; Wood, DE | 1 |
| Bootsma, GP; Bussink, J; Corstens, FH; Oyen, WJ; Verhagen, AF | 1 |
| Buck, AK; Glatting, G; Reske, SN | 1 |
| Akhurst, T; Bains, MS; Downey, RJ; Gonen, M; Larson, S; Rusch, V; Vincent, A | 1 |
| Davis, E; Rosenberg, RJ; Solis, V; Spencer, RP | 1 |
| Bares, R; Besenfelder, H; Bitzer, M; Dittmann, H; Eschmann, SM; Friedel, G; Horger, M; Paulsen, F; Pfannenberg, AC; Reimold, M | 1 |
| Dooms, C; Fischer, BM; Mortensen, J; Vansteenkiste, J | 1 |
| Aquino, SL; Fischman, AJ | 1 |
| Ball, DL; Binns, D; Hicks, RJ; Hogg, A; Mac Manus, MP; Matthews, JP; Peters, LJ; Rischin, D | 1 |
| Ball, D; Bayne, M; Hicks, R; Leong, T; MacManus, M; Peters, L | 1 |
| Bar-Shalom, R; Ben-Nun, A; Guralnik, L; Haim, N; Israel, O; Keidar, Z; Wollner, M | 1 |
| Black, QC; Grills, IS; Kestin, LL; Martinez, AA; Wong, CY; Wong, JW; Yan, D | 1 |
| Fulham, MJ; Modi, D; Mohamed, A | 1 |
| Franzius, C | 1 |
| Hellwig, D; Ukena, D | 1 |
| Passlick, B | 1 |
| Mornex, F | 1 |
| Chapet, O; Lagerwaard, FJ; Senan, S; Ten Haken, RK | 1 |
| Fox, JL; Giraud, P; Rosenzweig, KE | 1 |
| Bartolucci, AA; Bryant, AS; Cerfolio, RJ; Ohja, B; Winokur, TS | 1 |
| Ball, DL; Hicks, RJ; Manus, MP; Rischin, D; Roberts, KB; Wirth, A; Wright, GM | 1 |
| Cerfolio, RJ; Chen, VK; Desmond, R; Eloubeidi, MA; Ojha, B; Syed, S | 1 |
| Birim, O; Bogers, AJ; Kappetein, AP; Stijnen, T | 1 |
| Liu, SW; Xing, LG; Yu, JM | 1 |
| Vansteenkiste, JF | 2 |
| Ishii, G; Murakami, K; Nagai, K; Niho, S; Nishimura, M; Nishiwaki, Y; Suzuki, K; Takamochi, K; Yoshida, J | 1 |
| Endo, K; Higuchi, T; Inoue, T; Oriuchi, N; Tian, M; Zhang, H | 1 |
| Deniaud-Alexandre, E; Lerouge, D; Moureau-Zabotto, L; Touboul, E | 1 |
| Higashi, K; Higuchi, T; Hiramatsu, Y; Ishikawa, T; Ito, K; Kuga, G; Matsunari, I; Miura, K; Sakuma, T; Tonami, H; Yamamoto, I | 1 |
| Bentzen, SM; Boersma, L; De Ruysscher, D; Hochstenbag, M; Lambin, P; Lamers, R; Lutgens, L; Nijsten, S; van Der Wel, A; Wanders, R; Wouters, B; Zimny, M | 1 |
| Allen, P; Cox, JD; Erasmus, J; Forster, K; Herbst, RS; Komaki, R; Macapinlac, H; Moran, CA; Podoloff, DA; Putnam, JB; Roth, JA; Sasaki, R | 1 |
| Fulham, MJ; McCaughan, BC; Modi, D; Mohamed, A | 1 |
| An, YS; Joh, CW; Lee, MH; Yoon, JK; Yoon, SN | 1 |
| Hoekstra, OS; Smit, EF; van Tinteren, H | 1 |
| Khuri, F; Saba, N | 1 |
| Boellaard, R; Hoekstra, CJ; Hoekstra, OS; Krak, NC; Lammertsma, AA; Twisk, JW | 1 |
| Baum, RP; Bonnet, R; Junker, K; Müller, KM; Schmücking, M | 1 |
| Hensing, TA | 1 |
| Bilfinger, TV; Franceschi, D; Komaroff, E; Sachs, S | 1 |
| Erdi, Y; Fox, JL; Leibel, SA; Nehmeh, S; O'Meara, W; Rengan, R; Rosenzweig, KE; Yorke, E | 1 |
| Naruke, T; Nomori, H; Ohtsuka, T; Orikasa, H; Suemasu, K; Uno, K; Watanabe, K; Yamazaki, K | 1 |
| Aquino, SL; Gilman, MD | 1 |
| Ball, DL; Hicks, RJ; Mac Manus, MP; Matthews, JP; Rischin, D; Wirth, A | 1 |
| Belderbos, JS; Boellaard, R; Borst, GR; Comans, EF; De Jaeger, K; Lammertsma, AA; Lebesque, JV | 1 |
| Canessa, J; Galaz, R; González, P; Humeres, P; Jofré, MJ; Massardo, T; Sierralta, P; Valdebenito, R | 1 |
| Abdel-Dayem, H; Ashamalla, H; Evola, A; Goswami, G; Guirguis, A; Kambam, S; Mokhtar, B; Parikh, K; Rafla, S; Ross, P | 1 |
| Gladish, GW; Macapinlac, HA; Marom, EM; Munden, RF; Podoloff, DA; Sabloff, BS; Truong, MT; Yi, JG | 1 |
| Bentzen, SM; Boersma, L; Buell, U; De Ruysscher, D; Dohmen, J; Geeraedts, W; Hochstenbag, M; Lambin, P; Minken, A; Rhami, A; Simons, J; Snoep, G; Thimister, P; Utama, I; van Baardwijk, A; van Haren, E; Verschueren, T; Wanders, S | 1 |
| De Ruysscher, D; Senan, S | 1 |
| Choi, JY; Chung, MJ; Han, J; Kim, BT; Kim, S; Kwon, OJ; Lee, EJ; Lee, KS; Shim, SS; Shim, YM | 1 |
| Hellwig, D; Kirsch, CM; Kremp, S; Nestle, U; Rübe, C; Schaefer-Schuler, A; Sebastian-Welsch, C | 1 |
| Erdi, YE; Humm, JL; Larson, SM; Nehmeh, SA | 1 |
| Deniaud-Alexandre, E; El Balaa, H; Foulquier, JN; Grahek, D; Grès, B; Keraudy, K; Kerrou, K; Lebeau, B; Lerouge, D; Milleron, B; Montravers, F; Petegnief, Y; Talbot, JN; Touboul, E | 2 |
| Graeter, TP; Gröschel, A; Hellwig, AP; Hellwig, D; Kirsch, CM; Nestle, U; Schäfers, HJ; Sybrecht, GW | 1 |
| Abe, K; Hayashi, K; Iwasaki, Y; Kosuda, S; Watanabe, S; Yano, F | 1 |
| Atkins, CD | 1 |
| Artioli, D; Castellone, P; Cattaneo, M; Ceresoli, GL; Fazio, F; Gregorc, V; Landoni, C; Messa, C; Picchio, M; Rizzo, G | 1 |
| Lardinois, D; Moch, H; Roudas, M; Stahel, RA; Steinert, HC; Tutic, M; von Schulthess, GK; Weder, W | 1 |
| Campa, MJ; Furumai, R; Howard, BA; Patz, EF; Rabbani, ZN; Vujaskovic, Z; Wang, XF | 1 |
| Bonardel, G; Foehrenbach, H; Gontier, E; Guigay, J; L'Her, P; Mantzarides, M; Salles, Y; Vaylet, F | 1 |
| Arenas de Pablo, A; Calero-García, R; García de Barajas, S; García-Lujan, R; Lopez-Encuentra, A; Maldonado, A; Martín de Nicolás, JL; Martín-Escribano, P; Martín-García, I; Pozo, MA; Pozo-Rodríguez, F; Sánchez-Nistal, MA | 1 |
| Gotoh, M; Haba, R; Kameyama, K; Monden, T; Nishiyama, Y; Ohkawa, M; Sasakawa, Y; Yamamoto, Y | 1 |
| Brada, M; Cook, G; Lavrenkov, K; Partridge, M | 1 |
| Bares, R; Budach, W; Dittmann, H; Eschmann, SM; Friedel, G; Hehr, T; Machulla, HJ; Paulsen, F; Reimold, M; Scheiderbauer, J; Vonthein, R | 1 |
| Biesma, B; Golding, RP; Hoekstra, CJ; Hoekstra, OS; Lammertsma, AA; Postmus, PE; Schramel, FJ; Smit, EF; Stroobants, SG; van Tinteren, H; van Zandwijk, N; Vansteenkiste, J | 1 |
| Alifano, M; Bellenot, F; Grahek, D; Lemeunier, P; Magdeleinat, P; Molina, T; Perrotin, C; Petino, A; Regnard, JF; Talbot, JN | 1 |
| Hu, M; Liu, BD; Su, L; Wang, HR; Xu, QS; Zhang, Y; Zhi, XY | 1 |
| Bachaud, JM; Bègue, M; Caselles, O; Courbon, F; Dygai, I; Gancel, M; Hamelin, D; Laprie, A; Marre, D; Zerdoud, S | 1 |
| de Langen, AJ; Hoekstra, OS; Paul, MA; Raijmakers, P; Riphagen, I | 1 |
| Chen, DL; Dehdashti, F | 1 |
| Knoepp, UW; Ravenel, JG | 1 |
| Antoch, G; Bockisch, A; Eberhardt, W; Gauler, T; Grehl, S; Levegrün, S; Marnitz, S; Pink, R; Pöttgen, C; Stamatis, G; Stuschke, M; Theegarten, D | 1 |
| Aronsky, A; Gates, GF; Ozgur, H | 1 |
| Gong, HY; Yu, JM | 1 |
| Rankin, SC | 1 |
| Cameron, RB; Czernin, J; Fishbein, MC; Phelps, ME; Schiepers, C; Weber, WA; Yap, CS | 1 |
| Asadpour, B; Buell, U; Coenen, HH; Demirel, C; Eble, MJ; Gagel, B; Hamacher, K; Kaiser, HJ; Pinkawa, M; Piroth, M; Reinartz, P; Stanzel, S; Zimny, M | 1 |
| Lardinois, D | 1 |
| Boers, M; Comans, EF; Groen, HJ; Herder, GJ; Hoekstra, OS; Kramer, H; Paul, MA; Postmus, PE; Pruim, J; Smit, EF; Teule, GJ; Uyl-de Groot, CA; van Tinteren, H; Verboom, P; Welling, A | 1 |
| Dimitrakopoulou-Strauss, A; Eisenhut, M; Georgoulias, V; Haberkorn, U; Herth, F; Koukouraki, S; Mäcke, HR; Strauss, LG | 1 |
| Bénard, F; Boileau, R; Boucher, L; Larivée, P; Prévost, S | 1 |
| Ebihara, A; Kaji, M; Naruke, T; Nomori, H; Ohtsuka, T; Suemasu, K; Uno, K; Watanabe, K | 1 |
| Bang, YJ; Chung, JK; Heo, DS; Im, SA; Kang, WJ; Kim, DW; Kim, TY; Kim, YW; Lee, KH; Lee, SH | 1 |
| Choe, G; Chung, JH; Chung, JK; Kim, SE; Lee, MC; Lee, WW; Park, SY; Sung, SW | 1 |
| Bryant, AS; Cerfolio, RJ; Klemm, KM; Ojha, B | 1 |
| Bares, R; Budach, W; Eschmann, SM; Friedel, G; Hehr, T; Kotzerke, J; Paulsen, F; Reimold, M; Scheiderbauer, J | 1 |
| Englmeier, KH; Schaefer, JF; Seemann, MD | 1 |
| Broemeling, LD; Bruzzi, JF; Gladish, GW; Macapinlac, HA; Marom, EM; Mawlawi, O; Munden, RF; Podoloff, DA; Truong, MT | 1 |
| Bryant, AS; Cerfolio, RJ | 4 |
| Choi, JY; Kim, BT; Kim, H; Kim, J; Kim, S; Kwon, OJ; Lee, KS; Shim, SS; Shim, YM | 1 |
| Herth, F; Kirsch, CM; Stoelben, E | 1 |
| Geinitz, H; Molls, M; Nieder, C; Schill, S; Schratzenstaller, U; Thamm, R; Zimmermann, FB | 1 |
| Bruzzi, JF; Macapinlac, HA; Marom, EM; Mawlawi, O; Munden, RF; Podoloff, DA; Truong, MT | 1 |
| Hany, TF; Husarik, DB; Schaefer, NG; Steinert, H; Strobel, K | 1 |
| Harpole, DH; McCall, LM; Posther, KE; Putnam, JB; Reed, CE; Rusch, VW; Siegel, BA | 1 |
| Krohn, KA; Linden, HM; Livingston, RB; Mankoff, DA | 1 |
| Bodenstein, C; Czernin, J; Dubinett, S; Dumont, RA; Herschman, H; Phelps, ME; Seimbille, Y; Su, H; Weber, W | 1 |
| Chung, JH; Chung, JK; Eo, JS; Jang, SJ; Kim, SE; Lee, MC; Lee, WW; Park, SY; So, Y; Sung, SW | 1 |
| Aliredjo, RP; Boerman, OC; de Geus-Oei, LF; Frielink, C; Krabbe, PF; Oyen, WJ; van Krieken, JH; Verhagen, AF | 1 |
| Gangarosa, LM; Khandani, AH; Socinski, MA; Stinchcombe, TE | 1 |
| Groeschel, A; Hellwig, D; Kirsch, CM; Kremp, S; Nestle, U; Rübe, C; Schaefer-Schuler, A | 1 |
| Demmy, T; Fischer, G; Glinianski, M; Lamonica, D; Nwogu, C; Tan, D | 1 |
| Bryant, AS; Cerfolio, RJ; Miller, DL; Pereira, SJ | 1 |
| Grosu, AL; Kremp, S; Nestle, U | 1 |
| Bhat, S; Bhatt, B; Camazine, B; Erickson, RA; Gupta, R; Jadhav, Y; Khan, A; Khode, R; Mukhopadhyay, P; Reddy, R; Shah, RS; Sharma, A; Sikka, P; Singh, P; Smith, DD; Yaqub, Y; Zheng, Q | 1 |
| Goor, C; Legrand, C; Manegold, C; Schramel, F; Surmont, V; van Klaveren, RJ; Van Meerbeeck, JP; Van Schil, P | 1 |
| Biehl, KJ; Bradley, JD; Dehdashti, F; El Naqa, I; Jin, JY; Kong, FM; Mutic, S; Siegel, BA | 1 |
| Bares, R; Budach, W; Eschmann, SM; Friedel, G; Hehr, T; Langen, HJ; Paulsen, F; Reimold, M | 1 |
| Akhurst, T | 1 |
| Bares, R; Budach, W; Dittmann, H; Eschmann, SM; Friedel, G; Hehr, T; Langen, HJ; Paulsen, F; Reimold, M | 1 |
| Cherk, MH; Foo, SS; Knight, SR; Murone, C; O'Keefe, GJ; Papenfuss, AT; Poon, AM; Sachinidis, JI; Saunder, TH; Scott, AM | 1 |
| Ginsberg, MS; Grewal, RK; Heelan, RT | 1 |
| Bryant, AS; Cerfolio, RJ; Garver, RI; Robert, F; Scott, E; Sharma, M; Spencer, SA | 1 |
| Brambilla, D; Catalano, G; de Braud, F; De Pas, TM; Leo, F; Paganelli, G; Putzu, C; Solli, PG; Spaggiari, L; Veronesi, G | 1 |
| Pfannschmidt, J | 1 |
| Bradley, K; Gondi, V; Howard, A; Khuntia, D; Mehta, M; Ritter, M; Tomé, W | 1 |
| Black, QC; Grills, IS; Kestin, LL; Martinez, AA; Wong, CY; Yan, D | 1 |
| Cook, GJ; Devaraj, A; Hansell, DM | 1 |
| Allen, MS; Aubry, MC; Daniels, CE; Jett, JR; Lowe, VJ | 1 |
| Kawano, M; Shimizu, Y; Takayanagi, T; Tanaka, N; Tsunezuka, Y | 1 |
| Chung, JH; Chung, JK; Kim, SE; Kim, YK; Lee, DS; Lee, MC; Lee, WW; Nguyen, XC; Park, SY; So, Y; Sung, SW | 1 |
| Kathula, SK; Mantil, J | 1 |
| Krüger, S; Mottaghy, FM; Pauls, S | 1 |
| Boersma, L; Bosmans, G; De Ruysscher, D; Dekker, A; Houben, R; Lambin, P; Minken, A; Ollers, M; van Baardwijk, A; van Kroonenburgh, M; Wanders, S | 1 |
| Bellón Guardia, M; Gómez Río, M; Llamas Elvira, JM; Pedraza Muriel, V; Ramos Font, C; Rodríguez Fernández, A; Sánchez-Palencia Ramos, A; Torné Poyatos, P | 1 |
| Aquino, SL; Fischman, AJ; Halpern, EF; Kuester, LB | 1 |
| Bova, D; Emami, B; Halama, J; Hong, R; Sethi, A | 1 |
| Blumstein, NM; Brambs, HJ; Buck, AK; Glatting, G; Halter, G; Hetzel, M; Hohl, K; Hombach, V; Krüger, S; Möller, P; Mottaghy, FM; Pauls, S; Reske, SN; Sunder-Plassmann, L | 1 |
| Choi, JY; Chung, MJ; Kim, BT; Kim, H; Kim, HY; Kim, YK; Kwon, OJ; Lee, KS; Shim, YM; Yi, CA | 1 |
| Chen, JH; Dai, HH; Du, JJ; Liu, Y; Meng, L; Zhang, L; Zhang, ZJ | 1 |
| Fletcher, JW; Forquer, JA; Hoopes, DJ; Lin, PF; Lo, SS; McGarry, RC; Tann, M; Timmerman, RD | 1 |
| Bentzen, SM; Boersma, L; Bosmans, G; Buijsen, J; De Ruysscher, D; Dehing-Oberije, C; Dekker, A; Hochstenbag, M; Houben, R; Lambin, P; van Baardwijk, A; van Kroonenburgh, M; van Suylen, RJ; Wanders, S | 1 |
| Govindan, R; Pillot, G; Siegel, BA | 1 |
| Bruzzi, JF; Erasmus, JJ; Munden, R; Sabloff, B; Truong, M; Zinner, R | 1 |
| Chen, SQ; Yu, JM | 1 |
| Hanna, WT; Hubner, KF; Long, MJ; Nahmias, C; Townsend, DW; Wahl, LM | 1 |
| Mahajan, P; Wong, CY; Yan, D | 1 |
| Cascini, GL; Greco, C; Rosenzweig, K; Tamburrini, O | 1 |
| Advani, RH; Allred, C; Benson, AB; Brown, E; Burstein, HJ; Carlson, RW; Coleman, RE; Czuczman, MS; Delbeke, D; Edge, SB; Ettinger, DS; Grannis, FW; Hillner, BE; Hoffman, JM; Kiel, K; Komaki, R; Larson, SM; Mankoff, DA; Podoloff, DA; Rosenzweig, KE; Skibber, JM; Yahalom, J; Yu, JM; Zelenetz, AD | 1 |
| Buell, U; De Ruysscher, D; Dehing-Oberije, C; Dooms, C; Hochstenbag, M; Lambin, P; Pastorekova, S; Rupa, D; Stroobants, S; van Baardwijk, A; van Suylen, RJ; Vansteenkiste, J; Verbeken, E | 1 |
| Bong, JS; Cheng, V; Chundru, S; Fink-Bennett, D; Gaskill, M; Grills, I; Kestin, L; Martinez, AA; Schmidt, J; Wong, CY; Yan, D | 1 |
| Bandoh, S; Chang, SS; Haba, R; Ishikawa, S; Kanaji, N; Kushida, Y; Nakano, J; Nishiyama, Y; Ohkawa, M; Yamamoto, Y | 1 |
| Akhurst, T; Downey, RJ; Gonen, M; Park, B; Rusch, V | 1 |
| Huang, LL; Liang, TJ; Nie, YX; Qin, SL; Wang, Q; Wang, Y; Yue, MG; Zhang, CQ; Zhao, YM | 1 |
| Czernin, J; Phelps, ME; Weber, WA | 1 |
| Bastian, P; Freeman, JD; Hawes, SE; Nguyen, HQ; Salskov, A; Stern, J; Vallières, E; Vesselle, H; Wiens, L; Wood, DE | 1 |
| Coleman, RE; Gauger, J; Herndon, JE; Patz, EF | 1 |
| Altorki, NK; Korst, RJ; Lee, PC; Liss, Y; Meherally, DN; Port, JL | 1 |
| Asadpour, B; Breuer, C; Eble, MJ; Gagel, B; Kaiser, HJ; Krohn, T; Pinkawa, M; Piroth, M; Reinartz, P; Schmachtenberg, A; Stanzel, S | 1 |
| Chetty, IJ; Eisbruch, A; Frey, KA; Hayman, JA; Kessler, M; Kong, FM; Lawrence, TS; Normolle, D; Quint, LE; Ten Haken, RK | 1 |
| Ackerly, T; Andrews, J; Ball, D; Binns, D; D'Costa, I; Everitt, S; Hicks, RJ; Lau, E; Macmanus, M; Weih, L | 1 |
| Dilege, S; Ece, T; Erelel, M; Halac, M; Mudun, A; Sonmezoglu, K; Toker, A; Turkmen, C; Yilmazbayhan, D | 1 |
| Al-Sarraf, N; Doddakula, K; Wedde, T; Young, V | 1 |
| Al-Sarraf, N; Aziz, R; Doddakula, K; Gately, K; McGovern, E; Wilson, L; Young, V | 1 |
| Comans, EF; Craanen, ME; Paul, MA; Smit, EF | 1 |
| Dahele, MR; Ung, YC | 1 |
| Gosselin, R; Kelles, A; Maddens, S; Tournoy, KG; Van Maele, G; van Meerbeeck, JP | 1 |
| Antoch, G; Beyer, T; Bockisch, A; Freudenberg, LS; Rosenbaum, SJ | 1 |
| Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B | 1 |
| Buscombe, J; Cook, G; Eisen, T; Gleeson, F; O'Brien, M; Peake, MD; Rowell, NP; Seymour, R; Spiro, SG | 1 |
| Corstens, FH; de Geus-Oei, LF; Hermsen, R; Krabbe, PF; Oyen, WJ; Pruim, J; Timmer-Bonte, JN; van der Heijden, HF; van Hoorn, BA; Visser, EP; Willemsen, AT | 1 |
| Corstens, FH; de Geus-Oei, LF; Oyen, WJ; van der Heijden, HF | 1 |
| Bootsma, G; De Ruysscher, D; Dehing-Oberije, C; Geraedts, W; Hochstenbag, M; Lambin, P; Pitz, C; Rahmy, A; Simons, J; Steck, H; Teule, J; Thimister, P; van der Weide, H | 1 |
| Koyama, H; Nogami, M; Ohbayashi, C; Ohno, Y; Sugimura, K; Takenaka, D; Yoshikawa, T; Yoshimura, M | 1 |
| Erasmus, JJ; Macapinlac, HA; Swisher, SG | 1 |
| Ballestín, C; Berrendero, JR; Cuezva, JM; García-García, E; López-Encuentra, A; López-Ríos, F; Ortega, AD; Pozo-Rodríguez, F; Sánchez-Aragó, M | 1 |
| Kunst, PW; Lee, P; Paul, MA; Senan, S; Smit, EF | 1 |
| Asakura, M; Bandoh, S; Ishikawa, S; Kanaji, N; Kimura, N; Nishiyama, Y; Ohkawa, M; Okuda, M; Yamamoto, Y | 1 |
| Endo, K; Hisada, T; Ishizuka, T; Kaira, K; Mori, M; Oriuchi, N; Sunaga, N; Tomizawa, Y; Yanagitani, N | 1 |
| Graeter, TP; Groeschel, A; Hellwig, D; Kirsch, CM; Schaefers, HJ; Sybrecht, GW; Ukena, D | 1 |
| Dang, TP; Davies, AM; de Vries, DJ; Eberhard, DA; Garland, LL; Herbst, RS; Johnson, BE; Lutzker, SG; Lyons, B; Melenevsky, Y; Mendelson, D; Miller, VA; Natale, RB; Schiller, JH; Van den Abbeele, AD | 1 |
| Fu, Z; Guo, HB; Han, AQ; Liu, LP; Yang, GR; Yu, JM | 1 |
| Dalesio, O; de Jong, WK; Groen, HJ; Oyen, WJ; Pruim, J; van der Heijden, HF | 1 |
| Boersma, L; Bosmans, G; De Ruysscher, D; Dekker, A; Lambin, P; Ollers, M; van Baardwijk, A; Wanders, S | 1 |
| Bellón Guardia, ME; Gómez Río, M; Llamas Elvira, JM; Pedraza Muriel, V; Ramos Font, C; Rodríguez Fernández, A; Sánchez-Palencia Ramos, A | 1 |
| Baek, H; Byun, BH; Cheon, GJ; Choe, DH; Kang, HJ; Koh, JS; Lee, JC; Na, II; Park, JH; Ryoo, BY; Yang, SH | 1 |
| Debruyne, C; Philippé, J; Van de Wiele, C; van Meerbeeck, JP; VandeVyver, F | 1 |
| Bentzen, SM; Boersma, L; De Ruysscher, D; Geraedts, W; Hochstenbag, M; Lambin, P; Minken, A; Pitz, C; Simons, J; van Haren, E; Verschueren, T; Wanders, R | 1 |
| Giaccone, G | 1 |
| Evans, WK; Gulenchyn, K; Lacchetti, C; Maziak, DE; Smith, CA; Ung, YC; Vanderveen, JA | 1 |
| Choi, JY; Kim, BT; Kim, S; Kwon, OJ; Lee, KS; Sung, YM; Yang, SO | 1 |
| Alard, S; Berghmans, T; Buvat, I; Castaigne, C; Dusart, M; Hossein-Foucher, C; Lafitte, JJ; Mascaux, C; Meert, AP; Moreau, M; Paesmans, M; Patz, EF; Roelandts, M; Scherpereel, A; Sculier, JP | 1 |
| Nguyen, BD; Roarke, MC | 1 |
| Hinterthaner, M; Stamatis, G | 1 |
| Aerts, HJ; Bosmans, G; De Ruysscher, D; Dekker, AL; Lambin, P; Oellers, MC; van Baardwijk, AA | 1 |
| Bonardel, G; Bonnichon, A; Foehrenbach, H; Le Floch, H; Mairovitz, A; Mantzarides, M; Margery, J; Marotel, C; Rivière, F; Staub, E; Vaylet, F | 1 |
| Macapinlac, HA | 1 |
| Price, P; Rembielak, A | 1 |
| Al-Sarraf, N; Gately, K; Lucey, J; McGovern, E; Wilson, L; Young, V | 1 |
| Chang, YC; Chen, KC; Cheng, MF; Lee, JM; Lee, YC; Wang, J; Wu, YW; Yen, RF | 1 |
| Dehdashti, F; Gao, F; Goodgame, B; Govindan, R; Meyers, BF; Patterson, A; Pillot, GA; Shriki, J; Siegel, BA; Yang, Z; Zoole, J | 1 |
| Baggstrom, MQ; Gao, F; Goodgame, B; Govindan, R; Morgensztern, D | 1 |
| De Leyn, P; Dooms, C; Nackaerts, K; Stroobants, S; Vansteenkiste, J; Verbeken, E | 1 |
| Chung, JH; Kim, SE; Lee, WW; Nguyen, XC; Park, SY; So, Y | 1 |
| Englmeier, KH; Seemann, MD | 1 |
| Bosmans, G; De Ruysscher, D; Geskes, G; Hochstenbag, M; Lambin, P; van Baardwijk, A; van Kroonenburgh, M; van Suylen, RJ | 1 |
| Alavi, A; Basu, S; Houseni, M; Kung, J; Tidmarsh, GF; Zhuang, H | 1 |
| Dong, ZM; Feng, Q; Hawes, SE; Jordan, CD; Kiviat, NB; Lu, H; Stern, JE; Vesselle, H; Wiens, L | 1 |
| Coan, AD; Coleman, RE; Herndon, JE; Hoagland, LF; Hoang, JK; Patz, EF | 1 |
| Gelblum, D; Greco, C; Jackson, A; Rosenzweig, KE; Sura, S; Yorke, ED | 1 |
| Cornet, J; Coulon, C; Distexhe, J; Hanin, FX; Lonneux, M; Noirhomme, P; Poncelet, AJ | 1 |
| Byun, BH; Cheon, GJ; Choe, DH; Kang, HJ; Kim, CH; Koh, JS; Lee, JC; Lim, SM; Na, II; Ryoo, BY; Yang, SH | 1 |
| Geus-Oei, LF; Oyen, WJ | 1 |
| De Grève, J; De Mey, J; Decoster, L; Everaert, H; Meysman, M; Neyns, B; Nieboer, K; Schallier, D | 1 |
| Aschoff, P; Brink, I; Claussen, CD; Eschmann, S; Hehr, T; Lichy, MP; Pfannenberg, C; Plathow, C; Schlemmer, HP | 1 |
| Nguyen, NC; Osman, MM; Sayed, MM; Taalab, K | 1 |
| Cox, JD; Erasmus, JJ; Kased, N; Komaki, R | 1 |
| Meng, X; Mu, DB; Sun, XD | 1 |
| Corstens, FH; de Geus-Oei, LF; Kaanders, JH; Kienhorst, L; Oyen, WJ; Philippens, ME; Visser, EP | 1 |
| Bockisch, A; Eberhardt, W; Gauler, T; Krbek, T; Kuehl, H; Levegruen, S; Poettgen, C; Stamatis, G; Stuschke, M; Teschler, H; Theegarten, D | 1 |
| Dewan, NA; Gobar, LS; Hauser, LG; Scott, WJ; Sugimoto, JT; Sunderland, JJ | 1 |
| Dussek, J; Gee, T; Griffin, S; Lewis, P; Malsey, M; Marsden, P; Nunan, T | 1 |
| Alpert, NM; Babich, JW; Choi, NC; Fischman, AJ; Hamberg, LM; Hunter, GJ | 1 |
| Greenough, RL; Meyer, CR; Orringer, MB; Quint, LE; Wahl, RL; White, RI | 1 |
| Choi, NC; Fischman, AJ; Hunter, GJ; McLoud, TC | 1 |
| Blahd, W; Brown, C; Khonsary, A; Mandelkern, M; Santiago, SM; Sazon, DA; Soo Hoo, GW; Williams, AJ | 1 |
| Akashi, Y; Fukumura, T; Ichiya, Y; Ishida, T; Kuwabara, Y; Masuda, K; Murayama, S; Sasaki, M; Sugio, K; Yoshida, T | 1 |
| Anscher, MS; Hebert, ME; Hoffman, JM; Lowe, VJ; Patz, EF | 1 |
| Alpert, NM; Choi, NC; Fischman, AJ; Hamberg, LM; Hunter, GJ | 1 |
| Miyauchi, T; Wahl, RL | 1 |
| Bury, T; Corhay, JL; D'Harcour, JB; Limet, R; Paulus, P; Radermecker, MF; Rigo, P; Weber, T | 1 |
| Gambhir, SS; Hoh, CK; Madar, I; Maddahi, J; Phelps, ME | 1 |
| Bury, T; Dowlati, A; Hustinx, R; Paulus, P; Radermecker, M; Rigo, P | 1 |
| Albert, A; Bury, T; Corhay, JL; Dowlati, A; Ghaye, B; Limet, R; Paulus, P; Radermecker, M; Rigo, P; Schoffers, J; Weber, T | 1 |
| Allemann, F; Berthold, T; Engel, H; Hauser, M; Steinert, HC; von Schulthess, GK; Weder, W | 1 |
| Guhlmann, A; Kotzerke, J; Moog, F; Reske, SN; Storck, M; Sunder-Plassmann, L | 1 |
| Schiepers, C | 1 |
| Makler, PT | 1 |
| De Leyn, PR; Dupont, PJ; Mortelmans, LA; Nackaerts, KL; Stroobants, SG; Vansteenkiste, JF; Verschakelen, JA | 1 |
| Bury, T; Corhay, JL; Dowlati, A; Ghaye, B; Hustinx, R; Paulus, P; Radermecker, M; Rigo, P | 1 |
| Carreras Delgado, JL; Torres García, AJ | 1 |
| Bogaert, J; De Leyn, PR; Demedts, MG; Deneffe, GJ; Dupont, PJ; Lerut, TE; Maes, A; Mortelmans, LA; Nackaerts, KL; Stroobants, SG; Vansteenkiste, JF; Verschakelen, JA | 1 |
| Barreto, A; Barthelemy, N; Bury, T; Daenen, F; Ghaye, B; Rigo, P | 1 |
| Ahuja, V; Coleman, RE; Herndon, J; Patz, EF | 1 |
| Bruchhaus, H; Hillinger, S; Schmid, RA; Steinert, HC; von Schulthess, GK; Weder, W | 1 |
| Bishop, H; Gill, H; Graeber, G; Gupta, N; Hurst, J; Stephens, T | 1 |
| Bogaert, JG; De Leyn, PR; De Wever, WF; Dupont, PJ; Maes, FP; Nuyts, JL; Stroobants, SG; Vansteenkiste, JF; Verbeken, EK | 1 |
| Gross, MD; Shreve, PD; Steventon, RS | 1 |
| De Leyn, PR; Dupont, PJ; Stroobants, SG; Vansteenkiste, JF; Verbeken, EK | 1 |
| Gambhir, SS; Scott, WJ; Shepherd, J | 1 |
| Bruchhaus, H; Hillinger, S; Largiadèr, F; Schmid, RA; Steinert, HC; von Schulthess, GK; Weder, W | 1 |
| Bishop, HA; Graeber, GM; Gupta, NC; Rogers, JS | 1 |
| Bartenstein, P; Enterrottacher, A; Häussinger, KE; King, B; Krapf, M; Lichte, H; Neverve, J; Präuer, HW; Schwaiger, M; Sklarek, J; Thetter, O; Treumann, T; Weber, WA; Ziegler, SI | 1 |
| Brown, RS; Flint, A; Kison, PV; Leung, JY; Wahl, RL; Zasadny, KR | 1 |
| Hellwig, D; Kirsch, CM; Licht, N; Motaref, B; Nestle, U; Nieder, C; Niewald, M; Schmidt, S; Schnabel, K; Sybrecht, GW; Ukena, D; Walter, K | 1 |
| De Leyn, PR; Demedts, MG; Deneffe, GJ; Dupont, PJ; Mortelmans, LA; Stroobants, SG; Vansteenkiste, JF; Verbeken, EK | 1 |
| Berlangieri, SU; Clarke, CP; Fitt, GJ; Hennessy, OF; Knight, SR; McKay, WJ; Scott, AM; Tochon-Danguy, HJ | 1 |
| Hoekstra, CJ; Hoekstra, OS; Lammertsma, AA | 1 |
| Bakker, PF; Heine, R; Lammers, JW; Schlösser, NJ; Stokkel, MP; Van Rijk, PP | 1 |
| Carretta, A; Del Maschio, A; Fazio, F; Gilardi, MC; Landoni, C; Lucignani, G; Magnani, P; Messa, C; Rizzo, G; Vanzulli, A; Zannini, P | 1 |
| Barthelemy, N; Bartsch, P; Bury, T; Corhay, JL; Daenen, F; Duysinx, B; Ghaye, B; Rigo, P | 1 |
| Arisaka, Y; Higashi, K; Nambu, Y; Oguchi, M; Sakurai, A; Seki, H; Tonami, H; Ueda, Y; Yagishita, M; Yamamoto, I | 1 |
| Connolly, J; Herndon, J; Patz, EF | 1 |
| Bishop, HA; Graeber, GM; Gupta, NC | 1 |
| Hellwig, AP; Hellwig, D; Kirsch, CM; Leutz, M; Palm, I; Rentz, K; Sybrecht, GW; Ukena, D | 1 |
| Bury, T; Rigo, P | 1 |
| Farrell, MA; Herndon, JE; McAdams, HP; Patz, EF | 1 |
| De Leyn, PR; De Wever, W; Gatti, GG; Huyskens, DP; Kutcher, GJ; Stroobants, SG; Vansteenkiste, JF; Vanuytsel, LJ; Verbeken, EK | 1 |
| Coleman, RE; Erasmus, JJ; Goodman, PC; McAdams, HP; Patz, EF; Rossi, SE | 1 |
| Fidler, V; Groen, HJ; Koëter, GH; Meuzelaar, JJ; Mooyaart, EL; Pieterman, RM; Pruim, J; Vaalburg, W; van Putten, JW | 1 |
| Berlangieri, SU; Scott, AM | 1 |
| Papatheofanis, FJ | 1 |
| Hara, T; Inagaki, K; Kosaka, N; Morita, T | 1 |
| Grosse, S; Guhlmann, A; Halter, G; Liewald, F; Reske, S; Storck, M; Sunder-Plassmann, L | 1 |
| Dietlein, M; Gandjour, A; Lauterbach, KW; Moka, D; Schicha, H; Theissen, P; Weber, K | 1 |
| Ball, DL; Binns, DS; Hicks, RJ; Hogg, A; Kalff, V; MacManus, MP; McKenzie, AF; Ware, RE | 1 |
| Case, L; Chin, R; Dunagan, D; Haponik, E; Harkness, B; McCain, T; Oaks, T | 1 |
| Donckier, JE; Pochet, JM; Roelants, V | 1 |
| Higashi, K; Katsuda, S; Murakami, M; Nambu, Y; Oguchi, M; Sakurai, A; Seki, H; Taki, S; Tonami, H; Ueda, Y; Wang, XM; Xu, L; Yamamoto, I | 1 |
| Breuer, R; Chisin, R; Rubinstein, R | 1 |
| Carette, MF; Cosset, JM; Deniaud-Alexandre, E; Giraud, P; Grahek, D; Housset, M; Julia, F; Montravers, F; Rosenwald, JC; Talbot, JN; Touboul, E | 1 |
| Angelides, S; Dixon, J; Roman, MR; Rossleigh, MA; Walker, BM | 1 |
| Alavi, A; Yamamoto, AJ; Zhuang, H | 1 |
| de Vries, EG; Groen, HJ; Jager, PL; Piers, DA; Pieterman, RM; van der Leest, A; van Putten, JW | 1 |
| Ball, DL; Hicks, RJ; Hogg, A; MacManus, MP; Matthews, JP; McKenzie, AF; Ware, RE; Wirth, A | 1 |
| Bishop, HA; Graeber, GG; Gupta, NC; Hobbs, GR; Tamim, WJ | 1 |
| Gröschel, A; Hellwig, D; Kirsch, CM; Rentz, K; Sybrecht, GW; Ukena, D | 1 |
| Coche, E; Lonneux, M; Noirhomme, P; Poncelet, AJ; Weynand, B | 1 |
| Laking, G; Price, P | 1 |
| Ball, DL; Hicks, RJ; Kalff, V; Khaw, P; Mac Manus, MP; Matthews, JP; McKenzie, A; Rischin, D; Salminen, E; Wirth, A | 1 |
| Mac Manus, M; Salminen, E | 2 |
| Ball, DL; Hicks, RJ; Kalff, V; MacManus, MP; Matthews, JP; McKenzie, AF; Ware, RE | 1 |
| Ball, DL; Hicks, RJ; Hogg, A; Kalff, V; MacManus, MP; Matthews, JP; McKenzie, AF; Ware, RE | 1 |
| Balon, H; Bohdiewicz, P; Chmielewski, GW; Dickinson, C; Dworkin, HJ; Fink-Bennett, D; Hill, JC; Nuñez, R; Pursel, SE; Ravikrishnan, KP; Welsh, RJ; Wong, CY | 1 |
| Balogh, JM; Caldwell, CB; Danjoux, CE; Ehrlich, LE; Ganguli, SN; Mah, K; Ung, YC | 1 |
| Haberkorn, U | 1 |
| Alavi, A; Aronchick, JM; Lee, J | 1 |
| Baumann, M; Fleckenstein, J; Hellwig, D; Kirsch, CM; Nestle, U; Rübe, C; Ukena, D; Walter, K | 1 |
| Dong, J; Guan, Y; He, S | 1 |
| Coleman, RE | 1 |
| Arisaka, Y; Higashi, K; Nambu, Y; Oguchi, M; Sakuma, T; Seki, H; Taki, S; Tonami, H; Ueda, Y; Yamamoto, I | 1 |
| Choi, NC; Fischman, AJ; Lynch, TJ; Mathisen, DJ; Ryu, JS | 1 |
| Colder, CD; Herder, GJ; Hoekstra, OS; Postmus, PE; Smit, EF; Teule, GJ; van den Bergh, JH; van Mansom, I; van Mourik, JC; van Velthoven, PC; Verboom, P | 1 |
| Braban, LE; Chui, CS; Erdi, AK; Erdi, YE; Hu, YC; Humm, JL; Larson, SM; Macapinlac, HA; Rosenzweig, K; Squire, OD; Yorke, ED | 1 |
| Akhurst, T; Bains, M; Downey, RJ; Ginsberg, MS; Ginsberg, RJ; Gonen, M; Korst, R; Larson, SM; Rusch, VW | 1 |
| Brown, CK; Bushnell, DL; Graham, MM; Kahn, DJ; Kernstine, KH; Madsen, MT; Mclaughlin, KA; Menda, Y; Rossi, NP | 1 |
| Albes, JM; Dohmen, BM; Schott, U; Schülen, E; Wehrmann, M; Ziemer, G | 1 |
| Balogh, JM; Caldwell, CB; Danjoux, CE; Ehrlich, LE; Ganguli, SN; Mah, K; Tirona, R; Ung, YC | 1 |
| Ball, DL; Binns, D; Ciavarella, F; Hicks, RJ; Hogg, A; Kalff, V; MacManus, MP; McKenzie, A; Salminen, E; Ware, R; Wirth, A | 1 |
| Bertin, F; Bonnaud, F; Ducloux, T; Gaillard, S; Laskar, M; Melloni, B; Monteil, J; Vandroux, JC; Vergnenegre, A; Vincent, F | 1 |
| Bartsch, P; Bury, T; Corhay, JL; Daenen, F; Duysinx, B | 1 |
| Lee, MH; Oh, YJ; Park, CH | 1 |
| Kahn, D; Menda, Y | 1 |
| Boers, M; Comans, EF; Diepenhorst, FW; Hoekstra, OS; Postmus, PE; Schreurs, AJ; Smit, EF; Stallaert, RA; Teule, GJ; van den Bergh, JH; van Mourik, JC; van Tinteren, H; van Velthoven, PC; Verboom, P | 1 |
| Croft, DR; Galvin, J; Gross, T; Kern, JA; Kernstine, K; Kirchner, P; McLennan, G; Mullan, B; Peterson, MW; Trapp, J | 1 |
| Bares, R; Budach, W; Dohmen, BM; Eschmann, SM; Friedel, G; Harer-Mouline, C; Paulsen, F | 1 |
| Lassen, U | 1 |
| Abe, Y; Fujiwara, T; Fukuda, H; Hatazawa, J; Ido, T; Itoh, M; Kubota, K; Matsuzawa, T; Tada, M; Yamaguchi, K | 1 |
142 review(s) available for fluorodeoxyglucose f18 and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Impact of Follow-up 18F-FDG PET on the Management in Patients With Lung Cancer: A Meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Recurrence, Local | 2021 |
A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC).
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Injury; Lung Neoplasms; Positron-Emission Tomography; Radiation Injuries; Radiosurgery | 2022 |
Prognostic Value of MTV and TLG of
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Tumor Burden | 2021 |
Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2022 |
Is Delayed Image of 18F-FDG PET/CT Necessary for Mediastinal Lymph Node Staging in Non-Small Cell Lung Cancer Patients?
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2022 |
Disease Burden on PET Predicts Outcomes for Advanced NSCLC Patients Treated with First-Line Immunotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2022 |
The Value of the Standardized Uptake Value (SUV) and Metabolic Tumor Volume (MTV) in Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Burden | 2022 |
FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients.
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Positron Emission Tomography Computed Tomography | 2022 |
PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Positron-Emission Tomography; Precision Medicine; Radioisotopes; Radiopharmaceuticals; Tissue Distribution | 2022 |
Diagnostic Accuracy of F18-fluorodeoxyglucose Positron Emission Tomography- computed Tomography for the Detection of Non-small Cell Lung Cancer Recurrence: A Systematic Review and Meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2022 |
[What dose escalation in the treatment of locally advanced non-small cell lung cancer?]
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated | 2022 |
[A Resected Case of Mesenteric Nodal Metastases from Small Cell Lung Carcinoma].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Small Cell Lung Carcinoma | 2022 |
PET/CT in treatment response assessment in lung cancer. When should it be recommended?
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2023 |
Are segmentectomy and lobectomy comparable in terms of curative intent for early stage non-small cell lung cancer?
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Prognosis; Tomography, X-Ray Computed | 2020 |
Topics: Carcinoma, Non-Small-Cell Lung; Fiducial Markers; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiography, Interventional; Radiopharmaceuticals; Treatment Outcome | 2020 |
FDG PET/CT in the Staging of Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2020 |
18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals | 2020 |
18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Whole Body Imaging | 2020 |
Radiotherapy Planning and Molecular Imaging in Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Molecular Imaging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted | 2020 |
Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography | 2020 |
Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Odds Ratio; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Predictive Value of Tests; Preoperative Period | 2021 |
PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies | 2021 |
Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Waiting Lists | 2021 |
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2017 |
Role of interim
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2017 |
Prognostic Value of
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals | 2018 |
Non-Small-Cell Lung Cancer PET Imaging Beyond F18 Fluorodeoxyglucose.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung; Lung Neoplasms; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Somatostatin | 2018 |
CT, MRI, and F-18 FDG PET for the detection of non-small-cell lung cancer (NSCLC): A protocol for a network meta-analysis of diagnostic test accuracy.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Early Detection of Cancer; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Network Meta-Analysis; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2018 |
18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node-negative non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis | 2019 |
[Application of Metabolic Parameters Measured by ¹⁸F-FDG PET/CT in the Evaluation of the Prognosis of Non-small Cell Lung Cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis | 2019 |
Fluorodeoxyglucose-positron-emission tomography/computed tomography imaging for adrenal masses in patients with lung cancer: review and diagnostic algorithm.
Topics: Adrenal Gland Neoplasms; Algorithms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
[Highly conformal radiotherapy of primary and secondary lung malignancies].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiosurgery; Radiotherapy, Conformal | 2013 |
Combination of intravitreal bevacizumab and systemic therapy for choroidal metastases from lung cancer: report of two cases and a systematic review of literature.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Intravitreal Injections; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiosurgery; Survival Rate | 2014 |
Diagnostic value of dual time-point 18 F-FDG PET/CT versus single time-point imaging for detection of mediastinal nodal metastasis in non-small cell lung cancer patients: a meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinum; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed | 2015 |
Metabolic imaging in non-small-cell lung cancer radiotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose-Response Relationship, Radiation; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Organs at Risk; Patient Selection; Positron-Emission Tomography; Precision Medicine; Radiation Injuries; Radiopharmaceuticals; Radiotherapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided | 2014 |
Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals | 2015 |
[Radiological evaluation of the tumour response after lung stereotactic radiotherapy].
Topics: Aftercare; Algorithms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Disease-Free Survival; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Incidence; Lung Neoplasms; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiation Injuries; Radiation Pneumonitis; Radiopharmaceuticals; Radiosurgery; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
The evolving role of molecular imaging in non-small cell lung cancer radiotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Molecular Imaging; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Prognosis; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2015 |
[18F]Fluorodeoxyglucose PET in Thoracic Malignancies.
Topics: Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mesothelioma; Neoplasm Staging; Pleural Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thoracic Neoplasms; Thymus Neoplasms | 2014 |
Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Tumor Burden | 2015 |
Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Multimodal Imaging; Pneumonectomy; Positron-Emission Tomography; Preoperative Care; Prognosis; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2016 |
Comparison of 18F-FDG PET/CT and DWI for detection of mediastinal nodal metastasis in non-small cell lung cancer: A meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2017 |
Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).
Topics: Carcinoma, Non-Small-Cell Lung; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mediastinoscopy; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
Prognosis and reevaluation of lung cancer by positron emission tomography imaging.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed | 2009 |
Measuring response with FDG-PET: methodological aspects.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy, Adjuvant; Uterine Cervical Neoplasms | 2009 |
Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2009 |
The role of positron emission tomography in the management of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
[Response judgement - conventional versus new methods].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cone-Beam Computed Tomography; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Patient Care Team; Positron-Emission Tomography; Quality of Life; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Survival Rate; Tomography, Spiral Computed; Treatment Outcome | 2009 |
Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Tissue Distribution; Treatment Outcome | 2009 |
Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Positron-Emission Tomography; Prospective Studies | 2010 |
Sentinel node and positron emission tomography mapping in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Coloring Agents; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Rosaniline Dyes; Technetium | 2009 |
Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Part
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate | 2010 |
PET and PET-CT in radiation treatment planning for lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiation Dosage; Radiation Injuries; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Sensitivity and Specificity; Tomography, X-Ray Computed | 2010 |
[PET/CT for diagnostics and therapy stratification of lung cancer].
Topics: Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diagnosis, Differential; Disease Progression; Energy Metabolism; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radiographic Image Enhancement; Radiotherapy Planning, Computer-Assisted; Sensitivity and Specificity; Tomography, Spiral Computed; Tomography, X-Ray Computed | 2010 |
The use of FDG-PET to target tumors by radiotherapy.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals | 2010 |
Assessing extracranial tumors using diffusion-weighted whole-body MRI.
Topics: Adenoma, Liver Cell; Blood Glucose; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Contrast Media; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Processing, Computer-Assisted; Liver Neoplasms; Lung Neoplasms; Male; Multiple Myeloma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prostatic Neoplasms; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2011 |
Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Evidence-Based Medicine; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Prognosis; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2011 |
Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed; Whole Body Imaging | 2011 |
Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Mediastinum; Meta-Analysis as Topic; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Combined contrast-enhanced computed tomography and 18-fluoro-2-deoxy-D-glucose-positron emission tomography in the diagnosis and staging of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
[Radiotherapy of lung cancer: Any room left for elective mediastinal irradiation in 2011?].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Irradiation; Lymphatic Metastasis; Mediastinum; Neoplasm Staging; Organs at Risk; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Unnecessary Procedures | 2011 |
[Interest of FDG-PET for lung cancer radiotherapy].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinum; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Time Factors; Treatment Outcome; Tumor Burden | 2011 |
The use and misuse of positron emission tomography in lung cancer evaluation.
Topics: Carcinoma, Non-Small-Cell Lung; Diagnostic Errors; Fluorodeoxyglucose F18; Health Services Misuse; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2011 |
Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinal Neoplasms; Mediastinoscopy; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidence.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Molecular Targeted Therapy; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2012 |
Intramuscular metastases on FDG PET-CT: a review of the literature.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Muscle Neoplasms; Muscle, Skeletal; Oculomotor Muscles; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non--small-cell lung cancer.
Topics: Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Early Detection of Cancer; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Treatment Outcome | 2012 |
(18)FDG-PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer: a meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinal Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Sensitivity and Specificity | 2012 |
[Role of FDG-PET scanning in stage IIIAN2 non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals | 2012 |
Meta-analysis study of lymph node staging by 18 F-FDG PET/CT scan in non-small cell lung cancer: comparison of TB and non-TB endemic regions.
Topics: Carcinoma, Non-Small-Cell Lung; Comorbidity; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Risk Factors; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2012 |
Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Radiopharmaceuticals; Tomography, X-Ray Computed; Young Adult | 2012 |
The role of surgery for locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Multimodal Imaging; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
Virtual 18F-FDG PET/CT bronchoscopy for lymph node staging in non-small-cell lung cancer patients: present and future applications.
Topics: Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Endoscopy; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
Topics: Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve; Tomography, X-Ray Computed | 2013 |
18F-FDG-PET evaluation of pathological tumour response to neoadjuvant therapy in patients with NSCLC.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Positron emission tomography: lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
[Cost-effective PET investigations in oncology].
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Cost-Benefit Analysis; Diagnosis, Differential; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Hungary; Lung Neoplasms; Lymphoma; Medicare; Melanoma; Neoplasm Staging; Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Solitary Pulmonary Nodule; Tomography, Emission-Computed; Tomography, X-Ray Computed; United States | 2002 |
Positron emission tomography (PET) and combined imaging modalities for staging lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
Value of FDG-PET in the management of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinum; Radiopharmaceuticals; Solitary Pulmonary Nodule; Tomography, Emission-Computed | 2003 |
[18F-fluorodeoxyglucose positron emission tomography in the diagnosis of lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Cell Division; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 2002 |
Positron emission tomography in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Male; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Treatment Outcome | 2003 |
Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Positron emission tomography scanning for the diagnosis and management of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Neoplastic Processes; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed; Treatment Outcome | 2004 |
Positron emission tomography in the management of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
The role of FDG-PET in the management of non-small cell lung carcinoma.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, Emission-Computed | 2004 |
Role of FDG-PET in the diagnosis and management of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Patient Care Planning; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
FDG PET: advantages for staging the mediastinum?
Topics: Carcinoma, Non-Small-Cell Lung; Cost Savings; Endosonography; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mediastinum; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Value of FDG PET in the management of NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
Defining target volumes for non-small cell lung carcinoma.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Radiation; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Tomography, Emission-Computed | 2004 |
Response to radiation.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Research Design; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed | 2005 |
[The impact of integrating images of positron emission tomography with computed tomography simulation on radiation therapy planning].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Neoplasms; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Sensitivity and Specificity; Tomography, X-Ray Computed | 2004 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid | 2005 |
Clinical evaluation and staging of patients who have lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography | 2005 |
State-of-the-Art FDG-PET imaging of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2005 |
[Use of positron-emission tomography with F18-fluorodeoxyglucose for the assessment of lung lesions suspicious of malignancy].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Solitary Pulmonary Nodule | 2005 |
Critical review of PET-CT for radiotherapy planning in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2005 |
PET in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mesothelioma; Neoplasm Recurrence, Local; Neoplasm Staging; Pleural Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2005 |
Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Movement; Neoplasm Staging; Positron-Emission Tomography; Pulmonary Atelectasis; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2005 |
[The impact of 18F-fluorodeoxyglucose positron emission tomography on the 3D conformal radiotherapy planning in patients with non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiometry; Radiopharmaceuticals; Radiotherapy, Conformal; Sensitivity and Specificity | 2005 |
The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mediastinal Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed | 2006 |
Advances in positron emission tomographic imaging of lung cancer.
Topics: Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Hypoxia; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
CT and PET imaging in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2006 |
[Current status of 18F-FDG PET in predicting outcome of cancer therapy].
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Treatment Outcome | 2004 |
[Diagnosis of non-small-cell lung carcinoma (NSCLC)].
Topics: Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Endoscopy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Practice Guidelines as Topic; Practice Patterns, Physicians'; Radiopharmaceuticals | 2006 |
Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, Emission-Computed | 2006 |
Lung cancer.
Topics: Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diagnosis, Computer-Assisted; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Incidence; Lung; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiography, Thoracic; Radiopharmaceuticals; Risk Factors; Sex Factors; Time Factors; Tomography, X-Ray Computed | 2007 |
Clinical implications of defining the gross tumor volume with combination of CT and 18FDG-positron emission tomography in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Tomography, X-Ray Computed | 2007 |
PET/CT in non-small cell lung cancer staging-promises and problems.
Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Cost-Benefit Analysis; False Negative Reactions; False Positive Reactions; Fluorodeoxyglucose F18; Health Care Costs; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results | 2006 |
[Advances in research on biological target volume and conformal intensity-modulated radiotherapy].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasms; Positron-Emission Tomography; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Tumor Burden | 2006 |
Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC).
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Radiation; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Conformal; Tomography, X-Ray Computed; Tumor Burden | 2007 |
PET versus PET/CT dual-modality imaging in evaluation of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2007 |
Ensuring the right PET scan for the right patient.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Prognosis; Referral and Consultation; Tomography, X-Ray Computed | 2008 |
Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals | 2007 |
18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review.
Topics: Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinal Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Solitary Pulmonary Nodule; Technology Assessment, Biomedical | 2007 |
Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lu
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Survival Analysis | 2008 |
[Role of mediastinoscopy and repeat mediastinoscopy today].
Topics: Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mediastinoscopy; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2008 |
[Positron emission tomography in the diagnosis and follow up of non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals | 2007 |
Clinical applications of positron emission tomography/computed tomography treatment planning.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2008 |
The role of PET in target localization for radiotherapy treatment planning.
Topics: Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Lymphatic Irradiation; Lymphoma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiation Injuries; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Predictive and prognostic value of FDG-PET.
Topics: Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals | 2008 |
Prognostic value of posttreatment [18F] fluorodeoxyglucose uptake of primary non-small cell lung carcinoma treated with radiation therapy with or without chemotherapy: a brief review.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed | 2008 |
[Contribution of positron emission tomography for the management of lung cancer].
Topics: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2000 |
The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Tomography, Emission-Computed | 2001 |
18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Impact of FDG-labelled positron emission tomography imaging on the management of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Prognosis; Radionuclide Imaging; Radiopharmaceuticals | 2001 |
Positron emission tomography (PET) of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Metastasis; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2001 |
PET in lung cancer staging.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2001 |
[18FDG-PET applications in thoracic oncology].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Forecasting; Humans; Lung Neoplasms; Radionuclide Imaging; Radiopharmaceuticals | 2001 |
Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Organotechnetium Compounds; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Solitary Pulmonary Nodule; Somatostatin | 2002 |
FDG-PET imaging in the management of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed; Treatment Outcome | 2002 |
Imaging in lung cancer: positron emission tomography scan.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Radiopharmaceuticals; Sensitivity and Specificity; Solitary Pulmonary Nodule; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
172 trial(s) available for fluorodeoxyglucose f18 and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Noninvasive Method for Predicting the Expression of Ki67 and Prognosis in Non-Small-Cell Lung Cancer Patients: Radiomics.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2022 |
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiotherapy Dosage | 2023 |
Standard deviation of CT radiomic features among malignancies in each individual: prognostic ability in lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Studies as Topic; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2023 |
PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Recurrence; Retrospective Studies; Tomography, X-Ray Computed | 2023 |
Independent association of metabolic tumor response on FDG-PET with pulmonary toxicity following risk-adaptive chemoradiation for unresectable non-small cell lung cancer: Inherent radiosensitivity or immune response?
Topics: Carboplatin; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immunity; Lung Neoplasms; Paclitaxel; Pneumonia; Positron Emission Tomography Computed Tomography; Radiation Pneumonitis; Radiation Tolerance | 2023 |
Predictive and Prognostic Value of
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Nucleoside-Phosphate Kinase; Positron Emission Tomography Computed Tomography; Predictive Value of Tests | 2019 |
Does Tumor FDG-PET Avidity Represent Enhanced Glycolytic Metabolism in Non-Small Cell Lung Cancer?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2020 |
Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2020 |
Correlation between Skip N2 Metastases and SUV
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography | 2020 |
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Proto-Oncogene Proteins p21(ras); Sorafenib | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results | 2021 |
Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron Emission Tomography Computed Tomography; Precision Medicine; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2017 |
Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Radiation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2017 |
Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Risk Assessment; Survival Analysis | 2017 |
An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Patient-Centered Care; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Treatment Outcome | 2017 |
Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2017 |
Multifunctional Assessment of Non-Small Cell Lung Cancer: Perfusion-Metabolic Correlation.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Positron Emission Tomography Computed Tomography; Tumor Burden | 2018 |
Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: Results from the Gating 2006 trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal | 2018 |
18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies | 2018 |
A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II-III NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Radiation Tolerance; Radiopharmaceuticals; Radiotherapy Dosage | 2018 |
Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-small-cell Lung Cancer (NCT02788461).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Quality of Life; Radiopharmaceuticals; Radiotherapy, Conformal; Research Design; Survival Rate; Young Adult | 2018 |
Comparing Two Imaging Methods for Follow-Up of Lung Cancer Treatment: A Randomized Pilot Study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Switzerland; Tomography, X-Ray Computed | 2019 |
The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy; Radiotherapy Planning, Computer-Assisted | 2019 |
Investigating the histopathologic correlates of 18F-FDG PET heterogeneity in non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tumor Burden | 2018 |
Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Treatment Outcome | 2019 |
Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Germany; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Treatment Outcome; Tumor Burden | 2019 |
Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG-PET/CT radiomics.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Positron Emission Tomography Computed Tomography; Retrospective Studies; Survival Rate | 2019 |
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nadroparin; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Pneumonectomy; Positron-Emission Tomography | 2019 |
Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Topics: Adult; Aged; Aged, 80 and over; Brazil; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Estonia; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; India; Jordan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pakistan; Positron Emission Tomography Computed Tomography; Prospective Studies; Quality Control; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Treatment Outcome; Turkey; Vietnam | 2019 |
Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial.
Topics: Adult; Aged; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2013 |
Four-year results of low-dose CT screening and nodule management in the ITALUNG trial.
Topics: Adenocarcinoma; Aged; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Small Cell Lung Carcinoma; Time Factors; Tomography, X-Ray Computed | 2013 |
Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Metabolic Clearance Rate; Middle Aged; Multimodal Imaging; Observer Variation; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic | 2013 |
18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2013 |
Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Topics: Adult; Aged; Algorithms; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Misonidazole; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tumor Burden | 2013 |
Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Treatment Outcome | 2013 |
Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Tomography, X-Ray Computed | 2014 |
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recurrence; Tomography, X-Ray Computed | 2014 |
[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiography; Radiopharmaceuticals; Survival Rate; Time Factors | 2014 |
Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2).
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Accuracy of fluorodeoxyglucose-positron emission tomography within the clinical practice of the American College of Surgeons Oncology Group Z4031 trial to diagnose clinical stage I non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results | 2014 |
Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2014 |
Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Remission Induction; ROC Curve; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Proliferation; Chemoradiotherapy; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Neutrophils; Organ Specificity; Platinum; Positron-Emission Tomography; Spleen; Tomography, X-Ray Computed | 2014 |
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Survival Analysis | 2015 |
Percutaneous microwave ablation for early-stage non-small cell lung cancer (NSCLC) in the elderly: a promising outlook.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Microwaves; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2015 |
Use of FDG-PET to guide dose prescription heterogeneity in stereotactic body radiation therapy for lung cancers with volumetric modulated arc therapy: a feasibility study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Tissue Distribution; Tumor Burden | 2014 |
Evaluating tumor response of non-small cell lung cancer patients with ¹⁸F-fludeoxyglucose positron emission tomography: potential for treatment individualization.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Precision Medicine; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Treatment Outcome | 2015 |
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
[Oligoprogression].
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Retreatment; Survival Rate; Treatment Failure | 2015 |
Improved inter-observer agreement of an expert review panel in an oncology treatment trial--Insights from a structured interventional process.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Double-Blind Method; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Observer Variation; Outcome Assessment, Health Care; Positron-Emission Tomography; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2015 |
Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Nitroimidazoles; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Nitroimidazoles; Oxygen; Oxygen Consumption; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Triazoles | 2016 |
Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
Topics: Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Kinetics; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Observer Variation; Positron-Emission Tomography; Prognosis; Tomography, X-Ray Computed; Tumor Burden | 2016 |
IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: A direct comparison of PET-based treatment planning.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Imaging, Three-Dimensional; Lung Neoplasms; Lymphatic Irradiation; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed | 2016 |
Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Multivariate Analysis; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Treatment Failure | 2015 |
Planned FDG PET-CT Scan in Follow-Up Detects Disease Progression in Patients With Locally Advanced NSCLC Receiving Curative Chemoradiotherapy Earlier Than Standard CT.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Denmark; Disease Progression; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiography | 2015 |
Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Prognosis; Survival Analysis; Treatment Failure | 2016 |
Comparing the Diagnostic Potential of 68Ga-Alfatide II and 18F-FDG in Differentiating Between Non-Small Cell Lung Cancer and Tuberculosis.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Peptides, Cyclic; Positron Emission Tomography Computed Tomography; Tuberculosis | 2016 |
Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography | 2016 |
Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Cisplatin; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Failure; Tumor Burden | 2016 |
Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Demography; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Reproducibility of Results | 2016 |
Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Europe; Female; Fluorodeoxyglucose F18; Humans; Internationality; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Positron Emission Tomography Computed Tomography; Practice Guidelines as Topic; Radiopharmaceuticals; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Sensitivity and Specificity; Treatment Outcome | 2016 |
Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable St
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis | 2016 |
Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702).
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Treatment Outcome | 2016 |
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Netherlands; Nitroglycerin; Paclitaxel; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Vasodilator Agents | 2017 |
Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Lung Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated | 2016 |
Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Tumor Burden; United States | 2017 |
Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT.
Topics: Adenocarcinoma; Aged; Biopsy, Fine-Needle; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dose-Response Relationship, Radiation; Female; Fiber Optic Technology; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mass Screening; Middle Aged; Patient Selection; Positron-Emission Tomography; Radiation Dosage; Research Design; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2009 |
Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Statistics, Nonparametric; Survival Rate; Tomography, X-Ray Computed | 2008 |
Volumetric response analysis during chemoradiation as predictive tool for optimizing treatment strategy in locally advanced unresectable NSCLC.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Radiopharmaceuticals; Radiotherapy Dosage; Regression Analysis; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2009 |
Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies.
Topics: Adult; Aged; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Regression Analysis; Survival Rate; Treatment Outcome | 2009 |
18F-FDG PET/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: consideration of lymph node calcification and distribution pattern to improve specificity.
Topics: Calcinosis; Carcinoma, Non-Small-Cell Lung; Contrast Media; Endemic Diseases; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiography, Thoracic; Sensitivity and Specificity; Tomography, X-Ray Computed; Tuberculosis | 2009 |
A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiosurgery | 2010 |
Positron emission tomography in staging early lung cancer: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Brain; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Correlation of ¹⁸F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer.
Topics: Adult; Aged; Antigens, CD34; Biological Transport; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Positron-Emission Tomography; Survival Rate; Survivin | 2009 |
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.
Topics: Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; Time Factors; TOR Serine-Threonine Kinases | 2009 |
CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiosurgery; Salvage Therapy; Survival Analysis; Tomography, Emission-Computed | 2010 |
Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Computer-Assisted; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2010 |
Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cyclin D1; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2010 |
Impact of (18)F-FDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer: A prospective multicenter study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; France; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2010 |
Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Protein Kinase Inhibitors; Receptor, IGF Type 1; Treatment Outcome | 2011 |
Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Randomized follow-up study of resected NSCLC patients: conventional versus 18F-DG coincidence imaging.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gamma Cameras; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 2010 |
[Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Decision Making; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Palliative Care; Patient Care Planning; Pneumonectomy; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Whole Body Imaging | 2010 |
Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI.
Topics: Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Contrast Media; Fluorodeoxyglucose F18; Glucose; Humans; Image Enhancement; Lung Neoplasms; Magnetic Resonance Imaging; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies | 2011 |
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Topics: Biological Transport; Blood Glucose; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Feasibility Studies; Fluorodeoxyglucose F18; Guideline Adherence; Humans; Internationality; Lung Neoplasms; Positron-Emission Tomography; Quality Control; Quinazolines; Treatment Outcome | 2011 |
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Survival Analysis; Thymidine | 2011 |
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines | 2011 |
Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mediastinoscopy; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Thoracotomy; Tomography, X-Ray Computed | 2011 |
Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prospective Studies; ROC Curve; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2011 |
FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Positron-Emission Tomography; Prognosis; Treatment Outcome | 2011 |
Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Risk Assessment; Risk Factors; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Additional value of FDG-PET to contrast enhanced-computed tomography (CT) for the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer: a Japanese multicenter clinical study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Japan; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Young Adult | 2011 |
Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Radioactive Tracers; Tomography, X-Ray Computed; Tumor Burden | 2011 |
SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer?
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Small Cell Lung Carcinoma; Survival Rate | 2012 |
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Time Factors; Treatment Outcome | 2011 |
A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Phenotype; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2012 |
Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Republic of Korea; Risk Assessment; Risk Factors; Sensitivity and Specificity; Statistics as Topic; Survival Analysis; Survival Rate; Tomography, X-Ray Computed | 2012 |
False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; False Negative Reactions; Female; Fluorodeoxyglucose F18; Humans; Incidence; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Risk Factors; Tomography, X-Ray Computed | 2012 |
18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Likelihood Functions; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Quinazolines; Survival Analysis; Time Factors | 2012 |
Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
Topics: Aged; Aged, 80 and over; Blood Circulation; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Lung Neoplasms; Male; Microvessels; Middle Aged; Multimodal Imaging; Perfusion Imaging; Positron-Emission Tomography; Radionuclide Imaging; Tomography, X-Ray Computed; Tumor Burden | 2012 |
FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Proportional Hazards Models; Proton Therapy; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Quinazolines; Treatment Outcome | 2012 |
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Niacinamide; Paclitaxel; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Sorafenib; Tomography, X-Ray Computed | 2013 |
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Lung metastases treated with image-guided stereotactic body radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cone-Beam Computed Tomography; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Radiosurgery; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Interpretation, Computer-Assisted; Life Tables; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organotechnetium Compounds; Radiopharmaceuticals; Reproducibility of Results; Survival Analysis; Time Factors; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Radiopharmaceuticals; Sensitivity and Specificity; Technetium Tc 99m Medronate; Tomography, Emission-Computed; Whole-Body Irradiation | 2002 |
Comparison of [18F]FDG-PET and L-3[123I]-iodo-alpha-methyl tyrosine (I-123 IMT)-SPECT in primary lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Methyltyrosines; Middle Aged; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Whole-Body Counting | 2002 |
Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Survival Analysis; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Thoracic Neoplasms; Time Factors | 2003 |
Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Female; Fluorodeoxyglucose F18; Health Care Costs; Humans; Lung Neoplasms; Male; Neoplasm Staging; Netherlands; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
Optimisation of the OS-EM algorithm and comparison with FBP for image reconstruction on a dual-head camera: a phantom and a clinical 18F-FDG study.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Phantoms, Imaging; Quality Control; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Single-Blind Method; Tomography, Emission-Computed | 2003 |
Comparative impact of standard approach, FDG PET and FDG dual-head coincidence gamma camera imaging in preoperative staging of patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Predictive Value of Tests; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA.
Topics: Adult; Aged; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Endosonography; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2004 |
Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer.
Topics: Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Division; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glioma; Glucose Transporter Type 1; Humans; Lung Neoplasms; Male; Middle Aged; Monosaccharide Transport Proteins; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic | 2004 |
FDG-PET in staging lung cancer: how does it change the algorithm?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed | 2004 |
Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diagnostic Errors; False Positive Reactions; Female; Fluorodeoxyglucose F18; Germinal Center; Glucose Transporter Type 1; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Monosaccharide Transport Proteins; Neoplasm Staging; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic | 2004 |
Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; False Negative Reactions; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Lung Diseases; Lung Neoplasms; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2004 |
The benefit of functional-anatomical imaging with [18F]fluorodeoxyglucose utilizing a dual-head coincidence gamma camera with an integrated X-ray transmission system in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Image Enhancement; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2004 |
Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans.
Topics: Aged; Biopsy, Fine-Needle; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Endometrial Neoplasms; Esophagoscopy; Female; Fluorodeoxyglucose F18; Granuloma; Histiocytosis; Histoplasmosis; Humans; Kidney Neoplasms; Lung Diseases; Lung Neoplasms; Lymphatic Diseases; Lymphatic Metastasis; Lymphoma; Male; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sarcoidosis; Silicosis; Tomography, X-Ray Computed; Ultrasonography, Interventional; Urinary Bladder Neoplasms | 2005 |
Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2005 |
Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; ROC Curve; Sensitivity and Specificity | 2005 |
[Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Survival Analysis | 2005 |
Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Irradiation; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiography; Radiopharmaceuticals | 2005 |
Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Patient Selection; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2006 |
Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2005 |
Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2005 |
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Monitoring; Europe; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Multivariate Analysis; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Single-Blind Method; Survival Analysis | 2005 |
[18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Misonidazole; Positron-Emission Tomography; Prospective Studies; Pulmonary Embolism; Radiopharmaceuticals; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Time Factors | 2006 |
FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mediastinum; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Sentinel Lymph Node Biopsy; Tomography, X-Ray Computed | 2006 |
Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose Fractionation, Radiation; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiation Injuries; Radiosurgery; Radiotherapy Dosage; Survival Analysis | 2006 |
18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Germany; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prevalence; Prognosis; Radiopharmaceuticals; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2007 |
Diagnosis efficacy of structural (CT) and functional (FDG-PET) imaging methods in the thoracic and extrathoracic staging of non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Tomography, X-Ray Computed | 2007 |
Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Taxoids; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Probability; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome; Tumor Burden; Vinblastine; Vinorelbine | 2007 |
The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prevalence; Prognosis; Radiography; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity | 2007 |
Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Netherlands; Positron-Emission Tomography; Prognosis; Reproducibility of Results; Sensitivity and Specificity; Survival Analysis; Survival Rate; Treatment Outcome | 2007 |
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Dimerization; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Protein Structure, Tertiary; Receptor, ErbB-2; Time Factors; Treatment Outcome | 2007 |
Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Movement; Neoplasm Staging; Observer Variation; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Respiration; Time Factors; Tomography, X-Ray Computed; Tumor Burden | 2008 |
HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose Fractionation, Radiation; Esophagus; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy, Conformal; Survival Analysis | 2008 |
Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Time Factors | 2009 |
Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Contrast Media; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Enhancement; Iohexol; Lung; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Observer Variation; Positron-Emission Tomography; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2008 |
Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Preoperative Care; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed | 1994 |
FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Lymphatic Metastasis; Mediastinal Neoplasms; Middle Aged; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1998 |
Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Pilot Projects; Prospective Studies; Radiopharmaceuticals; Survival Analysis; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1998 |
Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
Imaging of lung cancer with fluorine-18 fluorodeoxyglucose: comparison of a dual-head gamma camera in coincidence mode with a full-ring positron emission tomography system.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
Staging of lymph nodes with FDG dual-headed PET in patients with non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
FDG PET of pleural effusions in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Pleural Effusion, Malignant; Radiopharmaceuticals; Tomography, Emission-Computed | 2000 |
Preoperative staging of non-small-cell lung cancer with positron-emission tomography.
Topics: Adult; Aged; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Staging; Prospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed; Ultrasonography | 2000 |
High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Predictive Value of Tests; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Survival Analysis | 2001 |
(18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Survival Analysis | 2001 |
FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Treatment Outcome; Vinblastine | 2002 |
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Radiopharmaceuticals; Thoracotomy; Time Factors; Tomography, Emission-Computed; Unnecessary Procedures | 2002 |
FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radionuclide Imaging; Radiopharmaceuticals | 2002 |
1147 other study(ies) available for fluorodeoxyglucose f18 and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
The expression of miRNA-216b is negatively correlated with 18F-FDG uptake in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; MicroRNAs; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2021 |
Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2021 |
Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Positron Emission Tomography Computed Tomography; Radiotherapy, Image-Guided; Ultrasonography | 2021 |
The importance of anatomical localization of non-small cell lung carcinoma in predicting mediastinal lymph node metastasis.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2022 |
Multi-level multi-modality (PET and CT) fusion radiomics: prognostic modeling for non-small cell lung carcinoma.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Prognosis; Tomography, X-Ray Computed | 2021 |
Isotoxic investigation of
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2021 |
Pre-surgical assessment of mediastinal lymph node metastases in patients having ≥ 30 mm non-small-cell lung cancers.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Retrospective Studies | 2021 |
Segmentectomy versus lobectomy for solid predominant cN0 lung cancer: analysis using visual evaluation of positron emission tomography.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Pneumonectomy; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Retrospective Studies | 2022 |
Pulmonary Sarcomatoid Carcinoma With Epiglottis and Ileum Metastasis Detected by 18F-FDG PET/CT.
Topics: Carcinoma; Carcinoma, Non-Small-Cell Lung; Epiglottis; Fluorodeoxyglucose F18; Humans; Ileum; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2022 |
Maximum Standardized Uptake Value: An Additional Feature for Stratifying Early-Stage Lung Cancer Patients.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2022 |
Effects of Tracer Uptake Time in Non-Small Cell Lung Cancer
Topics: Carcinoma, Non-Small-Cell Lung; Cross-Sectional Studies; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms | 2022 |
Relationship between 18F-FDG PET/CT radiometabolic markers and EGFR mutation, positive ALK Expression in patients with non-small cell lung cancer.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mutation; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2021 |
Which will carry more weight when CTR > 0.5, solid component size, CTR, tumor size or SUVmax?
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2022 |
Tumorous tissue characterization using integrated 18F-FDG PET/dual-energy CT in lung cancer: Combining iodine enhancement and glycolytic activity.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Iodine; Lung Neoplasms; Neoplasm Staging; Pilot Projects; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2022 |
Visual Assessment of 18F-FDG Uptake on PET to Predict Survival Benefit to PD-1 Blockade in Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Programmed Cell Death 1 Receptor; Radiopharmaceuticals; Retrospective Studies | 2022 |
Differentiation of Reactive Lymph Nodes and Tumor Metastatic Lymph Nodes With 68Ga-FAPI PET/CT in a Patient With Squamous Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Epithelial Cells; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Positron Emission Tomography Computed Tomography; Quinolines | 2022 |
Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Necrosis; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2022 |
Test-retest repeatability and interobserver variation of healthy tissue metabolism using 18F-FDG PET/CT of the thorax among lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Observer Variation; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Thorax | 2022 |
Predictive value of multiple metabolic and heterogeneity parameters of
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mutation; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2022 |
Tumor response evaluation by combined modalities of chest magnetic resonance imaging and computed tomography in locally advanced non-small cell lung cancer after concurrent chemoradiotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Prognosis; Tomography, X-Ray Computed; Treatment Outcome | 2022 |
SUVmax to tumor perimeter distance: a robust radiomics prognostic biomarker in resectable non-small cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2022 |
Prediction of cardiac events following concurrent chemoradiation therapy for non-small-cell lung cancer using FDG PET.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2022 |
Pretherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography robust radiomic features predict overall survival in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Retrospective Studies | 2022 |
Detection of Recurrence After Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2022 |
Evaluation of Amide Proton Transfer-Weighted Imaging for Lung Cancer Subtype and Epidermal Growth Factor Receptor: A Comparative Study With Diffusion and Metabolic Parameters.
Topics: Amides; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Protons; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2022 |
Synergistic impact of motion and acquisition/reconstruction parameters on
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Retrospective Studies | 2022 |
Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiosurgery; Recurrence; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Treatment Outcome | 2022 |
The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT.
Topics: B7-H1 Antigen; Biopsy; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Pilot Projects; Positron Emission Tomography Computed Tomography; Retrospective Studies; Tomography, X-Ray Computed | 2022 |
Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2022 |
Pituitary Metastasis of Non-Small Cell Lung Cancer With High FDG Uptake on PET/CT Pituitary Metastasis of Non-Small Cell Lung Carcinoma.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Pituitary Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2022 |
Diagnostic Value of Nodal Staging of Lung Cancer With Usual Interstitial Pneumonia Using PET.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Lymph Nodes; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Retrospective Studies; Sensitivity and Specificity | 2022 |
Different Prognostic Values of Dual-Time-Point FDG PET/CT Imaging Features According to Treatment Modality in Patients with Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2022 |
Delineating and sparing functional nephrons for radiotherapy in the case of lymphoma with polycystic kidney disease.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Male; Nephrons; Polycystic Kidney Diseases; Radiopharmaceuticals | 2022 |
Role of fluorodeoxyglucose-positron emission tomography in predicting the pathological response and prognosis after neoadjuvant chemoradiotherapy for locally advanced non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoadjuvant Therapy; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2022 |
Prognostic value of node-to-primary tumor maximum standardized uptake value ratio in T1-4N1-3M0 non-small cell lung cancer patients treated with concurrent chemo-radiotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Prognosis; Retrospective Studies | 2022 |
Necrosis on pre-radiotherapy 18F-FDG PET/CT is a predictor for complete metabolic response in patients with non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Necrosis; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2022 |
Predictive value of quantitative metabolic tumor volume and metabolic index analysis in lung cancer stereotactic radiotherapy with F-18 FDG PET/CT.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Tumor Burden | 2022 |
Contribution of Metabolic Tumor Volume and Total Lesion Glycolysis to Predict Prognosis in Early-Stage Lung Cancer at Preoperative Staging.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2022 |
Clinical Effects of PET-CT Before Definite Concurrent Chemoradiotherapy in Patients With Unresectable Stage IIIA-IIIB Squamous Cell Carcinoma of the Lungs.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2022 |
Potential advantages of FDG-PET radiomic feature map for target volume delineation in lung cancer radiotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
Editorial for "Computed DWI Results in Superior Capability for N-Stage Assessment of Non-Small Cell Lung Cancer than that of Actual DWI, STIR Imaging and FDG-PET/CT".
Topics: Carcinoma, Non-Small-Cell Lung; Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
Topics: Adenocarcinoma; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2022 |
The correlation between PD-L1 expression and metabolic parameters of
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2022 |
Negative Correlation Between
Topics: Animals; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Lung Neoplasms; Mice; Oligopeptides; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Programmed Cell Death 1 Receptor | 2022 |
PM2.5 promotes NSCLC carcinogenesis through translationally and transcriptionally activating DLAT-mediated glycolysis reprograming.
Topics: Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Lung Neoplasms; Particulate Matter; Positron Emission Tomography Computed Tomography | 2022 |
Assessment of Correlation between Dual-Energy Ct (De-Ct)-Derived Iodine Concentration and Local Flourodeoxyglucose (Fdg) Uptake in Patients with Primary Non-Small-Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Iodine; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2022 |
Prognostic impact of the tumor volume doubling time in clinical T1 non-small cell lung cancer with solid radiological findings.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Tumor Burden | 2022 |
Comparison of lung cancer aggressiveness in patients who never smoked compared to those who smoked.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; Smoke | 2022 |
Personalized mid-course FDG-PET based adaptive treatment planning for non-small cell lung cancer using machine learning and optimization.
Topics: Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Machine Learning; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Retrospective Studies | 2022 |
Integrated 18F-FDG PET/CT parameter defines metabolic oligometastatic non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2022 |
FDG PET/CT in Isolated Nasal Cavity Metastasis From Squamous Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Epithelial Cells; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Nasal Cavity; Positron Emission Tomography Computed Tomography | 2022 |
Comparison of 18 F-FDG PET/CT and 68 Ga-FAPI-04 PET/CT in patients with non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Quinolines; Retrospective Studies; Tomography, X-Ray Computed | 2022 |
IMPORTANCE of PRETREATMENT 18F-FDG PET/CT TEXTURE ANALYSIS in PREDICTING EGFR and ALK MUTATION in PATIENTS with NON-SMALL CELL LUNG CANCER.
Topics: Anaplastic Lymphoma Kinase; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mutation; Positron Emission Tomography Computed Tomography | 2022 |
Prognostic Potential of Metabolic Activity on 18 F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade.
Topics: Albumins; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Prognosis; Programmed Cell Death 1 Receptor; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2022 |
Correlation of [18F]FDG PET activity with expressions of Ki-67 in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2022 |
Predictive Value of
Topics: Adenocarcinoma of Lung; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2023 |
Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non-Small Cell Lung Cancer from Tuberculosis.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 8; Cell-Free Nucleic Acids; DNA, Neoplasm; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tuberculosis | 2023 |
Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study.
Topics: Carcinoma, Non-Small-Cell Lung; Early Detection of Cancer; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2022 |
Systematic endoscopic staging of mediastinum to determine impact on radiotherapy for locally advanced lung cancer (SEISMIC): protocol for a prospective single arm multicentre interventional study.
Topics: Carcinoma, Non-Small-Cell Lung; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Multicenter Studies as Topic; Neoplasm Staging; Prospective Studies | 2022 |
Invasive area to tumor ratio is a significant prognostic factor for non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Retrospective Studies | 2022 |
Preoperative prediction of mediastinal lymph node metastasis in non-small cell lung cancer based on
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Nomograms; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2023 |
A whole-body FDG-PET/CT Dataset with manually annotated Tumor Lesions.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2022 |
A novel analytical approach for outcome prediction in newly diagnosed NSCLC based on [
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2023 |
PET morphology helps distinguish solitary and solid pulmonary tuberculosis from non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tuberculosis, Pulmonary | 2023 |
Consistency and prognostic value of preoperative staging and postoperative pathological staging using
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2022 |
Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Fluorodeoxyglucose F18; Glucose; Glucose Transporter Type 1; Humans; Lung Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors | 2023 |
Comments on "dynamic
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lung Neoplasms; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Tumor Burden | 2022 |
The combined tumor-nodal glycolytic entropy improves survival stratification in nonsmall cell lung cancer with locoregional disease.
Topics: Carcinoma, Non-Small-Cell Lung; Entropy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2023 |
Application of 18 F-fluorodeoxyglucose PET/CT radiomic features and machine learning to predict early recurrence of non-small cell lung cancer after curative-intent therapy.
Topics: Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Machine Learning; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Retrospective Studies | 2023 |
Whole-Body PET Imaging: A Catalyst for Whole-Person Research?
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Whole Body Imaging | 2023 |
Role of
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Sarcopenia; Tumor Burden | 2023 |
Prognostic role of baseline
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2023 |
Benign lymphoid hyperplasia mimicking oligometastasis from non-small cell lung cancer after stereotactic ablative radiotherapy.
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Hyperplasia; Lung Neoplasms; Male; Radiosurgery | 2022 |
Developing a primary tumor and lymph node 18F-FDG PET/CT-clinical (TLPC) model to predict lymph node metastasis of resectable T2-4 NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2023 |
Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis.
Topics: Carcinoma; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2023 |
Do fine needle aspirate cytomorphological features correlate with positron emission tomography findings of metastatic non-small cell lung carcinoma in lymph nodes?
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies | 2023 |
Inflammation after catheterisation mimicking tumour with squamous cell lung carcinoma in positron emission tomography.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Epithelial Cells; Fluorodeoxyglucose F18; Humans; Inflammation; Lung; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Deep learning model integrating positron emission tomography and clinical data for prognosis prediction in non-small cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Deep Learning; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2023 |
Usefulness of 18 F-FDG PET/computed tomography metabolic parameters in predicting sarcopenia and prognosis of treatment-naive patients with non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Positron Emission Tomography Computed Tomography; Prognosis; Quality of Life; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2023 |
Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2023 |
Estimation of an Image Biomarker for Distant Recurrence Prediction in NSCLC Using Proliferation-Related Genes.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2023 |
A machine learning tool to improve prediction of mediastinal lymph node metastases in non-small cell lung cancer using routinely obtainable [
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2023 |
Genomic and Glycolytic Entropy Are Reliable Radiogenomic Heterogeneity Biomarkers for Non-Small Cell Lung Cancer.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Entropy; Fluorodeoxyglucose F18; Genomics; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Retrospective Studies | 2023 |
Predictive value of
Topics: Bone Diseases; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Hydrolases; Lung Neoplasms; Metabolic Diseases; Positron Emission Tomography Computed Tomography; Programmed Cell Death 1 Receptor; Retrospective Studies | 2023 |
Metabolic patterns on [
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2023 |
Chemical Exchange Saturation Transfer MRI: Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non-Small Cell Lung Cancer Patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals | 2023 |
The value on SUV-derived parameters assessed on
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Positron Emission Tomography Computed Tomography | 2023 |
Prognostic value of TLR from FDG PET/CT in patients with margin-negative stage IB and IIA non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2023 |
Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes.
Topics: Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Programmed Cell Death 1 Receptor | 2023 |
Automated detection, delineation and quantification of whole-body bone metastasis using FDG-PET/CT images.
Topics: Carcinoma, Non-Small-Cell Lung; Computers; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tomography, X-Ray Computed | 2023 |
18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial: Should dose intensification be discontinued or should accelerated schemes r
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Atypical radiological onset of lung cancer: An exceptional PET/CT image.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Re-Irradiation; Retrospective Studies; Tumor Burden | 2023 |
Diagnostic value of [ 68 Ga]Ga-Pentixafor versus [ 18 F]FDG PET/CTs in non-small cell lung cancer: a head-to-head comparative study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Middle Aged; Positron Emission Tomography Computed Tomography | 2023 |
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Risk Factors | 2023 |
The Utility of SUVmax as an Adaptation Criterion for Limited Resection in Stage IA Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2023 |
Accuracy of nodal staging by 18F-FDG-PET/CT in limited disease small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Retrospective Studies; Sensitivity and Specificity; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2023 |
The Effect of GLUT1 and HIF-1α Expressions on Glucose Uptake and Patient Survival in Non-Small-Cell Lung Carcinoma.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Glucose; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Clinical utility of [
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphadenopathy; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
18 F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2023 |
A Prospective Study Comparing Dosimetry between Computed Tomography (CT) based Radiation Planning and Positron Emission Computed Tomography (PET-CT) based Radiation Planning in Treatment of Non-Metastatic Non Small Cell Lung Carcinoma.
Topics: Carcinoma, Non-Small-Cell Lung; Electrons; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2023 |
Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lung Neoplasms; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Retrospective Studies; Treatment Outcome | 2023 |
[
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lung Neoplasms; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography | 2023 |
Exploring the correlation between HER2 alterations and
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2023 |
Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Liver; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2023 |
A novel [
Topics: Animals; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Mice; Positron Emission Tomography Computed Tomography; Programmed Cell Death 1 Receptor | 2023 |
Asymptomatic Penetrating Atherosclerotic Ulcer Findings on 18 F-FDG PET/CT.
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Penetrating Atherosclerotic Ulcer; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2023 |
Prognostic Impact of Cancer Inflammation Prognostic Index for Non-small Cell Lung Cancer.
Topics: Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Inflammation; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies | 2023 |
Early Prediction of Radiotherapeutic Efficacy in a Mouse Model of Non-Small Cell Lung Carcinoma Using
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Combination of tumor asphericity and an extracellular matrix-related prognostic gene signature in non-small cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Precision Medicine; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2023 |
Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tumor Burden | 2020 |
Positron Emission Tomography in T3/T4 Non-Small Cell Lung Cancer After Induction Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2020 |
Development and Validation of a
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2020 |
Effects of alterations in positron emission tomography imaging parameters on radiomics features.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Phantoms, Imaging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2019 |
Bone Marrow and Tumor Radiomics at
Topics: Aged; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Retrospective Studies; Risk Assessment | 2019 |
Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gamma Rays; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Positron Emission Tomography Computed Tomography; Prognosis; Progression-Free Survival; Proportional Hazards Models; Radiopharmaceuticals; Remission Induction; Retrospective Studies; Taxoids; Tumor Burden; Vinorelbine | 2019 |
Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Tumor Burden | 2019 |
Usefulness of gradient tree boosting for predicting histological subtype and EGFR mutation status of non-small cell lung cancer on
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Mutation; Positron Emission Tomography Computed Tomography; ROC Curve | 2020 |
Value of pre-therapy
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mutation; Positron Emission Tomography Computed Tomography | 2020 |
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Tumor Burden | 2020 |
Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy.
Topics: Carbon; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2020 |
Prognostic value of dual-point fluorine-18 fluorodeoxyglucose PET imaging, partial volume correction and glucose transporter-1 expression in resected nonsmall cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Survival Analysis | 2020 |
Prognostic value of 18F-FDG PET parameters in patients with locally advanced non-small cell lung cancer treated with induction chemotherapy.
Topics: Adenocarcinoma of Lung; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate | 2020 |
Comparison Between
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Radiomics of
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prospective Studies; Retrospective Studies | 2020 |
Homological radiomics analysis for prognostic prediction in lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Databases, Factual; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Pattern Recognition, Automated; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Radiometry; Reproducibility of Results; Treatment Outcome; Wavelet Analysis | 2020 |
The Effect of Carbogen Breathing on
Topics: A549 Cells; Animals; Carbon Dioxide; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Heterografts; Humans; Hypoxia; Immunohistochemistry; Lung; Lung Neoplasms; Mice; Mice, Nude; Oxygen; Positron-Emission Tomography; Tissue Distribution | 2019 |
Correlation between combining
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mutation; Positron Emission Tomography Computed Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2020 |
Influx rate constant of
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Positron-Emission Tomography | 2020 |
18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1-Positive Non-Small Cell Lung Cancer.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Crizotinib; Fluorodeoxyglucose F18; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Pyrazoles; Radiopharmaceuticals | 2020 |
Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission tomography/computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer: a two-center propensity score-matched analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Consolidation Chemotherapy; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Propensity Score; Radiopharmaceuticals; Retrospective Studies | 2020 |
The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate | 2020 |
Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Imaging Genomics; Lung; Lung Neoplasms; Machine Learning; Male; Mutation; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity | 2021 |
Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2020 |
Robust, independent and relevant prognostic 18F-fluorodeoxyglucose positron emission tomography radiomics features in non-small cell lung cancer: Are there any?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis | 2020 |
Topics: Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2020 |
Reply: Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2020 |
Less is more in radiotherapy target volume planning: lessons from the PET-plan trial.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography | 2020 |
Tumor-to-liver standard uptake ratio using fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography effectively predict occult lymph node metastasis of non-small cell lung cancer patients.
Topics: Adult; Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Liver; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Preoperative Period; Retrospective Studies; Risk Factors | 2020 |
Stereotactic body radiotherapy in patients with lung tumors composed of mainly ground-glass opacity.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiosurgery; Retrospective Studies; Tomography, X-Ray Computed | 2020 |
Topics: Aged; Betacoronavirus; Carcinoma, Non-Small-Cell Lung; Coronavirus Infections; COVID-19; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Pandemics; Pneumonia, Viral; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; SARS-CoV-2 | 2020 |
Topics: B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Transcriptome; Tumor Microenvironment | 2020 |
Prediction of FDG-PET stage and uptake for non-small cell lung cancer on non-contrast enhanced CT scans via fractal analysis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Fractals; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2020 |
Optimal image guidance for tumor biopsy in non-small-cell lung cancer.
Topics: Biomarkers; Biopsy; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Lung Neoplasms; Positron Emission Tomography Computed Tomography | 2020 |
Tumor Segmentation and Feature Extraction from Whole-Body FDG-PET/CT Using Cascaded 2D and 3D Convolutional Neural Networks.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neural Networks, Computer; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2020 |
SUR for mediastinal metastatic lymph node status in non-small-cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Mediastinum | 2020 |
Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Retrospective Studies; ROC Curve; Tomography, X-Ray Computed | 2020 |
Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis.
Topics: Adult; Aged; Aspirin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tumor Microenvironment | 2020 |
[Target volume reduction by
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Reference Standards | 2020 |
Is FDG-PET/CT used correctly in the combined approach for nodal staging in NSCLC patients?
Topics: Adult; Aged; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; Endosonography; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2020 |
Pre-surgical assessment of mediastinal lymph node metastases in Stage IA non-small-cell lung cancers.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2020 |
Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Phenotype; Positron Emission Tomography Computed Tomography | 2020 |
Predictive value of interim 18F-FDG-PET in patients with non-small cell lung cancer treated with definitive radiation therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prognosis; Progression-Free Survival; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tumor Burden | 2020 |
Segmentation in Non-Small Cell Lung Tumors Using 18F-FDG PET/CT: Tips and Rules.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography | 2020 |
Nivolumab-Induced Periaortitis Demonstrated by FDG PET/CT.
Topics: Aged; Aortitis; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Nivolumab; Positron Emission Tomography Computed Tomography | 2020 |
[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors | 2020 |
Relationship between SP142 PD-L1 Expression and
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Positron Emission Tomography Computed Tomography | 2020 |
18F-fluorodeoxyglucose positron emission tomography/computed tomography findings in descending necrotizing mediastinitis and cervical vertebral osteomyelitis in a cancer patient: A case report.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cervical Vertebrae; Fatal Outcome; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mediastinitis; Osteomyelitis; Positron Emission Tomography Computed Tomography | 2020 |
Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiosurgery; Retrospective Studies; Time Factors | 2020 |
Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed | 2020 |
Diagnosis of recurrence and follow-up using FDG-PET/CT for postoperative non-small-cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2021 |
Tumor metabolic volume by
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Adding the temporal domain to PET radiomic features.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Time Factors | 2020 |
Correlation between preoperative
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Idiopathic Interstitial Pneumonias; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Positron Emission Tomography Computed Tomography; Postoperative Period; Preoperative Period; Prognosis; Survival Rate; Time Factors | 2021 |
Value of interim
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Progression-Free Survival; Retrospective Studies | 2020 |
Sensitivity analysis of FDG PET tumor voxel cluster radiomics and dosimetry for predicting mid-chemoradiation regional response of locally advanced lung cancer.
Topics: Adult; Aged; Algorithms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiometry; ROC Curve; Treatment Outcome; Tumor Burden | 2020 |
Machine learning based on clinico-biological features integrated
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Machine Learning; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2021 |
The potential of
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2020 |
COV is a readily available quantitative indicator of metabolic heterogeneity for predicting survival of patients with early and locally advanced NSCLC manifesting as central lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Evaluation Studies as Topic; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Survival Rate | 2020 |
FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Tumor Burden | 2020 |
Long-term Survival with 18-Fluorodeoxyglucose Positron Emission Tomography-directed Therapy in Non-small Cell Lung Cancer with Synchronous Solitary Brain Metastasis.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2021 |
Can alternative PET reconstruction schemes improve the prognostic value of radiomic features in non-small cell lung cancer?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Risk Assessment | 2021 |
Machine learning-based diagnostic method of pre-therapeutic
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Machine Learning; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2021 |
Plausibility and redundancy analysis to select FDG-PET textural features in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Positron-Emission Tomography; Reproducibility of Results; Tomography, X-Ray Computed | 2021 |
PET standardized uptake values of primary lung cancer for comparison with tumor volume doubling times.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2021 |
Quantifying intratumor heterogeneity of lung neoplasms with radiomics.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Fractals; Humans; Lung Neoplasms; Tomography, X-Ray Computed | 2021 |
Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Monocytes; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2021 |
Association between
Topics: Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Lung; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2021 |
Prognostic impact of maximum standardized uptake value on
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2021 |
Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?
Topics: Aged; Carcinoma; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; High-Throughput Nucleotide Sequencing; Humans; Lung; Lung Neoplasms; Male; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2021 |
Impact of EBUS-TBNA in addition to [
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Mediastinum; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2021 |
Improving accuracy of 18F-fluorodeoxyglucose PET computed tomography to diagnose nodal involvement in non-small cell lung cancer: utility of using various predictive models.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Sensitivity and Specificity | 2021 |
Positron Emission Tomography in Segmentectomy for cT1N0M0 Nonsmall Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden | 2021 |
Multiblock Discriminant Analysis of Integrative
Topics: Aged; Aged, 80 and over; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Discriminant Analysis; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Statistics, Nonparametric; Tumor Burden | 2021 |
Recurrent feature fusion learning for multi-modality pet-ct tumor segmentation.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Positron Emission Tomography Computed Tomography | 2021 |
Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2021 |
Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Energy Metabolism; Female; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Progression-Free Survival; Radiopharmaceuticals; Retrospective Studies; Time Factors; Tumor Microenvironment | 2021 |
Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors.
Topics: Aged; Aged, 80 and over; Cachexia; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Radiographic Image Interpretation, Computer-Assisted; Retrospective Studies; Treatment Outcome | 2021 |
Can surgical adhesives may cause false positivity in follow-up positron emission tomography after lung cancer resection?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; False Positive Reactions; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2021 |
Correlation between PET/CT findings and pathological features of mediastinal lymph nodes in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Mediastinum; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2022 |
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Clinical Decision-Making; Female; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome; Tumor Burden | 2021 |
Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy and chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2021 |
Prognostic Value of Computed Tomography and/or
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2021 |
FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Expressed Sequence Tags; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Mediastinum; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Practice Guidelines as Topic; Prospective Studies; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed; Workflow | 2021 |
Editorial Comment: Metabolic Tumor Volume on FDG PET/CT for Predicting Lymphovascular Invasion of Non-Small Cell Lung Cancer-Proceed With Caution.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tumor Burden | 2021 |
Prospective Evaluation of the First Integrated Positron Emission Tomography/Dual-Energy Computed Tomography System in Patients With Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Pilot Projects; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2021 |
Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Surgically Treated Stage I Lung Adenocarcinoma Patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Tumor Burden | 2021 |
Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution.
Topics: Carcinoma; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2021 |
Osteogenic and brain metastases after non-small cell lung cancer resection.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Positron-Emission Tomography; Quality of Life; Retrospective Studies | 2021 |
The optimal timing of FDG-PET/CT in non-small cell lung cancer diagnosis and staging in an Australian centre.
Topics: Adenocarcinoma; Aged; Australia; Biopsy; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Trees; Female; Fluorodeoxyglucose F18; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2021 |
Preoperative Maximum Standardized Uptake Value Associated With Recurrence Risk in Early Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2022 |
The diagnostic value of metabolic, morphological and heterogeneous parameters of 18F-FDG PET/CT in mediastinal lymph node metastasis of non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Positron Emission Tomography Computed Tomography | 2021 |
Maximum standardized uptake value of the primary tumor does not improve candidate selection for sublobar resection.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Retrospective Studies | 2022 |
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2021 |
Fully Integrated Quantitative Multiparametric Analysis of Non-Small Cell Lung Cancer at 3-T PET/MRI: Toward One-Stop-Shop Tumor Biological Characterization at the Supervoxel Level.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Positron-Emission Tomography | 2021 |
Lung Cancers Associated With Cystic Airspaces: Natural History, Pathologic Correlation, and Mutational Analysis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2017 |
Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunohistochemistry; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Pneumonectomy; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Time Factors | 2017 |
Spatial Evidential Clustering With Adaptive Distance Metric for Tumor Segmentation in FDG-PET Images.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Positron-Emission Tomography | 2018 |
FDG PET/CT as theranostic imaging in diagnosis of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Neoplasm Staging; Outcome Assessment, Health Care; Positron Emission Tomography Computed Tomography; Prognosis; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Theranostic Nanomedicine | 2017 |
Dose painting by means of Monte Carlo treatment planning at the voxel level.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Monte Carlo Method; Photons; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2017 |
The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; ROC Curve; Tumor Burden | 2017 |
Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy - the influence of the choice of the reference region and conversion function.
Topics: Aorta; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Hypoxia; Lung Neoplasms; Muscles; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Image-Guided; Reference Standards | 2017 |
Response assessment of stereotactic body radiation therapy using dynamic contrast-enhanced integrated MR-PET in non-small cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Contrast Media; Disease Progression; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiosurgery; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cohort Studies; Deoxyglucose; Female; Fluorodeoxyglucose F18; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucose; Glucose Transporter Type 1; Glycolysis; Humans; Hydroxybenzoates; Lung; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Phenotype; Positron-Emission Tomography; Prognosis; Survival Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
Topics: Academic Medical Centers; Adult; Aged; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Cause of Death; Databases, Factual; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prognosis; Retrospective Studies; ROC Curve; Statistics, Nonparametric; Survival Analysis | 2017 |
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autoantibodies; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Fluorodeoxyglucose F18; HLA-DR Antigens; Humans; Hypothyroidism; Immunoglobulins, Thyroid-Stimulating; Iodide Peroxidase; Iron-Binding Proteins; Killer Cells, Natural; Lung Neoplasms; Male; Melanoma; Middle Aged; Monocytes; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Thyroid Function Tests; Thyroiditis; Thyrotropin; Thyroxine; Triiodothyronine; Young Adult | 2017 |
Reply: Repeatability of Quantitative Whole-Body
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2017 |
Assessment of nodal involvement in non-small-cell lung cancer with 18F-FDG-PET/CT: mediastinal blood pool cut-off has the highest sensitivity and tumour SUVmax/2 has the highest specificity.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gated Blood-Pool Imaging; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies; ROC Curve | 2017 |
Survival and central photopenia detected by fluorine-18 fluoro-deoxy-glucose positron emission tomography (FDG-PET) in patients with locoregional non-small cell lung cancer treated with radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals | 2017 |
Can Laws Be a Potential PET Image Texture Analysis Approach for Evaluation of Tumor Heterogeneity and Histopathological Characteristics in NSCLC?
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2018 |
The value of ultrasound-guided biopsy of fluorodeoxy-glucose positron emission tomography (FDG-PET)-positive supraclavicular lymph nodes in patients with suspected lung cancer.
Topics: Aged; Anaplastic Lymphoma Kinase; Biopsy, Large-Core Needle; Carcinoma, Non-Small-Cell Lung; Clavicle; Endoscopic Ultrasound-Guided Fine Needle Aspiration; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Receptor Protein-Tyrosine Kinases; Reproducibility of Results; Retrospective Studies | 2017 |
Is post-treatment standardized uptake value a prognostic factor in unresectable non-small cell lung carcinoma?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals | 2017 |
Positron emission tomography/computed tomography (PET/CT) and CT for N staging of non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2017 |
Metabolic tumor burden quantified on [
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Tumor Burden | 2017 |
Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; ROC Curve; Treatment Outcome; Tumor Burden | 2017 |
Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2017 |
Topics: Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Fluorodeoxyglucose F18; Humans; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Tumor Suppressor Proteins | 2017 |
Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Contrast Media; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Hypoxia | 2017 |
A new method to assess pulmonary changes using
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage | 2017 |
Dynamic Contrast-Enhanced Perfusion Area-Detector CT: Preliminary Comparison of Diagnostic Performance for N Stage Assessment With FDG PET/CT in Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Models, Theoretical; Neoplasm Staging; Observer Variation; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; ROC Curve | 2017 |
A comparative analysis of dual-phase dual-energy CT and FDG-PET/CT for the prediction of histopathological invasiveness of non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiography, Dual-Energy Scanned Projection; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed | 2017 |
Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Tumor Burden | 2018 |
Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Combined Modality Therapy; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Retrospective Studies; Tumor Burden | 2018 |
18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Nitroimidazoles; Positron Emission Tomography Computed Tomography; Preoperative Care; Prospective Studies; Radiopharmaceuticals | 2018 |
Clustering of multi-parametric functional imaging to identify high-risk subvolumes in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cluster Analysis; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis | 2017 |
Tumour functional sphericity from PET images: prognostic value in NSCLC and impact of delineation method.
Topics: Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Prognosis; Tumor Burden | 2018 |
Impact of tumour motion compensation and delineation methods on FDG PET-based dose painting plan quality for NSCLC radiation therapy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Motion; Positron Emission Tomography Computed Tomography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy Setup Errors; Respiratory-Gated Imaging Techniques | 2018 |
Prognostic value of combining a quantitative image feature from positron emission tomography with clinical factors in oligometastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals | 2018 |
Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed; Weight Loss | 2018 |
A SUV
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Clinical Decision-Making; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Positron Emission Tomography Computed Tomography; Prognosis; Propensity Score; Radiopharmaceuticals; Radiosurgery; Survival Rate | 2018 |
Differences in lung injury after IMRT or proton therapy assessed by
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Linear Models; Lung Injury; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Proton Therapy; Radiation Dosage; Radiation Injuries; Radiation Pneumonitis; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2018 |
Associations Between PET Textural Features and GLUT1 Expression, and the Prognostic Significance of Textural Features in Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glucose Transporter Type 1; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2018 |
Is central lung tumour location really predictive for occult mediastinal nodal disease in (suspected) non-small-cell lung cancer staged cN0 on 18F-fluorodeoxyglucose positron emission tomography-computed tomography?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Pneumonectomy; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Risk Factors | 2018 |
A decision tree model for predicting mediastinal lymph node metastasis in non-small cell lung cancer with F-18 FDG PET/CT.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Decision Trees; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Multimodal Imaging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2018 |
To be or not to be central-does this really matter?
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Spinal Cord | 2018 |
Evaluation of third treatment week as temporal window for assessing responsiveness on repeated FDG-PET-CT scans in Non-Small Cell Lung Cancer patients.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Time Factors; Treatment Outcome | 2018 |
Tumour metabolic activity measured by fluorodeoxyglucose positron emission tomography for radiotherapy planning as a prognostic factor for locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Radiotherapy; Treatment Outcome | 2018 |
Systematic Compared With Targeted Staging With Endobronchial Ultrasound in Patients With Lung Cancer.
Topics: Adult; Aged; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Spain | 2018 |
Prognostic stratification model for patients with stage I non-small cell lung cancer adenocarcinoma treated with surgical resection without adjuvant therapies using metabolic features measured on F-18 FDG PET and postoperative pathologic factors.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Models, Theoretical; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Postoperative Complications; Prognosis; Retrospective Studies | 2018 |
[Role of PET/CT in primitive non-small cell bronchopulmonary cancer].
Topics: Aged; Aged, 80 and over; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Morocco; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2017 |
Correlation Between Tumor Metabolism and Semiquantitative Perfusion Magnetic Resonance Imaging Metrics in Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Contrast Media; Female; Fluorodeoxyglucose F18; Glucose; Humans; Image Enhancement; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Perfusion Imaging; Positron Emission Tomography Computed Tomography | 2018 |
Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Retrospective Studies | 2018 |
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Cancer-Associated Fibroblasts; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gene Expression Profiling; Glucose Transporter Type 1; Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing); Glycolysis; Glycosylation; Hexosamines; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Positron-Emission Tomography; Prognosis; Survival Analysis; Tumor Microenvironment | 2018 |
How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2018 |
Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reference Standards; Tumor Burden | 2018 |
Clinically simplified screening methods to evaluate maximum standard uptake value from F-18-FDG-PET/CT in patients with non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies; ROC Curve; Sensitivity and Specificity | 2018 |
18F-FDG PET intensity correlates with a hypoxic gene signature and other oncogenic abnormalities in operable non-small cell lung cancer.
Topics: Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Genomics; Humans; Lung Neoplasms; Male; Middle Aged; Oncogenes; Positron-Emission Tomography; Prognosis; Tumor Hypoxia | 2018 |
Single-source Dual-energy CT as a Part of
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Iodine; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2018 |
Comparison of SUVmax and SUVpeak based segmentation to determine primary lung tumour volume on FDG PET-CT correlated with pathology data.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Tumor Burden | 2018 |
Integrated texture parameter of 18F-FDG PET may be a stratification factor for the survival of nonoperative patients with locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies | 2018 |
Computational delineation and quantitative heterogeneity analysis of lung tumor on 18F-FDG PET for radiation dose-escalation.
Topics: Adult; Aged; Algorithms; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Radiation; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lung; Lung Neoplasms; Male; Middle Aged; Organs at Risk; Positron-Emission Tomography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2018 |
[Is 18F-PET-CT the First Choice for Preoperative Screening
for Ia Non-small Cell Lung Cancer?]
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Preoperative Period | 2018 |
Intra-tumoural heterogeneity characterization through texture and colour analysis for differentiation of non-small cell lung carcinoma subtypes.
Topics: Adenocarcinoma; Aged; Algorithms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Differentiation; Color; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron Emission Tomography Computed Tomography; Retrospective Studies; ROC Curve; Support Vector Machine | 2018 |
Correlation of quantified metabolic activity in nonsmall cell lung cancer with tumor size and tumor pathological characteristics.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Linear Models; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Statistics, Nonparametric; Tumor Burden | 2018 |
Metabolic positron emission tomography parameters predict failure patterns in early non-small-cell lung cancer treated with stereotactic body radiation therapy: a single institution experience.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Radiosurgery; Retrospective Studies | 2018 |
Metabolic tumor heterogeneity analysis by F-18 FDG PET/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity | 2018 |
Discovery of pre-therapy 2-deoxy-2-
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Survival Analysis | 2019 |
Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; ROC Curve | 2018 |
Solid part size is an important predictor of nodal metastasis in lung cancer with a subsolid tumor.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Retrospective Studies; Risk Assessment; Risk Factors; Tertiary Care Centers; Tomography, X-Ray Computed | 2018 |
Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Positron-Emission Tomography; Prognosis; Radiometry; Radiopharmaceuticals; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2018 |
Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
Topics: Aged; Biological Transport; Calibration; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Reference Standards; Retrospective Studies | 2019 |
Pretreatment
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Parenchymal Tissue; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiosurgery; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Survival Rate; Treatment Outcome | 2019 |
A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Photons; Positron Emission Tomography Computed Tomography; Proton Therapy; Radiation Pneumonitis; Radiopharmaceuticals | 2019 |
Significance of
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Burden | 2019 |
Non‑invasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDG‑PET/CT and CT.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mice; Mice, SCID; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden | 2019 |
Standardization of image reconstruction parameters for dynamic fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Phantoms, Imaging; Positron Emission Tomography Computed Tomography; Quality Control; Reference Standards; Signal-To-Noise Ratio | 2018 |
Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Tumor Burden | 2019 |
Delineation of lung cancer with FDG PET/CT during radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiotherapy Planning, Computer-Assisted | 2018 |
EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
Topics: A549 Cells; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; NADPH Oxidase 4; Positron Emission Tomography Computed Tomography; Reactive Oxygen Species; Retrospective Studies; ROC Curve | 2019 |
Unsupervised machine learning of radiomic features for predicting treatment response and overall survival of early stage non-small cell lung cancer patients treated with stereotactic body radiation therapy.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Radiopharmaceuticals; Radiosurgery; Tomography, X-Ray Computed; Unsupervised Machine Learning | 2018 |
Prognostic Impact of Intratumoral Heterogeneity Based on Fractal Geometry Analysis in Operated NSCLC Patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Fractals; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Positron Emission Tomography Computed Tomography; Prognosis | 2019 |
Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: FDG Uptake and Risk Stratification.
Topics: Adult; Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Proportional Hazards Models; Response Evaluation Criteria in Solid Tumors; Risk Assessment | 2019 |
Identification of multiple cardiac metastases from nonsmall-cell lung cancer by 18F-FDG PET/CT: A case report.
Topics: Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Fluorodeoxyglucose F18; Heart Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2018 |
Prognostic Value and Clinical Impact of Pretreatment FDG PET in Pulmonary Lymphoepithelioma-Like Carcinoma.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Epithelial Cells; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pneumonectomy; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Survival Analysis | 2019 |
Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Proportional Hazards Models; Retrospective Studies | 2019 |
Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.
Topics: Aged; Antineoplastic Agents, Immunological; Biliary Tract Diseases; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gastrointestinal Diseases; Humans; Immunotherapy; Lung Neoplasms; Male; Nivolumab; Positron Emission Tomography Computed Tomography; Radiography, Abdominal; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2019 |
Centrally located lung cancer and risk of occult nodal disease: an objective evaluation of multiple definitions of tumour centrality with dedicated imaging software.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Logistic Models; Lung Neoplasms; Male; Mediastinum; Middle Aged; Neoplasm Staging; Pneumonectomy; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Retrospective Studies; Software; Texas | 2019 |
18F-FDG PET/CT Findings in Disseminated Genital Herpes in an Immunocompetent Patient With Anaplastic Lymphoma Kinase Rearranged Advanced Nonsmall Cell Lung Cancer.
Topics: Adult; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Herpes Genitalis; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2019 |
[18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Observer Variation; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Risk Assessment | 2019 |
Association between 18F-FDG uptake in PET/CT, Nrf2, and NQO1 expression and their prognostic significance in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2019 |
Dynamic Contrast-enhanced Area-detector CT vs Dynamic Contrast-enhanced Perfusion MRI vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Fluorine-18-fluorodeoxyglucose-positron emission tomography evaluation in metastatic bone lesions in lung cancer: Possible prediction of pain and skeletal-related events.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Cancer Pain; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Sensitivity and Specificity; Small Cell Lung Carcinoma | 2019 |
The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Bone and Bones; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Imaging; Morpholines; Osteoclasts; Positron Emission Tomography Computed Tomography; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome; X-Ray Microtomography | 2019 |
Pre-treatment
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung; Lung Neoplasms; Machine Learning; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Reproducibility of Results; Survival Analysis | 2019 |
Comparison of prognostic values of primary tumor and nodal
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2019 |
An exceptional group of non-small cell lung cancer difficult to diagnose: Evaluation of lipid-poor adrenal lesions.
Topics: Adrenal Gland Neoplasms; Aged; Biopsy; Blood Glucose; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Humans; Lipids; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Retrospective Studies; ROC Curve; Sensitivity and Specificity | 2019 |
Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Programmed Cell Death 1 Receptor; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors | 2019 |
Impact of free-breathing CT on quantitative measurements of static and quiescent period-gated PET Images.
Topics: Aged; Algorithms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Movement; Positron-Emission Tomography; Prospective Studies; Respiration; Respiratory-Gated Imaging Techniques | 2019 |
18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; ROC Curve; Treatment Outcome | 2019 |
Solitary pulmonary nodule: Comparison of quantitative capability for differentiation and management among dynamic CE-perfusion MRI at 3 T system, dynamic CE-perfusion ADCT and FDG-PET/CT.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Perfusion Imaging; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Solitary Pulmonary Nodule; Tomography, Spiral Computed; Tomography, X-Ray Computed | 2019 |
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Topics: Aged; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Nivolumab; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms; Survival Analysis; Thyroid Gland; Thyroiditis; Thyrotropin; Thyroxine; Triiodothyronine | 2019 |
Quantification of global lung inflammation using volumetric 18F-FDG PET/CT parameters in locally advanced non-small-cell lung cancer patients treated with concurrent chemoradiotherapy: a comparison of photon and proton radiation therapy.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Photons; Pneumonia; Positron Emission Tomography Computed Tomography; Proton Therapy; Radiation Injuries; Retrospective Studies | 2019 |
Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Netherlands; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Time Factors | 2019 |
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2019 |
Response to "Comment on "metabolic tumor heterogeneity analysis by F-18 FDG PET/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2″".
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Mediastinum; Positron Emission Tomography Computed Tomography | 2019 |
Comment on "Metabolic tumor heterogeneity analysis by F-18 FDG PET/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2".
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2019 |
PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Pneumonia; Positron Emission Tomography Computed Tomography; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |
FDG-PET Follow-up of Non-Small Cell Lung Cancer: Not Dead Yet.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals | 2020 |
Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Leukocyte Count; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |
The association between 18F-fluorodeoxyglucose PET intratumoral metabolic heterogeneity and pathological parameters in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Young Adult | 2019 |
NSCLC subtype prediction using cytologic fluid specimens from needle aspiration biopsies.
Topics: Aged; Antigens, Neoplasm; Area Under Curve; Biomarkers, Tumor; Biopsy, Needle; Body Fluids; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cytodiagnosis; Female; Fluorodeoxyglucose F18; Humans; Keratin-19; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity | 2013 |
Screening for brain metastases in patients with stage III non-small cell lung cancer: Is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain?
Topics: Aged; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
Usefulness of (18)F-FDG PET/CT in a rare case of malignant pseudothyroiditis.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Thyroiditis; Tomography, X-Ray Computed | 2014 |
Time in radiation oncology - keep it short!
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Time-to-Treatment; Tomography, X-Ray Computed | 2013 |
High performance of F-fluorodeoxyglucose positron emission tomography and contrast-enhanced CT in a rapid outpatient diagnostic program for patients with suspected lung cancer.
Topics: Aged; Ambulatory Care; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2013 |
A rare case of non-small cell lung cancer metastasizing to the pituitary gland: detection with (18)F-FDG PET-CT.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Pituitary Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2014 |
The Maximum standardized uptake value is more reliable than size measurement in early follow-up to evaluate potential pulmonary malignancies following radiofrequency ablation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Catheter Ablation; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
PET-based delineation of tumour volumes in lung cancer: comparison with pathological findings.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tumor Burden | 2013 |
The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Data Interpretation, Statistical; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Reference Standards | 2013 |
PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nitroimidazoles; Positron-Emission Tomography; Tumor Burden | 2013 |
FDG PET-CT in non-small cell lung cancer: relationship between primary tumor FDG uptake and extensional or metastatic potential.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2013 |
Abdominal lymph node metastasis in patients with non-small-cell lung cancer as shown by PET/CT.
Topics: Abdominal Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Whole Body Imaging | 2013 |
Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
Topics: Carcinoma, Non-Small-Cell Lung; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Normal Distribution; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2013 |
Predictive value of primary fluorine-18 fluorodeoxyglucose standard uptake value for a better choice of systematic nodal dissection or sampling in clinical stage ia non--small-cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Abscopal [corrected] effects after conventional and stereotactic lung irradiation of non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Radiosurgery | 2013 |
An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antigens, Surface; Carcinoma, Non-Small-Cell Lung; Cross-Sectional Studies; Female; Fluorodeoxyglucose F18; Humans; Immunophenotyping; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2013 |
Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiosurgery; Tomography, X-Ray Computed; Tumor Burden | 2013 |
A prediction model for pathologic N2 disease in lung cancer patients with a negative mediastinum by positron emission tomography.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Mediastinoscopy; Middle Aged; Models, Statistical; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Survival Rate | 2013 |
New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Recurrence; Risk Assessment; Risk Factors; Tomography, X-Ray Computed | 2013 |
Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Radiosurgery; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Lung Neoplasms; Positron-Emission Tomography; Radiographic Image Enhancement; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Observer Variation; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Tomography, X-Ray Computed | 2013 |
Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Tumor Burden | 2013 |
Neural networks for nodal staging of non-small cell lung cancer with FDG PET and CT: importance of combining uptake values and sizes of nodes and primary tumor.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Neural Networks, Computer; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
Variation in background intensity affects PET-based gross tumor volume delineation in non-small-cell lung cancer: the need for individualized information.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden | 2013 |
The mediastinal staging accuracy of 18F-Fluorodeoxyglycose positron emission tomography/computed tomography in non-small cell lung cancer with variable time intervals to surgery.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Time Factors; Tomography, X-Ray Computed | 2013 |
Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Lung; Male; Middle Aged; Multimodal Imaging; Pilot Projects; Positron-Emission Tomography; Radiation Pneumonitis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
¹⁸F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dihydrouracil Dehydrogenase (NADP); Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Microvessels; Middle Aged; Neovascularization, Pathologic; Neuroendocrine Tumors; Orotate Phosphoribosyltransferase; Positron-Emission Tomography; Radiopharmaceuticals; Thoracic Neoplasms; Thymidylate Synthase; Thymus Neoplasms; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiosurgery | 2016 |
Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed | 2013 |
Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Docetaxel; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed; Tumor Burden; Tumor Cells, Cultured | 2013 |
Outcome analysis of (18)F-fluorodeoxyglucose positron-emission tomography in patients with lung cancer after partial volume correction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Phantoms, Imaging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate | 2013 |
Lesion detection and characterization with context driven approximation in thoracic FDG PET-CT images of NSCLC studies.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed | 2014 |
Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Positron-Emission Tomography; ROC Curve; Tomography, X-Ray Computed; Tumor Burden; Tumor Suppressor Protein p53 | 2013 |
Feasibility study of FDG PET/CT-derived primary tumour glycolysis as a prognostic indicator of survival in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2014 |
Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Risk Factors; ROC Curve; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
18F-deoxyglucose uptake in stage I non-small-cell lung cancer: time to move to randomized trials.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Radionuclide Imaging; Radiopharmaceuticals; Radiosurgery; Randomized Controlled Trials as Topic | 2014 |
Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Retrospective Studies | 2014 |
NF-κB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism.
Topics: Aged; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; NF-kappa B; Positron-Emission Tomography; Prognosis; Recurrence; Tissue Array Analysis; Up-Regulation | 2014 |
Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Decision Making; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Mediastinum; Multimodal Imaging; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
TIGAR is correlated with maximal standardized uptake value on FDG-PET and survival in non-small cell lung cancer.
Topics: Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Glycolysis; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Phosphoric Monoester Hydrolases; Positron-Emission Tomography | 2013 |
Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Topics: Antigens, CD34; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Glucose; Glucose Transporter Type 1; Glucose Transporter Type 3; Hexokinase; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Neovascularization, Pathologic; Positron-Emission Tomography; Prognosis; PTEN Phosphohydrolase; Signal Transduction; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
[Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2013 |
Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positro
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2014 |
FDG uptake heterogeneity evaluated by fractal analysis improves the differential diagnosis of pulmonary nodules.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2014 |
Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Esophagitis; Esophagus; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiation Injuries; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
High FDG uptake predicts poorer survival in locally advanced nonsmall cell lung cancer patients undergoing curative radiotherapy, independently of tumor size.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiosurgery; Radiotherapy Planning, Computer-Assisted | 2014 |
Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2014 |
Absence of a relationship between tumor ¹⁸F-fluorodeoxyglucose standardized uptake value and survival in patients treated with definitive radiotherapy for non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tumor Burden | 2014 |
Risk factors for mediastinal lymph node metastasis in non-small-cell lung cancer by PET/CT.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed; Young Adult | 2014 |
Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Early Diagnosis; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Postoperative Period; Prognosis; Radiopharmaceuticals; Radiosurgery; Reproducibility of Results; Retrospective Studies; Time Factors; Tomography, X-Ray Computed | 2014 |
Increasing the accuracy of 18F-FDG PET/CT interpretation of "mildly positive" mediastinal nodes in the staging of non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Multimodal Imaging; Neoplasm Staging; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SCID mouse model using [¹⁸F] FDG PET-CT.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Ciliary body metastasis in a patient with non-small cell lung carcinoma--incidental detection with 18F-FDG PET/CT.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Ciliary Body; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lung Neoplasms; Male; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Uveal Neoplasms | 2014 |
Influence of experience and qualification on PET-based target volume delineation. When there is no expert--ask your colleague.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Clinical Competence; Combined Modality Therapy; Cooperative Behavior; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Interdisciplinary Communication; Lung Neoplasms; Male; Observer Variation; Positron-Emission Tomography; Professional Competence; Radiotherapy Planning, Computer-Assisted; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Tomography, X-Ray Computed | 2014 |
Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum Compounds; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals | 2014 |
Avoidance of false-positive findings on ¹⁸F-FDG-PET/CT using PET/ultrasound fusion: displaced laryngeal silicone implant versus recurrent cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; False Positive Reactions; Female; Fluorodeoxyglucose F18; Foreign-Body Migration; Humans; Laryngeal Neoplasms; Lung Neoplasms; Positron-Emission Tomography; Prostheses and Implants; Radiography; Radiopharmaceuticals; Silicones; Ultrasonography | 2014 |
Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Survival Rate | 2016 |
Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer.
Topics: Aged; Aged, 80 and over; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Conformal; Sensitivity and Specificity; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
Prognostic impact of [18F]fluorodeoxyglucose positron emission tomography scanning in the era of molecular oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals | 2014 |
Reply to J.-S. Ryu et al and A.T. Berman et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals | 2014 |
Predicting survival in non-small-cell lung cancer using positron emission tomography: several conclusions from multiple comparisons.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals | 2014 |
Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging.
Topics: Animals; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dideoxynucleosides; Diffusion; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Kinetics; Lung Neoplasms; Mice; Positron-Emission Tomography | 2014 |
Influence of thyroid transcription factor-1 on fluorodeoxyglucose uptake and prognosis of non-small cell lung cancer.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Transcription Factors | 2014 |
Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2014 |
Risk factors for N2 metastasis in patients with non-small-cell lung cancer: multivariate analyses of 18F-FDG PET/CT data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; China; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Tomography, X-Ray Computed; Young Adult | 2014 |
PET-CT in the assessment of lung cancer at Rikshospitalet from 2007-2011.
Topics: Aged; Algorithms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chemoradiotherapy; Dideoxynucleosides; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Survival Analysis; Tomography, X-Ray Computed | 2014 |
Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Grading; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Remission Induction; ROC Curve; Treatment Outcome | 2014 |
Overestimated value of (18)F-FDG PET/CT to diagnose pulmonary nodules: Analysis of 298 patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2014 |
Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Observer Variation; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Analysis | 2014 |
Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and 18F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy: A Mono-institutional Pilot Experience.
Topics: Adult; Aged; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pilot Projects; Positron-Emission Tomography; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2015 |
Should We Routinely Investigate Incidental Head and Neck Findings on 18-Fluorodeoxyglucose Positron Emission Tomography in Patients Being Staged for Non-small Cell Lung Cancer? A Retrospective Analysis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Incidental Findings; Lung Neoplasms; Male; Neoplasms, Second Primary; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity | 2015 |
Early detection of disease progression after palliative chemotherapy in NSCLC patients by (18)F-FDG-PET.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Germany; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Sensitivity and Specificity | 2014 |
Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; ROC Curve; Tomography, X-Ray Computed | 2014 |
Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Positron-Emission Tomography; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tomography, X-Ray Computed | 2014 |
Roles of Ki-67, p53, transforming growth factor-β and lysyl oxidase in the metastasis of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Lung Neoplasms; Male; Multimodal Imaging; Positron-Emission Tomography; Protein-Lysine 6-Oxidase; Radiopharmaceuticals; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Transforming Growth Factor beta; Tumor Suppressor Protein p53 | 2014 |
Prediction of recurrence for non-small cell lung cancer by combined analysis of molecular markers and 18F 2-fluoro-2-deoxy-D-glucose positron emission tomography.
Topics: Aged; Aged, 80 and over; Biomarkers; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tissue Array Analysis | 2014 |
Non-small-cell lung cancer resectability: diagnostic value of PET/MR.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Observer Variation; Positron-Emission Tomography; Preoperative Period; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Comparison of primary target volumes delineated on four-dimensional CT and 18 F-FDG PET/CT of non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2014 |
Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Embolism; Female; Fluorodeoxyglucose F18; Humans; Indoles; Keratins; Leukocyte Common Antigens; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Neoplastic Cells, Circulating; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Risk Assessment; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis.
Topics: Adult; Aged; Aged, 80 and over; Austria; Biopsy; Carcinoma, Non-Small-Cell Lung; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Germany; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiosurgery; Radiotherapy Dosage; Risk | 2015 |
Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and (18)F-FDG PET.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Reproducibility of Results; Sensitivity and Specificity | 2014 |
Validation of nonrigid registration in pretreatment and follow-up PET/CT scans for quantification of tumor residue in lung cancer patients.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Prospective Studies; Regression Analysis; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Lymphatic Metastasis; Male; Metabolic Clearance Rate; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Heterogeneity in [18F]fluorodeoxyglucose positron emission tomography/computed tomography of non-small cell lung carcinoma and its relationship to metabolic parameters and pathologic staging.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Topics: Adult; Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; False Positive Reactions; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Inflammation; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed; Tyrosine | 2014 |
Erlotinib-induced cutaneous toxicity: findings on 18F-FDG PET/CT imaging.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Skin Diseases; Tomography, X-Ray Computed | 2015 |
In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Hypoxia; Image Interpretation, Computer-Assisted; Image Processing, Computer-Assisted; Imidazoles; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Triazoles | 2014 |
[False positive result of 18F-FDG PET in patient with lung cancer due to sarcoid-like reaction in regional lymph nodes].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Positron-Emission Tomography; Sarcoidosis | 2014 |
Impact of PET reconstruction algorithm and threshold on dose painting of non-small cell lung cancer.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiation Dosage; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Retrospective Studies | 2014 |
Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2014 |
In-treatment assessment of response in locally advanced NSCLC: paving the way for personalized medicine.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography | 2014 |
Monte-Carlo simulations of clinically realistic respiratory gated (18)F-FDG PET: application to lesion detectability and volume measurements.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Lung Neoplasms; Monte Carlo Method; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Respiratory Mechanics | 2015 |
Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
Topics: Analysis of Variance; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Trees; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Probability; Tomography, X-Ray Computed | 2015 |
Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiotherapy Dosage; ROC Curve; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Are the simplified methods to estimate Ki in 18F-FDG PET studies feasible in clinical routine? Comparison between three simplified methods.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals | 2018 |
Differentiation of an adrenal mass in patients with non-small cell lung cancer by means of a normal range of adrenal standardized uptake values on FDG PET/CT.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenal Glands; Adult; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Liver; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Organ Size; Positron-Emission Tomography; Radiopharmaceuticals; Reference Values; Sensitivity and Specificity; Tomography, X-Ray Computed | 2015 |
Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2015 |
Comparison of texture features derived from static and respiratory-gated PET images in non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals; Respiratory-Gated Imaging Techniques; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Recurrence; Retrospective Studies; Risk Factors; Survival Analysis; Tomography, X-Ray Computed | 2015 |
The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Prospective Studies; Regression Analysis; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Early assessment of metabolic response by 18F-FDG PET during concomitant radiochemotherapy of non-small cell lung carcinoma is associated with survival: a retrospective single-center study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed | 2015 |
The role of FDG-PET/CT in detecting unsuspected and unknown distant metastasis in the initial staging of NSCLC.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2014 |
Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Clinical Trials as Topic; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prospective Studies; Risk Factors; ROC Curve; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2015 |
Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Whole Body Imaging | 2015 |
Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Correlation of 18F-FDG PET avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer. In regard to Shusharina et al.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Small Cell Lung Carcinoma | 2014 |
Correlation of 18F-FDG PET avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer. In reply to Saraiya et al.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Small Cell Lung Carcinoma | 2014 |
Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mediastinum; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
Parathyroid adenoma upstaging the lung cancer.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Male; Mediastinum; Middle Aged; Neoplasm Staging; Parathyroid Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Predictive value of 18F-FDG PET and CT morphologic features for recurrence in pathological stage IA non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Health Status; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Pneumonectomy; Positron-Emission Tomography; Radiosurgery; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2015 |
Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Predictive significance of standardized uptake value parameters of FDG-PET in patients with non-small cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies | 2015 |
A novel partial volume effects correction technique integrating deconvolution associated with denoising within an iterative PET image reconstruction.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Signal-To-Noise Ratio | 2015 |
Brown fat FDG uptake abolished by radiotherapy.
Topics: Adipose Tissue, Brown; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy; Tomography, X-Ray Computed | 2015 |
Diffusion-weighted magnetic resonance imaging in preoperative assessment of non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Invasiveness; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Glucose; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals; Time Factors | 2015 |
Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
Topics: Adult; Aged; Artifacts; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden | 2015 |
The reverse Warburg effect and 18F-FDG uptake in non-small cell lung cancer A549 in mice: a pilot study.
Topics: Animals; Blood Glucose; Body Weight; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Diet; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoxia; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Nitroimidazoles; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tumor Microenvironment | 2015 |
FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer.
Topics: Adult; Aged; Analgesics, Opioid; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Palliative Care; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiotherapy; Retrospective Studies; Treatment Outcome | 2015 |
(18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Heterogeneity in [¹⁸F]fluorodeoxyglucose positron emission tomography/computed tomography of non-small cell lung carcinoma and its relationship to metabolic parameters and pathologic staging.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2014 |
Comparison of primary tumour volumes delineated on four-dimensional computed tomography maximum intensity projection and (18) F-fluorodeoxyglucose positron emission tomography computed tomography images of non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tumor Burden | 2015 |
[Density and SUV ratios from PET/CT in the detection of mediastinal lymph node metastasis in non-small cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2015 |
FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Analysis | 2015 |
Thoracic staging of non-small-cell lung cancer using integrated (18)F-FDG PET/MR imaging: diagnostic value of different MR sequences.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Evaluation of the factors affecting the maximum standardized uptake value of metastatic lymph nodes in different histological types of non-small cell lung cancer on PET-CT.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Pneumonectomy; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2015 |
Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Lung Neoplasms; Male; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Tomography, X-Ray Computed | 2015 |
Standardized Uptake Values in the Primary Lesions of Non-Small-Cell Lung Cancer in FDG-PET/CT Can Predict Regional Lymph Node Metastases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Survival Rate; Tomography, X-Ray Computed | 2015 |
Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Radiation Dosage; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Survival Prognostic Value of Morphological and Metabolic variables in Patients with Stage I and II Non-Small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cone-Beam Computed Tomography; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2015 |
18F-FDG PET-CT: predicting recurrence in patients following percutaneous cryoablation treatment for stage I primary non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cryosurgery; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Recurrence; Retrospective Studies; Tomography, X-Ray Computed | 2015 |
Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using ¹⁸F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft model A549.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Rats; Treatment Outcome | 2015 |
Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Topics: Aged; Aged, 80 and over; Artifacts; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Movement; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiosurgery; Respiration; Retrospective Studies; Treatment Outcome | 2015 |
Would you bet on PET? Evaluation of the significance of positive PET scan results post-microwave ablation for non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2015 |
FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiosurgery; Treatment Outcome | 2015 |
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Signal Transduction; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2015 |
The Value of Establishing the Quantitative Accuracy of PET/CT Imaging.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2015 |
Optimal Scan Time of 18F-FDG PET in Identifying Therapeutic Efficacy Secondary to Radiofrequency Ablation of Lung Cancer: Case Report.
Topics: Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed | 2015 |
Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non-Small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Repeatability of Tumor SUV Quantification: The Role of Variable Blood SUV.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2015 |
Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2015 |
Stage III Non-Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2016 |
Multiparametric MR and PET Imaging of Intratumoral Biological Heterogeneity in Patients with Metastatic Lung Cancer Using Voxel-by-Voxel Analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Glucose; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography | 2015 |
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Survival Rate | 2015 |
Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals; Recurrence; Retrospective Studies; Tomography, X-Ray Computed | 2016 |
Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer p
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diffusion Magnetic Resonance Imaging; Echo-Planar Imaging; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed | 2015 |
STatistically Assigned Response Criteria in Solid Tumors (STARCIST).
Topics: Algorithms; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Neoplasms; Normal Distribution; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Reply: Repeatability of Tumor SUV Quantification: The Role of Variable Blood SUV.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2015 |
Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Time Factors | 2015 |
Clinical Correlation Between Tumor Maximal Standardized Uptake Value in Metabolic Imaging and Metastatic Tumor Characteristics in Advanced Non-small Cell Lung Cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sex Factors; Smoking; Tomography, X-Ray Computed | 2015 |
Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas.
Topics: Adenocarcinoma; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2016 |
Quantification of Intratumoral Metabolic Macroheterogeneity on 18F-FDG PET/CT and Its Prognostic Significance in Pathologic N0 Squamous Cell Lung Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Biopsy; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Respiratory Function Tests; Survival Rate; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Tomography, X-Ray Computed | 2015 |
Correlation between FDG-PET/CT findings and solid type non-small cell cancer prognostic factors: are there differences between adenocarcinoma and squamous cell carcinoma?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2015 |
[The prognostic impact of preoperative PET-CT on postoperative recurrence for completely resected stage I non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Postoperative Period; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2015 |
FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Proto-Oncogene Proteins p21(ras); Radiopharmaceuticals | 2015 |
Use of FDG PET/CT in Patients with Pancoast Tumors: Does It Add Any Contribution to Patient Management?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Pancoast Syndrome; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Prognostic value of early response assessment using 18F-FDG PET/CT in chemotherapy-treated patients with non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1α and glucose transporter 1 in non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
Prognostic Value of FDG Uptake in Stage I Non-Small-Cell Lung Cancer: Fact or Bias?
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography".
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
18F-FDG-PET partial volume effect correction using a modified recovery coefficient approach based on functional volume and local contrast: physical validation and clinical feasibility in oncology.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography | 2017 |
Is the Glut expression related to FDG uptake in PET/CT of non-small cell lung cancer patients?
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Lung Neoplasms; Male; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Dynamic FDG-PET Imaging to Differentiate Malignancies from Inflammation in Subcutaneous and In Situ Mouse Model for Non-Small Cell Lung Carcinoma (NSCLC).
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Inflammation; Kinetics; Lung Neoplasms; Mice; Mice, Inbred C57BL; Positron-Emission Tomography | 2015 |
Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Analysis | 2017 |
Evaluating the use of optimally respiratory gated 18F-FDG-PET in target volume delineation and its influence on radiation doses to the organs at risk in non-small-cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Organs at Risk; Positron-Emission Tomography; Radiation Dosage; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Respiratory-Gated Imaging Techniques; Retrospective Studies | 2016 |
FDG uptake at the bronchial stump after curative lobectomy for non-small cell lung cancer.
Topics: Aged; Bronchi; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Postoperative Period; Radiopharmaceuticals | 2016 |
Dual time point imaging for F18-FDG-PET/CT does not improve the accuracy of nodal staging in non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; ROC Curve | 2016 |
Dexamethasone Suppression FDG PET/CT for Differentiating between True- and False-Positive Pulmonary and Mediastinal Lymph Node Metastases in Non-Small Cell Lung Cancer: A Pilot Study of FDG PET/CT after Oral Administration of Dexamethasone.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Diagnosis, Differential; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
Limited Prognostic Value of SUV max Measured by F-18 FDG PET/CT in Newly Diagnosed Small Cell Lung Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Disease-Free Survival; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Models, Biological; Multimodal Imaging; Positron-Emission Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Republic of Korea; Risk Assessment; Risk Factors; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed | 2015 |
FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Treatment Outcome | 2016 |
18F-FDG PET/Contrast-Enhanced CT for Initial Staging and Strategic Treatment of Non-Small Cell Lung Cancer: A Prospective Study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
18F-FDG PET-Derived Textural Indices Reflect Tissue-Specific Uptake Pattern in Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography | 2015 |
Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Denmark; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2016 |
Influence of Body Mass Index on the Prognostic Value of Tumor ¹⁸F-FDG Uptake in Stage I Non-Small Cell Lung Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
Prediction of occult lymph node metastasis using volume-based PET parameters in small-sized peripheral non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Coordination Complexes; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Nitroimidazoles; Organometallic Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Thiosemicarbazones | 2016 |
Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Esophagitis; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiation Injuries | 2016 |
Metabolic-structural concordance in paraneoplastic limbic encephalitis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Limbic Encephalitis; Lung Neoplasms; Magnetic Resonance Imaging; Male; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
Molecular Imaging of Chemokine Receptor CXCR4 in Non-Small Cell Lung Cancer Using 68Ga-Pentixafor PET/CT: Comparison With 18F-FDG.
Topics: Carcinoma, Non-Small-Cell Lung; Coordination Complexes; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Multimodal Imaging; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
Trends in the Use of (18)F-Fluorodeoxyglucose PET Imaging in Surveillance of Non-Small-Cell Lung and Colorectal Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Decision Making; Evidence-Based Medicine; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Medicare; Neoplasm Staging; Population Surveillance; Positron-Emission Tomography; Radiopharmaceuticals; SEER Program; United States | 2016 |
False-Positive Axillary Lymph Nodes Due to Silicone Adenitis on (18)F-FDG PET/CT in an Oncological Setting.
Topics: Axilla; Breast Implants; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphadenitis; Lymphatic Metastasis; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Silicones; Transgender Persons | 2016 |
Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Patient Selection; Pneumonectomy; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Survival Rate | 2016 |
Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals | 2016 |
18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Retrospective Studies; Treatment Outcome; Tumor Burden | 2016 |
Prognostic Value of Volumetric Parameters on Staging and Posttreatment FDG PET/CT in Patients With Stage IV Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cone-Beam Computed Tomography; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiosurgery; Retrospective Studies; Treatment Outcome | 2016 |
Potential Use of (18)F-fluorodeoxyglucose Positron Emission Tomography-Based Quantitative Imaging Features for Guiding Dose Escalation in Stage III Non-Small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Image-Guided; Reference Values | 2016 |
Prognostic significance of volume-based 18F-FDG PET/CT parameter in patients with surgically resected non-small cell lung cancer. Comparison with immunohistochemical biomarkers.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Republic of Korea; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Tumor Burden | 2016 |
Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MR and PET/CT.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pneumonectomy; Positron Emission Tomography Computed Tomography; Preoperative Period; Prospective Studies; Radiopharmaceuticals; ROC Curve | 2016 |
Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Preoperative Care; Prognosis; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2016 |
Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment.
Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Clinical Competence; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Positron-Emission Tomography; Radiation Oncology; Radiology; Radiopharmaceuticals; Radiosurgery; Response Evaluation Criteria in Solid Tumors; ROC Curve; Sensitivity and Specificity; Time Factors; Tomography, X-Ray Computed | 2016 |
Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Tumor Burden | 2016 |
18F-FDG PET/CT assessment of histopathologically confirmed mediastinal lymph nodes in non-small cell lung cancer using a penalised likelihood reconstruction.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Carcinoma, Non-Small-Cell Lung; Epidemiologic Methods; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
[Asymptomatic skeletal muscle metastases from non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Muscle Neoplasms; Muscle, Skeletal; Positron-Emission Tomography; Prognosis | 2015 |
Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Survival Analysis | 2016 |
Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2016 |
Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Treatment Outcome; Tumor Burden | 2016 |
Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cytological Techniques; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Keratin-19; Male; Middle Aged; Mutation; Positron-Emission Tomography; Serpins; Tomography, X-Ray Computed | 2016 |
F-18-FDG-avid lymph node metastasis along preferential lymphatic drainage pathways from the tumor-bearing lung lobe on F-18-FDG PET/CT in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drainage; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies; Sensitivity and Specificity | 2016 |
FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Data Interpretation, Statistical; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Lung Neoplasms; Models, Biological; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tumor Burden | 2016 |
An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2016 |
Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of (18)F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies | 2016 |
A Case of Lung Squamous Cell Carcinoma With Duodenal Metastasis on FDG PET/CT.
Topics: Carcinoma, Non-Small-Cell Lung; Duodenal Neoplasms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
Radiogenomic Analysis Demonstrates Associations between (18)F-Fluoro-2-Deoxyglucose PET, Prognosis, and Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Epithelial-Mesenchymal Transition; Female; Fluorodeoxyglucose F18; Genomics; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2016 |
Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution; Whole Body Imaging | 2016 |
Performance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy.
Topics: Adult; Aged; Algorithms; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Proportional Hazards Models | 2016 |
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cytokines; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Immunologic Factors; Lung Neoplasms; Male; Middle Aged; Molecular Imaging; Positron-Emission Tomography; Preoperative Care; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic | 2016 |
Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)US-NA information in addition to PET-CT for delineation?
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated | 2016 |
Primary Sarcomatoid Carcinoma of the Lung: Radiometabolic ((18)F-FDG PET/CT) Findings and Correlation with Clinico-Pathological and Survival Results.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Survival Rate | 2016 |
Estimation of Recurrence Risk After Normal (18)F-FDG PET/CT in Nonsmall-Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Risk Factors | 2016 |
Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; ROC Curve; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2016 |
Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Comorbidity; Disease Management; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Survival Rate; United States | 2018 |
Standardized visual reading of F18-FDG-PET in patients with non-small cell lung cancer scheduled for preoperative thoracic lymph node staging.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Liver; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Grading; Neoplasm Staging; Observer Variation; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity | 2016 |
Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pleura; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Tumor Burden | 2016 |
Fluorodeoxyglucose Uptake in Advanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis.
Topics: Adult; Aged; Carcinoma; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Tumor Burden | 2016 |
The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers.
Topics: Aged; Aged, 80 and over; Algorithms; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tumor Burden | 2016 |
18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Retrospective Studies | 2016 |
Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Observer Variation; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Tumor Burden | 2016 |
Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Bone Marrow; Bone Marrow Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2017 |
PET/CT fusion in radiotherapy planning for lung cancer--Case reports.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2016 |
Changes of Brain Glucose Metabolism in the Pretreatment Patients with Non-Small Cell Lung Cancer: A Retrospective PET/CT Study.
Topics: Biological Transport; Brain; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2016 |
Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2016 |
Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography.
Topics: ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Contrast Media; Drug Resistance, Neoplasm; ErbB Receptors; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Positron-Emission Tomography; Quinazolines; Substrate Specificity | 2016 |
The role of
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Serum Albumin | 2017 |
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cisplatin; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Monitoring, Physiologic; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neutrophil Infiltration; Nivolumab; Pemetrexed; Pneumonectomy; Positron-Emission Tomography; Radiopharmaceuticals | 2016 |
Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Protein Kinase Inhibitors; Retrospective Studies | 2016 |
18F-FDG PET/CT Evaluation of Ceritinib Therapy in Metastatic ALK-Positive Non-small Cell Lung Cancer.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Pyrimidines; Radiopharmaceuticals; Receptor Protein-Tyrosine Kinases; Sulfones | 2016 |
(18)F-Fluorodeoxyglucose Positron Emission Tomography Can Quantify and Predict Esophageal Injury During Radiation Therapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Esophagitis; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiation Injuries; Radiopharmaceuticals; Radiotherapy, Conformal; Radiotherapy, Image-Guided; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2016 |
Metabolic Evaluation of Non-Small Cell Lung Cancer Patient-Derived Xenograft Models Using 18F-FDG PET: A Potential Tool for Early Therapy Response.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Mice, Nude; Mice, SCID; Molecular Imaging; Outcome and Process Assessment, Health Care; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2017 |
Cholinergic PET imaging in infections and inflammation using
Topics: Acetylcholinesterase; Adult; Aged; Animals; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholinesterase Inhibitors; Donepezil; Female; Fluorodeoxyglucose F18; Humans; Indans; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Middle Aged; Piperidines; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Staphylococcal Infections; Swine; Vesicular Acetylcholine Transport Proteins | 2017 |
Association Between microRNA-125a rs12976445 C>T Polymorphism and 18F-Fluorodeoxyglucose (18FDG) Uptake: Clinical and Metabolic Response in Patients with Non-Small Cell Lung Cancer.
Topics: A549 Cells; Base Sequence; Carcinoma, Non-Small-Cell Lung; Demography; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Genes, Reporter; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Luciferases; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Polymorphism, Single Nucleotide; Transfection; Vascular Endothelial Growth Factor A | 2016 |
Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2017 |
Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies | 2017 |
FDG-PET parameters predicting mediastinal malignancy in lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Fluorodeoxyglucose F18; Humans; Logistic Models; Lung Neoplasms; Lymph Nodes; Male; Mediastinal Neoplasms; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; ROC Curve; Spain | 2016 |
Repeatability of Quantitative Whole-Body
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2017 |
Clinical Significance of Positron Emission Tomography in Subcentimeter Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Survival Rate | 2017 |
Dynamic contrast-enhanced perfusion area-detector CT assessed with various mathematical models: Its capability for therapeutic outcome prediction for non-small cell lung cancer patients with chemoradiotherapy as compared with that of FDG-PET/CT.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Models, Theoretical; Multimodal Imaging; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, Spiral Computed; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
eComment. Surgery for isolated adrenal metastasis from non-small-cell lung cancer: the role of preoperative PET/CT scan".
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2017 |
The predictive value of
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2017 |
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy Dosage; ROC Curve; Time Factors; Treatment Failure; Tumor Burden | 2017 |
Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Benzeneacetamides; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Glutaminase; Glutamine; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Radiopharmaceuticals; RNA Interference; Thiadiazoles; Transplantation, Heterologous | 2017 |
Lung Nodule with Increasing Fluorodeoxyglucose Uptake in a Patient with a History of Lung Carcinoma and Talc Pleurodesis Evaluated by EBUS-TBNA On-Site Assessment.
Topics: Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Pleural Effusion; Pleurodesis; Radiopharmaceuticals; Talc; Tomography, X-Ray Computed | 2017 |
Need for Glucose Correction for
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2017 |
Relation between tumor FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following curative resection.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platelet Count; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Sex Factors; Smoking; Young Adult | 2017 |
Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Carbonic Anhydrase IX; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival; Tomography, X-Ray Computed; Tumor Burden | 2017 |
Diagnostic impact of integrated 18F-FDG PET/MRI in cerebral staging of patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2017 |
Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Time | 2008 |
Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Whole-Body Counting | 2008 |
Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; Contrast Media; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Gadolinium; Heterocyclic Compounds; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2008 |
Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging.
Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Female; Fluorodeoxyglucose F18; Gadolinium DTPA; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed; Whole Body Imaging | 2008 |
The effects of bone erosion from aortic aneurysm on the regional uptake of FDG.
Topics: Aged; Aortic Aneurysm; Bone and Bones; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Inflammation; Lung Neoplasms; Male; Positron-Emission Tomography; Thoracic Vertebrae; Tomography, X-Ray Computed | 2008 |
Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2009 |
Evaluation of gross tumor size using CT, 18F-FDG PET, integrated 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Lung Neoplasms; Male; Middle Aged; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Systems Integration; Tomography, X-Ray Computed | 2009 |
A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiotherapy Planning, Computer-Assisted; Sensitivity and Specificity; Tumor Burden | 2008 |
Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
Re: Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Data Interpretation, Statistical; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Prognosis; Radionuclide Imaging; Radiopharmaceuticals | 2008 |
(18)F-FDG-PET/CT findings of granulocyte colony stimulating factor (G-CSF)-producing lung tumors.
Topics: Adenocarcinoma; Aged; Bone Marrow; Carcinoma; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed | 2008 |
Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiography, Thoracic; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
[Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Sensitivity and Specificity; Time Factors | 2008 |
Lung cancer: new opportunities--changing algorithm in staging.
Topics: Algorithms; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinoscopy; Neoplasm Staging; Positron-Emission Tomography | 2008 |
Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cicatrix; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Thoracotomy; Treatment Outcome; Whole Body Imaging | 2008 |
Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Neoplasm Metastasis; Neoplasm Staging; Observer Variation; Positron-Emission Tomography; Referral and Consultation; Tomography, X-Ray Computed | 2009 |
Unexpected 99mTc-tetrofosmin findings during myocardial perfusion scintigraphy: intraindividual comparison with PET/computed tomography.
Topics: Aged; Breast Neoplasms, Male; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Female; Fluorodeoxyglucose F18; Heart; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Perfusion Imaging; Organophosphorus Compounds; Organotechnetium Compounds; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Thymoma; Thymus Neoplasms; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2008 |
Prognostic value of metabolic imaging in non-small cell lung cancers with neoplasic pleural effusion.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2008 |
The prognostic value of 18F-fluorodeoxyglucose uptake by using serial positron emission tomography and computed tomography in patients with stage III nonsmall cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
F-18 FDG PET in a patient with polycythemia vera.
Topics: Aged; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Myeloid Progenitor Cells; Polycythemia Vera; Positron-Emission Tomography; Tomography, X-Ray Computed | 2008 |
18F-fluoro-2-deoxy-D-glucose standardized uptake value in cavitating non-small-cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Glycolysis; Humans; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Reference Standards; Tomography, X-Ray Computed | 2008 |
Potential of magnetization transfer MRI for target volume definition in patients with non-small-cell lung cancer.
Topics: Artifacts; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, Emission-Computed | 2008 |
Impact of manual and automated interpretation of fused PET/CT data on esophageal target definitions in radiation planning.
Topics: Automation; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Thoracic Neoplasms; Tomography, X-Ray Computed; Uterine Cervical Neoplasms | 2008 |
Isolated asymptomatic skeletal muscle metastasis in a potentially resectable non-small cell lung cancer: detection with FDG PET-CT scanning.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Muscle Neoplasms; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Long-Term Care; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Respiration-averaged CT for attenuation correction in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Respiration; Tomography, X-Ray Computed | 2009 |
11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma.
Topics: Acetates; Adenocarcinoma; Carbon; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Differentiation; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed | 2008 |
Detection of metastatic involvement of the pericardium on F-18 FDG-PET/CT imaging.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Heart Neoplasms; Humans; Male; Middle Aged; Pericardium; Positron-Emission Tomography; Tomography, X-Ray Computed | 2009 |
Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy.
Topics: Aged; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Forced Expiratory Volume; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Models, Statistical; Nomograms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Severity of Illness Index; Sex Factors; Survival Analysis; Survival Rate; Tumor Burden | 2009 |
Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; alpha-Methyltyrosine; Antigens, CD34; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Large Neutral Amino Acid-Transporter 1; Lung Neoplasms; Male; Microvessels; Middle Aged; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Positron-Emission Tomography; Radiopharmaceuticals; Thoracotomy; Vascular Endothelial Growth Factor A | 2009 |
Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer.
Topics: Adolescent; Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiography; Radionuclide Imaging; Retrospective Studies | 2009 |
Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
Transbronchial needle aspiration in lung cancer patients suitable for operation with positive mediastinal positron emission tomography.
Topics: Aged; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mediastinoscopy; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Predictive Value of Tests; Preoperative Care; Prospective Studies; Risk Assessment; Sensitivity and Specificity; Treatment Outcome | 2009 |
Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?
Topics: Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Survival Rate; Tomography, Emission-Computed; Tomography, X-Ray Computed; Tumor Burden | 2009 |
[Correlation between SUV of (18)F-FDG PET-CT and the expression of GLUT1, MVD and Ki67 in non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antigens, CD34; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Ki-67 Antigen; Lung Neoplasms; Lymphatic Metastasis; Male; Microvessels; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Burden | 2008 |
Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Predictive Value of Tests; Prospective Studies; Radiation Injuries; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2009 |
Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancer
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed | 2009 |
Focal increased activity in the liver on 18F-FDG PET scan secondary to brachiocephalic vein and superior vena cava obstruction.
Topics: Brachiocephalic Veins; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Liver; Lung Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Superior Vena Cava Syndrome; Tomography, X-Ray Computed | 2008 |
Quantification of tryptophan transport and metabolism in lung tumors using PET.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Rectal Neoplasms; Tryptophan | 2009 |
Thin-section CT of the mediastinum in preoperative N-staging of non-small cell lung cancer: comparison with FDG PET.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Iohexol; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, Spiral Computed | 2010 |
Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Needle; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Osteoblasts; Positron-Emission Tomography; Risk Assessment; Treatment Outcome | 2009 |
Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Radiation Injuries; Radiopharmaceuticals; Radiotherapy Dosage; Tomography, X-Ray Computed; Tumor Burden | 2009 |
[The maximum standardized uptake value (18)F-FDG PET is independent of the immunohistochemical expression of platelet derived endothelial growth factor in patients with non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Thymidine Phosphorylase | 2009 |
Bone metastasis in patients with non-small cell lung cancer: the diagnostic role of F-18 FDG PET/CT.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Radiography; Radionuclide Imaging; Retrospective Studies; Young Adult | 2010 |
Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results | 2009 |
[The advantage of Positron Emission Tomography combined with Computer Tomography (PET-CT) in the diagnosis of lung cancer (experience with 408 patients)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Hungary; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Sensitivity and Specificity; Thoracotomy; Tomography, X-Ray Computed | 2009 |
Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Logistic Models; Lung Neoplasms; Neoplasm Staging; Radiation Injuries; Radiopharmaceuticals; Radiotherapy Dosage; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2009 |
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Statistics, Nonparametric; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Personnel radiation dose considerations in the use of an integrated PET-CT scanner for radiotherapy treatment planning.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Radiation; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Technology, Radiologic; Tomography, Emission-Computed; Tomography, X-Ray Computed; Workforce | 2009 |
Detection of prostatic glandular adenocarcinoma during staging of non-small-cell lung carcinoma with F-18 FDG PET.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prostatic Neoplasms; Tomography, X-Ray Computed | 2009 |
F-18 fluorodeoxyglucose PET/CT findings in active hiccups.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Hiccup; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2009 |
The maximum standardized 18F-fluorodeoxyglucose uptake on positron emission tomography predicts lymph node metastasis and invasiveness in clinical stage IA non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Blood Vessels; Body Weight; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Databases as Topic; Female; Fluorodeoxyglucose F18; Humans; Keratin-19; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pleura; Pneumonectomy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Thoracotomy | 2009 |
18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Fluorodeoxyglucose F18; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2010 |
Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Combined Modality Therapy; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Subtraction Technique; Systems Integration; Tomography, X-Ray Computed; X-Ray Film | 2010 |
The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer.
Topics: Aged; Alkaline Phosphatase; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Medical Records; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Technetium Tc 99m Medronate; Tomography, X-Ray Computed; Whole Body Imaging | 2009 |
Impact of FDG-PET-induced treatment choices on long-term outcome in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Belgium; Carcinoma, Non-Small-Cell Lung; Choice Behavior; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2010 |
Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kinetics; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Retrospective Studies; ROC Curve; Time Factors; Tomography, X-Ray Computed | 2009 |
Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Kinetics; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Retrospective Studies; ROC Curve; Time Factors; Tomography, X-Ray Computed | 2009 |
Dual-time point scanning of integrated FDG PET/CT for the evaluation of mediastinal and hilar lymph nodes in non-small cell lung cancer diagnosed as operable by contrast-enhanced CT.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Moon; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed; Young Adult | 2010 |
Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Burden | 2009 |
Selection of sublobar resection for c-stage IA non-small cell lung cancer based on a combination of structural imaging by CT and functional imaging by FDG PET.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Patient Selection; Pneumonectomy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2009 |
Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Predictive Value of Tests; Prospective Studies; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Logistic Models; Lung Neoplasms; Male; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Survival Rate; Tomography, Emission-Computed | 2009 |
[Impact of FDG-PET on radiation therapy: economic results of a STIC study].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; France; Hodgkin Disease; Humans; Lung Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT.
Topics: Bone and Bones; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Fluorides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Retrospective Studies; Sensitivity and Specificity; Technetium Tc 99m Medronate; Tomography, X-Ray Computed | 2009 |
Small bowel metastasis from lung cancer detected on FDG PET/CT.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Intestine, Small; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
[Clinical significance of (18)F-FDG PET-CT in evaluation of the therapeutic efficacy of chemotherapy for lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2009 |
[Value of (18)F-FDG PET-CT in the preoperative N staging of non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Period; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2009 |
Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2009 |
Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
Topics: Aged, 80 and over; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Contrast Media; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Gadolinium; Heterocyclic Compounds; History, 18th Century; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Organometallic Compounds; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2009 |
Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Epidemiologic Methods; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
Biological correlates of the maximum 18-fluoro-2-deoxy-glucose uptake on positron emission tomography in non-small cell lung carcinoma after induction chemotherapy.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Remission Induction | 2009 |
(18)F-FDG PET-CT simulation for non-small-cell lung cancer: effect in patients already staged by PET-CT.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Remission Induction; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Evaluation of (18)F-FDG PET-CT for differentiation of pulmonary pathology in an approach of outpatient fast track assessment.
Topics: Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2009 |
Prognostic value of serial [18F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Radiotherapy, Adjuvant; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Subtraction Technique; Survival Analysis; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Standard uptake value predicts survival in non-small cell lung cancer.
Topics: Aged; Algorithms; Biopsy; Blood Glucose; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Smoking; Tomography, X-Ray Computed | 2009 |
Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2009 |
Biological significance of the maximum standardized uptake values on positron emission tomography in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Vascular Endothelial Growth Factor A | 2009 |
Accuracy of 18F-FDG PET/CT for lymph node staging in non-small-cell lung cancers.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies | 2009 |
Prognostic value of 18-FDG uptake in early stage NSCLC.
Topics: Aged; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Patient Selection; Pneumonectomy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
The effect of intravenous contrast on photon radiation therapy dose calculations for lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Fluorodeoxyglucose F18; Humans; Infusions, Intravenous; Iohexol; Lung Neoplasms; Photons; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed | 2010 |
18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; alpha-Methyltyrosine; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Survival Rate | 2009 |
Postsurgical atypical F-18 fluorodeoxyglucose positron emission tomography uptake.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed | 2009 |
Computer-aided detection (CAD) and assessment of malignant lesions in the liver and lung using a novel PET/CT software tool: initial results.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diagnosis, Computer-Assisted; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Liver; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Molecular Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Software; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Fluorodeoxyglucose uptake predicts survival in a CT screening trial.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mass Screening; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Survival Rate | 2009 |
Micropapillary pattern in lung adenocarcinoma: aspect on 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Phytotherapy; Pneumonectomy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Differentiation; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Proliferating Cell Nuclear Antigen; Radiopharmaceuticals; Tumor Suppressor Protein p53 | 2009 |
Nonrigid versus rigid registration of thoracic 18F-FDG PET and CT in patients with lung cancer: an intraindividual comparison of different breathing maneuvers.
Topics: Aged; Algorithms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Observer Variation; Positron-Emission Tomography; Radiography, Thoracic; Respiration; Retrospective Studies; Thorax; Tomography, X-Ray Computed | 2009 |
Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2010 |
The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Early Detection of Cancer; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Observer Variation; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Epidemiologic Methods; Female; Fluorodeoxyglucose F18; Health Care Costs; Humans; Long-Term Care; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Quality of Life; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
"One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms; Tomography, X-Ray Computed | 2011 |
[Comparison between PET(-FDG) and computed tomography in the staging of lung cancer. Consequences for operability in 94 patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2009 |
Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Technetium Tc 99m Medronate; Tomography, X-Ray Computed | 2010 |
[Application of standardized uptake value for FDG PET-CT in predicting radiation pneumonitis].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiation Dosage; Radiation Pneumonitis; Radiopharmaceuticals; Radiotherapy, Conformal; Tomography, X-Ray Computed | 2009 |
PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Retrospective Studies; Sensitivity and Specificity | 2010 |
Prediction of lymph node metastases in NSCLC. Three dimensional anatomical parameters do not substitute FDG-PET-CT.
Topics: Aged; Automation; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiography; Retrospective Studies; ROC Curve; Sensitivity and Specificity | 2010 |
Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation?
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Regression Analysis; Tomography, X-Ray Computed; Tumor Burden | 2010 |
[Evaluation of the diagnostic value of (18)F-FDG PET-CT and enhanced CT for staging of lymph node metastasis in non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Spiral Computed | 2009 |
Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
FDG-PET/CT imaging in assessing mucin-producing non-small cell lung cancer with pathologic correlation.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Mucins; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed | 2010 |
18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiotherapy target volume definition in non-small-cell lung cancer: delineation by radiation oncologists vs. joint outlining with a PET radiologist?
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiation Oncology; Radiopharmaceuticals; Remission Induction; Statistics, Nonparametric; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (stage III and IV) non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
Usefulness of dynamic contrast enhanced computed tomography in patients with non-small-cell lung cancer scheduled for radiation therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Therapy; Feasibility Studies; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiographic Image Enhancement; Radiotherapy, Computer-Assisted; Tomography, X-Ray Computed | 2010 |
Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Whole Body Imaging | 2010 |
Volume or position changes of primary lung tumor during (chemo-)radiotherapy cannot be used as a surrogate for mediastinal lymph node changes: the case for optimal mediastinal lymph node imaging during radiotherapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Lung Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Movement; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Tumor Burden | 2011 |
Prognostic value of fluorodeoxyglucose uptake in non-small cell lung cancer: time for standardization and validation.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Validation Studies as Topic | 2010 |
Carbonic anhydrase IX expression correlates with FDG uptake by primary non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glucose; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tissue Distribution | 2010 |
Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2011 |
Parotid incidentaloma detected during thoracic PET imaging: how should these lesions be managed?
Topics: Adenolymphoma; Adenoma, Pleomorphic; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lung Neoplasms; Male; Middle Aged; Parotid Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2010 |
Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Radiotherapy Dosage; Regression Analysis; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies | 2010 |
Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance.
Topics: Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Pneumonectomy; Positron-Emission Tomography; Postoperative Complications; Reoperation; Surgery, Computer-Assisted; Tomography, X-Ray Computed | 2011 |
Dosimetric implications of the addition of 18 fluorodeoxyglucose-positron emission tomography in CT-based radiotherapy planning for non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiation Dosage; Radiation Protection; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cellular Structures; Female; Fibrosis; Fluorodeoxyglucose F18; Glucose; Humans; Inflammation; Lung Neoplasms; Male; Middle Aged; Necrosis; Positron-Emission Tomography | 2010 |
The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA, Neoplasm; Female; Fluorodeoxyglucose F18; Genotype; Glucose Transporter Type 1; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Vascular Endothelial Growth Factor A | 2010 |
Non-small cell carcinoma: comparison of postoperative intra- and extrathoracic recurrence assessment capability of qualitatively and/or quantitatively assessed FDG-PET/CT and standard radiological examinations.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Magnetic Resonance Imaging; Male; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2011 |
Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Thoracotomy | 2010 |
Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Whole Body Imaging | 2010 |
Long-term survival of 42 patients with resected N2 non-small-cell lung cancer: the impact of 2-(18)F-fluoro-2-deoxy-D-glucose positron emission tomogram mediastinal staging.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Epidemiologic Methods; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Postoperative Complications; Prognosis; Radiopharmaceuticals; Treatment Outcome | 2011 |
The registration of diagnostic versus planning fluorodeoxyglucose positron emission tomography/computed tomography in radiotherapy planning for non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2010 |
Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage.
Topics: Aged; Algorithms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Linear Models; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Sensitivity and Specificity | 2010 |
Reproducibility of "intelligent" contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Nuclear Medicine; Observer Variation; Positron-Emission Tomography; Prospective Studies; Radiation Oncology; Radiology; Radiopharmaceuticals; Reproducibility of Results; Sample Size; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Incidence; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed | 2011 |
High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiography | 2010 |
Unusual gallbladder metastasis from non-small-cell lung cancer detected by F-18 FDG PET/CT with intravenous contrast enhancement.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Contrast Media; Fluorodeoxyglucose F18; Gallbladder Neoplasms; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Tomography, X-Ray Computed | 2010 |
Biologic correlates of ¹⁸F-FDG uptake on PET in pulmonary pleomorphic carcinoma.
Topics: Aged; Aged, 80 and over; Biomarkers; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2011 |
Defining radiotherapy target volumes using 18F-fluoro-deoxy-glucose positron emission tomography/computed tomography: still a Pandora's box?
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Impact of [18F]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Esophagus; Female; Fluorodeoxyglucose F18; Heart; Humans; Lung; Lung Neoplasms; Lymphatic Irradiation; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Tumor Burden | 2011 |
[A study on the application of 18F-FDG-PET-CT for the radiotherapy of patients with stage III non-small cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiotherapy Dosage; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2010 |
Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lung; Lung Neoplasms; Lymphatic Irradiation; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Radiation Pneumonitis; Radiopharmaceuticals; Radiotherapy Dosage; Time Factors | 2011 |
Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Prediction of residual metabolic activity after treatment in NSCLC patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Retrospective Studies; Treatment Failure | 2010 |
Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Glucose; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Nitroimidazoles; Pilot Projects; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals | 2010 |
Autocontouring and manual contouring: which is the better method for target delineation using 18F-FDG PET/CT in non-small cell lung cancer?
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Pattern Recognition, Automated; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2010 |
Cost-benefit of minimally invasive staging of non-small cell lung cancer: a decision tree sensitivity analysis.
Topics: Australia; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Trees; Endosonography; Fluorodeoxyglucose F18; Health Care Costs; Humans; Lung Neoplasms; Mediastinoscopy; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2010 |
Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Excitatory Amino Acid Transporter 2; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 3; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden | 2011 |
[¹⁸F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dyspnea; Female; Fluorodeoxyglucose F18; Humans; Logistic Models; Lung; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Odds Ratio; Positron-Emission Tomography; Radiation Pneumonitis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2011 |
Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Reference Standards; Reproducibility of Results; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Inter-comparison of 18F-FDG PET/CT standardized uptake values in Korea.
Topics: Adolescent; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Korea; Lung Neoplasms; Male; Middle Aged; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed; Young Adult | 2011 |
Microscopic disease extension in three dimensions for non-small-cell lung cancer: development of a prediction model using pathology-validated positron emission tomography and computed tomography features.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Neoplasm Invasiveness; Netherlands; Positron-Emission Tomography; Preoperative Care; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Regression Analysis; Risk Factors; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients wit
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Misonidazole; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Target delineation of gross tumor volume for radiation therapy planning using fusion images of ¹⁸F-fluorodeoxyglucose positron emission tomography and computed tomography.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed | 2010 |
Gradient-based delineation of the primary GTV on FDG-PET in non-small cell lung cancer: a comparison with threshold-based approaches, CT and surgical specimens.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Phantoms, Imaging; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results | 2010 |
Positron emission tomography/computed tomography and lymphovascular invasion predict recurrence in stage I lung cancers.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2011 |
Defining radiotherapy target volumes using 18F-fluoro-deoxy-glucose positron emission tomography/computed tomography: still a Pandora's box?: in regard to Devic et al. (Int J Radiat Oncol Biol Phys 2010).
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Should patient setup in lung cancer be based on the primary tumor? An analysis of tumor coverage and normal tissue dose using repeated positron emission tomography/computed tomography imaging.
Topics: Aged; Aged, 80 and over; Anatomic Landmarks; Bone and Bones; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Multimodal Imaging; Organs at Risk; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Small Cell Lung Carcinoma; Spinal Cord; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Unexpected small bowel intussusception caused by lung cancer metastasis on 18F-fluorodeoxyglucose PET-CT.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Intussusception; Jejunal Diseases; Jejunal Neoplasms; Laparotomy; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiosurgery; Retrospective Studies; Salvage Therapy | 2010 |
Intestinal metastasis from non-small-cell lung cancer initially detected by ¹⁸F-fluorodeoxyglucose positron emission tomography.
Topics: Aged; Biopsy; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Double-Balloon Enteroscopy; Fatal Outcome; Fluorodeoxyglucose F18; Humans; Jejunal Neoplasms; Lung; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals | 2010 |
[Prognostic value of (18)F-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy, Conformal; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2010 |
Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2011 |
Is fluorine 18 fluorodeoxyglucose positron emission tomography scanning a suitable diagnostic test for histologically active large-vessel vasculitis?
Topics: Aged; Aneurysm; Aorta; Brachiocephalic Trunk; Carcinoma, Non-Small-Cell Lung; Comorbidity; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Vasculitis | 2011 |
Early metabolic response evaluation after stereotactic radiotherapy for lung cancer: pilot experience with 18F-fluorodeoxyglucose positron emission tomography-computed tomography.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Tomography, X-Ray Computed | 2011 |
Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT.
Topics: Amino Acid Substitution; Animals; Binding, Competitive; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Imaging; Mutant Proteins; Mutation; Positron-Emission Tomography; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2011 |
Conventional 3D staging PET/CT in CT simulation for lung cancer: impact of rigid and deformable target volume alignments for radiotherapy treatment planning.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Computer Simulation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Tumor Burden | 2011 |
Lymph node involvement in T1 non-small-cell lung cancer: could glucose uptake and maximal diameter be predictive criteria?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Preoperative Care; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Is there a common SUV threshold in oncological FDG PET/CT, at least for some common indications? A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Reference Standards; Retrospective Studies; Sensitivity and Specificity; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2011 |
Significance of smoking history and FDG uptake for pathological N2 staging in clinical N2-negative non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Smoking | 2011 |
Relationship between pretreatment FDG uptake and local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer: the preliminary results.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure | 2011 |
Seizures and radionecrosis from non-small-cell lung cancer presenting as increased fluorodeoxyglucose uptake on positron emission tomography.
Topics: Anticonvulsants; Brain Injuries; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radiation Injuries; Radiopharmaceuticals; Seizures | 2011 |
Repeat FDG-PET for predicting pathological tumor response and prognosis after neoadjuvant treatment in nonsmall cell lung cancer: comparison with computed tomography.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
PET and PET-CT of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Small Cell Lung Carcinoma; Tomography, Emission-Computed | 2011 |
PET-CT in radiotherapy for lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Small Cell Lung Carcinoma; Tomography, Emission-Computed | 2011 |
Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Point Mutation; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Tomography, X-Ray Computed | 2011 |
Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Movement; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Respiration; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
Topics: Aged; Aged, 80 and over; Cancer Care Facilities; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Ontario; Positron-Emission Tomography; Prospective Studies; Radiation Injuries; Radiopharmaceuticals; Radiosurgery; Radiotherapy, Image-Guided; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2012 |
Accuracy of positron emission tomography in mediastinal node assessment in coal workers with lung cancer.
Topics: Adenocarcinoma; Aged; Anthracosis; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Coal; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinoscopy; Mediastinum; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pleural Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed; Turkey | 2012 |
Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (Stage I and II) non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Autocontouring versus manual contouring.
Topics: Algorithms; Automation; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed | 2011 |
Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Burden; Tumor Microenvironment | 2012 |
Is there any maximum standardized uptake value variation among positron emission tomography scanners for mediastinal staging in non-small cell lung cancer?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Equipment Design; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Observer Variation; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Quality of Health Care; Radiopharmaceuticals; Reproducibility of Results; Thoracotomy; Tomography, X-Ray Computed; Turkey | 2011 |
F-18 FDG PET/CT imaging and bronchoscopic image of tracheal recurrence in patient with non-small-cell lung cancer.
Topics: Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Tomography, X-Ray Computed; Trachea | 2011 |
F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Observer Variation; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tumor Burden | 2011 |
Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
Topics: Area Under Curve; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Survival Rate; Tumor Burden | 2011 |
Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Percutaneous radiofrequency ablation of clinical stage I non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiography, Interventional; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Recombinant Proteins; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Impact of dual-time-point F-18 FDG PET/CT in the assessment of pleural effusion in patients with non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Positron-Emission Tomography; Retrospective Studies; ROC Curve; Time Factors; Tomography, X-Ray Computed | 2011 |
Value of dual-time-point FDG PET/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity.
Topics: Carcinoma, Non-Small-Cell Lung; Comorbidity; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Lung Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Time Factors; Tomography, X-Ray Computed | 2011 |
Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Positron-Emission Tomography; Predictive Value of Tests; Retrospective Studies; ROC Curve; Time Factors; Tomography, X-Ray Computed | 2011 |
Simultaneous occurrence of typical carcinoid and non-small-cell lung cancer in the same lung lobe: value of nuclear medicine.
Topics: Aged; Carcinoid Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasms, Multiple Primary; Positron-Emission Tomography | 2011 |
Disparities in lung cancer staging with positron emission tomography in the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Survival Rate; Treatment Outcome | 2011 |
Can Hyperpolarized Helium MRI add to radiation planning and follow-up in lung cancer?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Helium; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Radiotherapy; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2011 |
Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Endemic Diseases; Female; Fluorodeoxyglucose F18; Granuloma; Humans; Likelihood Functions; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Sensitivity and Specificity; Solitary Pulmonary Nodule; Tennessee | 2011 |
Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies.
Topics: Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tumor Burden | 2011 |
Radiological changes after stereotactic radiotherapy for stage I lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Pulmonary Fibrosis; Radiation Pneumonitis; Radiopharmaceuticals; Radiosurgery; Retrospective Studies; Tomography, X-Ray Computed | 2011 |
Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2011 |
[Positron emission tomography with 18F-FDG and cancer response to chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Drug Monitoring; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2011 |
The standardize uptake value: light and shade of positron emission tomography.
Topics: Carcinoma, Non-Small-Cell Lung; Equipment Design; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Observer Variation; Positron-Emission Tomography; Predictive Value of Tests; Quality of Health Care; Radiopharmaceuticals; Reproducibility of Results | 2011 |
Lymph node involvement in T1 non-small-cell lung cancer: do not miss radical lymphadenectomy.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Radiopharmaceuticals | 2012 |
PET-CT in the staging and treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Is mediastinoscopy still the gold standard to evaluate mediastinal lymph nodes in patients with non-small cell lung carcinoma?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Turkey | 2012 |
Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2012 |
The role of extended cervical mediastinoscopy in staging of non-small cell lung cancer of the left lung and a comparison with integrated positron emission tomography and computed tomography: does integrated positron emission tomography and computed tomogr
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mediastinoscopy; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prognosis; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed | 2011 |
Comparison of clinical and surgical-pathological staging in IIIA non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mediastinoscopy; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Dynamic respiratory gated (18)FDG-PET of lung tumors - a feasibility study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Respiration; Tomography, X-Ray Computed | 2011 |
Diagnostic and staging impact of radiotherapy planning FDG-PET-CT in non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Whole Body Imaging | 2011 |
Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Fluorodeoxyglucose F18; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: are early posttreatment PET findings predictive of treatment outcome?
Topics: Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Contrast Media; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiography; Radiopharmaceuticals; Treatment Outcome | 2011 |
Pattern and predictors of false positive lymph node involvement on positron emission tomography in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Japan; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2012 |
Combined treatment of non-small cell lung cancer with synchronous brain metastases: a single center experience.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Italy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neurosurgical Procedures; Odds Ratio; Pneumonectomy; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Non-small cell lung cancer: prognostic importance of positive FDG PET findings in the mediastinum for patients with N0-N1 disease at pathologic analysis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2011 |
Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Iodine; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2012 |
Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2011 |
Prediction of response to targeted therapies in lung cancer using dynamic imaging: still far from clinical implementation.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Quinazolines | 2011 |
Histological subtypes of lung adenocarcinoma have differential ¹⁸F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glucose Transporter Type 1; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prognosis; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed | 2011 |
The role of the ¹⁸f-fluorodeoxyglucose-positron emission tomography scan in the Nederlands Leuvens Longkanker screenings Onderzoek lung cancer screening trial.
Topics: Adenocarcinoma; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mass Screening; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prognosis; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Small Cell Lung Carcinoma; Survival Rate | 2011 |
Spontaneous regression of primary lung cancer arising from an emphysematous bulla.
Topics: Blister; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Fluorodeoxyglucose F18; Frozen Sections; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Regression, Spontaneous; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Pulmonary Emphysema; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Burden | 2011 |
Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT).
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiosurgery; Treatment Outcome | 2011 |
Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; User-Computer Interface | 2011 |
N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2011 |
Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients wi
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Organoplatinum Compounds; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tomography, Spiral Computed; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Topics: Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: practical implications of using a broad or sharp brush.
Topics: Brachial Plexus; Carcinoma, Non-Small-Cell Lung; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Esophagus; Fluorodeoxyglucose F18; Heart; Humans; Lung; Lung Neoplasms; Lymphatic Metastasis; Positron-Emission Tomography; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Spinal Cord; Treatment Outcome | 2011 |
MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Mucin-1; Neoplasm Grading; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Young Adult | 2012 |
Osteoblastic healing response: discordant PET/CT findings.
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Osteoblasts; Positron-Emission Tomography; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Netherlands; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals; Radiosurgery; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2011 |
[Comparison of the biodistribution of four contrast agents in nude mice bearing NCI-H358 human lung cancer and evaluation of their value in diagnostic imaging].
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Organotechnetium Compounds; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Thiocarbamates; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 2011 |
Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Combined Modality Therapy; Comorbidity; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Positron-Emission Tomography; Precision Medicine; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2012 |
The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Burden | 2012 |
[The use of PET/CT in radiotherapy of patients with non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Heart; Humans; Imaging, Three-Dimensional; Lung; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Computer-Assisted; Spinal Cord; Spine; Tomography, X-Ray Computed | 2011 |
Growth of a solitary pulmonary nodule after 6years diagnosed as oncocytic carcinoid tumour with a high 18-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography-computed tomography (PET-CT).
Topics: Carcinoid Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Illinois; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Survival Analysis; Survival Rate; Tomography, X-Ray Computed | 2012 |
Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
Topics: Adult; Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Contrast Media; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
The management impact of clinically significant incidental lesions detected on staging FDG PET-CT in patients with non-small cell lung cancer (NSCLC): an analysis of 649 cases.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Neoplasms, Second Primary; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Induction Chemotherapy; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2012 |
Standard uptake value of positron emission tomography in clinical stage I lung cancer: clinical application and pathological correlation.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Epidemiologic Methods; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Retrospective Studies; Survival Analysis | 2012 |
Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
(18)F-FDG PET/CT and (99m)Tc-MDP imaging of non-small cell lung carcinoma osseous metastases.
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Positron-Emission Tomography; Technetium Tc 99m Medronate; Tomography, X-Ray Computed | 2012 |
The clinical significance of incidental intra-abdominal findings on positron emission tomography performed to investigate pulmonary nodules.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Incidental Findings; Lung Neoplasms; Male; Middle Aged; Multiple Pulmonary Nodules; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2012 |
Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Preoperative Care; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Targeted lymph node biopsy in mediastinoscopy using 3D FDG-PET/CT movies: a feasibility study.
Topics: Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Lymph Nodes; Male; Mediastinoscopy; Mediastinum; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Surgery, Computer-Assisted; Tomography, X-Ray Computed | 2012 |
FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Fluorodeoxyglucose F18; Humans; Indazoles; Lung Neoplasms; Mice; Mice, SCID; Phenylurea Compounds; Positron-Emission Tomography; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2012 |
Quantitative assessment of heterogeneity in tumor metabolism using FDG-PET.
Topics: Adult; Aged; Blood Volume; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Phosphorylation; Positron-Emission Tomography; Radiopharmaceuticals | 2012 |
Indeterminate pleural metastasis on contrast-enhanced chest CT in non-small cell lung cancer: improved differential diagnosis with (18)F-FDG PET/CT.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Contrast Media; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Grading; Pleural Neoplasms; Positron-Emission Tomography; Radiography, Thoracic; Retrospective Studies; Tomography, X-Ray Computed | 2012 |
Accuracy and predictive features of FDG-PET/CT and CT for diagnosis of lymph node metastasis of T1 non-small-cell lung cancer manifesting as a subsolid nodule.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiosurgery; Survival Analysis; Time Factors; Tumor Burden | 2012 |
Defining target volumes for stereotactic ablative radiotherapy of early-stage lung tumours: a comparison of three-dimensional 18F-fluorodeoxyglucose positron emission tomography and four-dimensional computed tomography.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiosurgery | 2012 |
Node/aorta and node/liver SUV ratios from (18)F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aorta; Aortography; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Liver; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
[Staging with 18F-FDG-PET/CT influences stage-specific survival in advanced non-small cell lung cancer (NSCLC)].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Survival Analysis; Survival Rate; Tomography, X-Ray Computed | 2012 |
Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Feasibility Studies; Female; Fluorodeoxyglucose F18; Gamma Rays; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed | 2012 |
Use of positron emission tomography in initial staging of nonsmall cell lung carcinoma: a regional teaching hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Neoplasms, Squamous Cell; Positron-Emission Tomography; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Discriminant Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2012 |
The role of positron emission tomography following radiosurgical treatment of malignant lung lesions.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Radiotherapy, Image-Guided; Tomography, X-Ray Computed | 2012 |
Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Lung Neoplasms; Male; Prognosis; Proportional Hazards Models; Radionuclide Imaging; Radiopharmaceuticals; Registries; Retrospective Studies; Survival Rate; Tumor Burden; Whole Body Imaging | 2013 |
Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Preoperative pathological diagnosis of lung cancer: is it always necessary?
Topics: Biopsy; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Preoperative Care; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data.
Topics: Aged; Aged, 80 and over; Bone and Bones; Carcinoma, Non-Small-Cell Lung; Case Management; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Patient Care Team; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Survival Analysis | 2012 |
The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Multivariate Analysis; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed; Whole Body Imaging | 2012 |
Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
Topics: Adolescent; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Child; China; Cost-Benefit Analysis; Female; Fluorodeoxyglucose F18; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prevalence; Quality of Life; Radiopharmaceuticals; Risk Factors; Survival Analysis; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2012 |
Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Genome, Human; Genomic Instability; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Oncogenes; Pneumonectomy; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome | 2012 |
Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer.
Topics: Animals; Biological Transport; Bromodeoxyuridine; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Misonidazole; Necrosis; Nitroimidazoles; Pilot Projects; Positron-Emission Tomography; Radioactive Tracers; Tumor Microenvironment | 2012 |
Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results.
Topics: Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Metagenomics; Microarray Analysis; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed | 2012 |
Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Netherlands; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiosurgery; Retrospective Studies; Time Factors; Treatment Outcome | 2012 |
Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Preoperative Period; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2012 |
¹⁸F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Tomography, X-Ray Computed | 2012 |
FDG-PET and chemotherapy for successful diagnosis and treatment of cardiac metastasis from non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Electrocardiography; Female; Fluorodeoxyglucose F18; Glutamates; Guanine; Heart Neoplasms; Humans; Lung Neoplasms; Middle Aged; Pemetrexed; Positron-Emission Tomography; Radiopharmaceuticals | 2012 |
Natural growth and disease progression of non-small cell lung cancer evaluated with 18F-fluorodeoxyglucose PET/CT.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2012 |
Prediction of true-negative lymph node metastasis in clinical IA non-small cell lung cancer by measuring standardized uptake values on positron emission tomography.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Republic of Korea; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Survival Rate; Treatment Outcome | 2012 |
Maximum SUV on positron emission tomography and serum CEA level as prognostic factors after curative resection for non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Analysis | 2012 |
Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Sensitivity and Specificity; Thorax; Tomography, X-Ray Computed | 2012 |
18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Asymptomatic Diseases; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Pneumonectomy; Positron-Emission Tomography; Postoperative Care; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy--a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diagnostic Errors; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Tomography, X-Ray Computed | 2012 |
New strategy for automatic tumor segmentation by adaptive thresholding on PET/CT images.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Pattern Recognition, Automated; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
Unilateral adrenal metastasis from non–small-cell lung cancer demonstrating very high FDG uptake with a standardized uptake value in excess of sixty.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
FDG injection site extravasation: potential pitfall of misinterpretation and missing metastases.
Topics: Carcinoma, Non-Small-Cell Lung; Extravasation of Diagnostic and Therapeutic Materials; Fluorodeoxyglucose F18; Humans; Injections; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Whole Body Imaging | 2013 |
[Prognostic factors in non-small cell lung cancer patients and prognostic importance of PET/CT SUV max value].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2012 |
Intramedullary metastasis detected with 18F FDG-PET/CT.
Topics: Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Multimodal Imaging; Muscle Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Spinal Cord Neoplasms; Tomography, X-Ray Computed | 2012 |
[Non small cell lung carcinoma - evaluation of tumor heterogeneity using CT texture analysis].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lung; Lung Neoplasms; Male; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed | 2012 |
Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Multivariate Analysis; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2014 |
Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Thymidine Kinase; Tomography, X-Ray Computed | 2013 |
Lung tumor segmentation in PET images using graph cuts.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Decision Support Systems, Clinical; Fluorodeoxyglucose F18; Fuzzy Logic; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Models, Statistical; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results | 2013 |
Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Topics: Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Burden | 2013 |
Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer.
Topics: Acute Disease; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose-Response Relationship, Radiation; Esophagitis; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2013 |
The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Positron-Emission Tomography; Sensitivity and Specificity | 2013 |
Surgical adhesive may cause false positives in integrated positron emission tomography and computed tomography after lung cancer resection.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; False Positive Reactions; Female; Fluorodeoxyglucose F18; Foreign-Body Reaction; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Proteins; Radiography; Radionuclide Imaging; Tissue Adhesives | 2013 |
Guidelines for the role of FDG-PET/CT in lung cancer management.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2012 |
Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diagnostic Errors; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiosurgery; Recurrence; Tomography, X-Ray Computed | 2013 |
[Correlation between regional node metastasis and imageological characteristics in non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Multimodal Imaging; Multivariate Analysis; Neoplasm Staging; Radiography; Radionuclide Imaging; Risk Factors; Tumor Burden | 2012 |
A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Contrast Media; Drug Therapy; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Positron-Emission Tomography; Prospective Studies; Sensitivity and Specificity; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Correlation between [¹⁸F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Multimodal Imaging; Perfusion Imaging; Positron-Emission Tomography; ROC Curve; Tomography, X-Ray Computed | 2013 |
Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
Illustrative cases of false positive biopsies after stereotactic body radiation therapy for lung cancer based on abnormal FDG-PET-CT imaging.
Topics: Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Tomography, X-Ray Computed | 2013 |
Flare response versus disease progression in patients with non-small cell lung cancer.
Topics: Acute Disease; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Disease Progression; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Non-small cell lung cancer evaluated with quantitative contrast-enhanced CT and PET-CT: net enhancement and standardized uptake values are related to tumour size and histology.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden | 2013 |
Primary tumor PET/CT [¹⁸F]FDG uptake is an independent predictive factor for regional lymph node metastasis in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Risk Assessment; Tomography, X-Ray Computed | 2013 |
Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Oxygen Radioisotopes; Prognosis; Tomography, Emission-Computed; Water | 2002 |
Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Trees; Fluorodeoxyglucose F18; Humans; Japan; Life Expectancy; Lung Neoplasms; Radiography; Radiopharmaceuticals; Sensitivity and Specificity; Survival Analysis; Tomography, Emission-Computed; Whole-Body Counting | 2002 |
[F-18 fluorodeoxyglucose positron emission tomography in lung lesions].
Topics: Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cost-Benefit Analysis; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Sensitivity and Specificity; Tomography, Emission-Computed | 2002 |
Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Korea; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Retrospective Studies; Statistics as Topic; Survival Rate; Tomography, Emission-Computed | 2002 |
The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer.
Topics: Biopsy; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed; Washington | 2002 |
Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Radiopharmaceuticals; Regression Analysis; Tomography, Emission-Computed; Treatment Outcome | 2002 |
Staging of non-small-cell lung cancer and application of FDG-PET. A cost modeling approach.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Female; Fluorodeoxyglucose F18; Hospital Costs; Humans; Lung Neoplasms; Male; Middle Aged; Models, Econometric; Neoplasm Staging; Netherlands; Preoperative Care; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed | 2002 |
PET diagnostic accuracy: improvement with in-line PET-CT system: initial results.
Topics: Abdominal Neoplasms; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Microcomputers; Middle Aged; Neoplasm Staging; Neoplasms; Otorhinolaryngologic Neoplasms; Sensitivity and Specificity; Software; Tomography, Emission-Computed; Tomography, Spiral Computed | 2002 |
[Optimization of radiotherapy planning for non-small cell lung cancer (NSCLC) using 18FDG-PET].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Radiopharmaceuticals; Radiotherapy, Computer-Assisted; Sensitivity and Specificity; Tomography, Emission-Computed | 2002 |
Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Probability; Tomography, Emission-Computed | 2002 |
Prospective use of serial questionnaires to evaluate the therapeutic efficacy of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Cohort Studies; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Surveys and Questionnaires; Tomography, Emission-Computed | 2003 |
The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Prospective Studies; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
Invasive aspergillosis mimicking stage IIIA non-small-cell lung cancer on FDG positron emission tomography.
Topics: Aged; Aspergillosis; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Radiography; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
Use of a dual-head coincidence camera and 18F-FDG for detection and nodal staging of non-small cell lung cancer: accuracy as determined by 2 independent observers.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Observer Variation; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Free Radicals; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy--survival correlates with metastatic disease burden.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Tomography, Emission-Computed | 2003 |
Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
PET-CT image registration in the chest using free-form deformations.
Topics: Algorithms; Artifacts; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Motion; Radiography, Thoracic; Radiopharmaceuticals; Subtraction Technique; Thorax; Tomography, Emission-Computed | 2003 |
New horizons in oncologic imaging.
Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Ferric Compounds; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Magnetics; Male; Medical Oncology; Nanotechnology; Neoplasm Staging; Prostatic Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Differentiation of synchronous tumors using FDG positron emission tomography.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
[PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Databases, Factual; Evidence-Based Medicine; Fluorodeoxyglucose F18; Germany; Humans; Lung Neoplasms; Neoplasm Staging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
The role of FDG-PET scan in staging patients with nonsmall cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
Radiation-induced esophagitis on FDG PET imaging.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Esophagitis; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Radiopharmaceuticals; Radiotherapy; Tomography, Emission-Computed | 2003 |
Non-small cell lung cancer: dual-modality PET/CT in preoperative staging.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Application of a neural network to improve nodal staging accuracy with 18F-FDG PET in non-small cell lung cancer.
Topics: Aged; Artificial Intelligence; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neural Networks, Computer; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2003 |
Positron emission tomography with 2-[18f]fluoro-2-deoxy-D-glucose: can it be used to accurately stage the mediastinum in non-small cell lung cancer as an alternative to mediastinoscopy?
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mediastinoscopy; Neoplasm Staging; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Confidence Intervals; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Probability; Prospective Studies; Sensitivity and Specificity; Technetium Tc 99m Pentetate; Tomography, Emission-Computed | 2004 |
Medical economics of whole-body FDG PET in patients suspected of having non-small cell lung carcinoma--reassessment based on the revised Japanese national insurance reimbursement system.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Female; Fluorodeoxyglucose F18; Humans; Insurance, Health, Reimbursement; Japan; Lung Neoplasms; Male; Models, Econometric; National Health Programs; Prevalence; Radiopharmaceuticals; Tomography, Emission-Computed; Whole-Body Counting | 2003 |
[Study on glucose metabolic rate in non-small cell lung cancer patients with blood stasis syndrome and non-blood stasis syndrome].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
A case of non-small cell lung cancer with false-positive staging by positron emission tomography.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
[18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; False Positive Reactions; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2004 |
Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mediastinoscopy; Neoplasm Staging; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Thoracotomy; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
FDG-PET in radiotherapy treatment planning: Pandora's box?
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Radiation Oncology; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Pilot Projects; Prospective Studies; Pulmonary Atelectasis; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Lymph node staging in lung cancer using [18F]FDG-PET.
Topics: Adenocarcinoma; Adult; Aged; Carcinoid Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Contrast Media; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Pleural Diseases; Pleural Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Tomography, Emission-Computed | 2004 |
Lepidic spread of primary lung adenocarcinoma on FDG-PET.
Topics: Adenocarcinoma; Aged; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Pulmonary Alveoli; Radionuclide Imaging; Radiopharmaceuticals | 2004 |
GLUT1 expression in tissue and (18)F-FDG uptake.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diagnostic Errors; False Positive Reactions; Female; Fluorodeoxyglucose F18; Germinal Center; Glucose Transporter Type 1; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Monosaccharide Transport Proteins; Neoplasm Staging; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic | 2004 |
Relationship between non-small cell lung cancer fluorodeoxyglucose uptake at positron emission tomography and surgical stage with relevance to patient prognosis.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Sensitivity and Specificity; Tomography, Emission-Computed | 2004 |
Quantification of 18F-FDG uptake in non-small cell lung cancer: a feasible prognostic marker?
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Neoplasm Staging; Prognosis; Radionuclide Imaging; Radiopharmaceuticals | 2004 |
Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.
Topics: Adult; Aged; Carcinoid Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Preoperative Care; Prognosis; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Tomography, Emission-Computed | 2004 |
Asymmetric tongue muscle uptake of F-18 FDG: possible marker for cranial nerve XII paralysis.
Topics: Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Hypoglossal Nerve Diseases; Middle Aged; Muscle, Skeletal; Paralysis; Positron-Emission Tomography; Radiopharmaceuticals; Tongue; Tongue Neoplasms | 2004 |
Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Sensitivity and Specificity; Solitary Pulmonary Nodule; Thoracic Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed; Whole-Body Counting | 2004 |
Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
In regard to Paulino and Johnstone: Use of PET and CT imaging data in radiation therapy planning. Int J Radit Oncol Biol Phys 2004;59:4-5.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Radiation Oncology; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Defining a radiotherapy target with positron emission tomography.
Topics: Body Weight; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Linear Models; Lung Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiography; Radiopharmaceuticals | 2004 |
Incidental situs inversus visualized with FDG PET/CT.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Diagnostic Errors; Fluorodeoxyglucose F18; Humans; Image Enhancement; Incidental Findings; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals; Situs Inversus; Subtraction Technique; Tomography, X-Ray Computed | 2004 |
Mediastinal staging (take home messages).
Topics: Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mediastinoscopy; Mediastinum; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed; Ultrasonography, Interventional | 2004 |
Introduction. Non-small cell lung cancer: some important questions to be solved.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prognosis; Radiotherapy; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed | 2004 |
PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Databases, Factual; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Palliative Care; Pneumonectomy; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2005 |
[Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2004 |
FDG-PET for lymph node staging in NSCLC: a major step forward, but beware of the pitfalls.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2005 |
Effect of mitomycin C and vinblastine on FDG uptake of human nonsmall-cell lung cancer xenografts in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Monitoring; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Neoplasm Transplantation; Neoplasms, Experimental; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Vinblastine | 2004 |
18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Japan; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Sensitivity and Specificity; Statistics as Topic | 2005 |
Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
Topics: Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Radiation; Esophagus; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Tomography, X-Ray Computed | 2005 |
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Rate | 2005 |
Intraluminal FDG uptake in a rectal polyp detected with PET CT: identification of an unsuspected synchronous primary bowel tumor.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Colonic Polyps; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lung Neoplasms; Male; Positron-Emission Tomography; Rectal Neoplasms; Subtraction Technique; Tomography, X-Ray Computed | 2005 |
False negative F-18 FDG PET/CT in nonsmall cell lung cancer bone metastases.
Topics: Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Subtraction Technique; Technetium Tc 99m Medronate; Tomography, X-Ray Computed | 2005 |
FDG-PET in addition to conventional work-up in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography | 2005 |
Increased standardized uptake value in the primary lesion predicts nodal or distant metastases at presentation in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2005 |
Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2005 |
False-positive findings on [18F]FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chemotherapy, Adjuvant; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Radiopharmaceuticals; Radiotherapy, Adjuvant; Tomography, Emission-Computed | 2005 |
Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Treatment Outcome | 2005 |
The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Observer Variation; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Conformal; Tomography, X-Ray Computed | 2005 |
Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Retrospective Studies; Thyroid Neoplasms; Tomography, Emission-Computed | 2005 |
Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2005 |
PET/CT in non-small-cell lung cancer: value of respiratory-gated PET.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2005 |
[Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Pulmonary Atelectasis; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Tomography, X-Ray Computed | 2005 |
Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Tomography, X-Ray Computed | 2005 |
Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Fluorodeoxyglucose F18; Health Care Costs; Humans; Japan; Lung Neoplasms; Lymphatic Metastasis; Mediastinoscopy; Mediastinum; Models, Economic; Positron-Emission Tomography; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Tomography, X-Ray Computed | 2005 |
Overestimation of the prognostic significance of SUV measurement by positron emission tomography for non-small-cell lung cancer.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Sensitivity and Specificity; Survival Analysis | 2005 |
Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cyclophilin A; Fluorodeoxyglucose F18; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; RNA Interference; Transfection | 2005 |
[18-FDG positon emission tomography and distal metastasis from lung cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Femur; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Muscle Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tibia; Whole Body Imaging | 2005 |
Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Observer Variation; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Single-Blind Method; Tomography, Spiral Computed | 2005 |
Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Time Factors | 2006 |
Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Incidence; Lung Neoplasms; Middle Aged; Outcome Assessment, Health Care; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Reference Values; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Survival Analysis; Survival Rate | 2006 |
[Results of FDG-PET scanning in the pre-operative staging of broncho-pulmonary tumors].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity | 2005 |
[Clinical value of computed tomography and fluorine-18 fluorodeoxyglucose positron remission tomography in diagnosis of mediastinal metastasis of non small cell lung cancer].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed | 2005 |
Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Retrospective Studies; Tomography, X-Ray Computed | 2006 |
Intracardiac extension of lung cancer demonstrated on PET scanning.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Heart Atria; Heart Neoplasms; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
Staging of non-small cell lung cancer (NSCLC).
Topics: Adrenal Gland Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2006 |
Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Thoracic Neoplasms | 2006 |
New horizons in staging for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Patient Care Planning; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2006 |
Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Proteins; Octreotide; Organometallic Compounds; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution | 2006 |
Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Hypercalcemia; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Thrombocytopenia; Thrombocytosis | 2006 |
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Time Factors; Treatment Outcome | 2006 |
FDG uptake and glucose transporter type 1 expression in lymph nodes of non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Immunohistochemistry; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Radiopharmaceuticals; Statistics, Nonparametric | 2006 |
Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Diagnostic Errors; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Prospective Studies; ROC Curve | 2006 |
Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2007 |
Virtual positron emission tomography/computed tomography-bronchoscopy: possibilities, advantages and limitations of clinical application.
Topics: Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Lymphatic Metastasis; Male; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
Interobserver and intraobserver variability of standardized uptake value measurements in non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Regression Analysis; Reproducibility of Results; Tomography, X-Ray Computed | 2006 |
The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Carcinoid Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Diagnosis, Differential; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Frozen Sections; Humans; Lung Diseases; Lung Diseases, Fungal; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Solitary Pulmonary Nodule; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2006 |
Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2006 |
Incidental findings on integrated PET/CT that do not accumulate 18F-FDG.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Incidental Findings; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Tomography, Emission-Computed | 2006 |
Pulmonary hypertrophic osteoarthropathy in a patient with nonsmall cell lung cancer: Diagnosis with FDG PET/CT.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lung Neoplasms; Male; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Paraneoplastic Syndromes; Positron-Emission Tomography; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed | 2006 |
Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer.
Topics: Aged; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Radiography; Radionuclide Imaging; Radiopharmaceuticals; Whole Body Imaging | 2006 |
Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Quinazolines; Radionuclide Imaging | 2006 |
Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2006 |
Consideration of serum glucose levels during malignant mediastinal lymph node detection in non-small-cell lung cancer by FDG-PET.
Topics: Blood Glucose; Carcinoma, Non-Small-Cell Lung; Diabetes Complications; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Radionuclide Imaging; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity | 2006 |
Biological correlates of FDG uptake in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Glucose Transporter Type 2; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Radionuclide Imaging; Radiopharmaceuticals | 2007 |
Lung cancer presenting with a solitary colon metastasis detected on positron emission tomography scan.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Computer-Assisted | 2007 |
Radioguided detection of lymph node metastasis in non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Pneumonectomy; Positron-Emission Tomography; Radiopharmaceuticals; Thorax | 2006 |
Satellite pulmonary nodule in the same lobe (T4N0) should not be staged as IIIB non-small cell lung cancer.
Topics: Aged; Algorithms; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Survival Analysis | 2006 |
Endoscopic ultrasound as a first test for diagnosis and staging of lung cancer: a prospective study.
Topics: Aged; Aged, 80 and over; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Endosonography; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed | 2007 |
Lessons to learn from EORTC study 08981: a feasibility study of induction chemoradiotherapy followed by surgical resection for stage IIIB non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2007 |
18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Linear Models; Lung Neoplasms; Neoplasms; Positron-Emission Tomography; Radiation Oncology; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2006 |
Use of anthropometric factors in 18F-FDG PET bone marrow SUVs.
Topics: Analysis of Variance; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Data Interpretation, Statistical; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2006 |
Lessons from the old masters: pragmatism or purity, FDG PET SUV, serum glucose and prediction of nodal status in non-small cell lung cancer.
Topics: Blood Glucose; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2006 |
Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radionuclide Imaging; Radiopharmaceuticals; Survival Analysis | 2007 |
Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Misonidazole; Neovascularization, Pathologic; Radionuclide Imaging; Radiopharmaceuticals; Statistics as Topic | 2006 |
The clinical stage of non-small cell lung cancer as assessed by means of fluorodeoxyglucose-positron emission tomographic/computed tomographic scanning is less accurate in cigarette smokers.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Smoking; Tomography, X-Ray Computed | 2006 |
Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Biopsy; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Endosonography; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Risk Factors; Sex Factors; Survival Analysis; Tomography, X-Ray Computed | 2006 |
Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies | 2007 |
Invited commentary.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography | 2007 |
Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Esophageal Diseases; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2007 |
The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
Topics: Adult; Aged; Biopsy; Carcinoid Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Solitary Pulmonary Nodule | 2007 |
Positron emission tomography in relation to Noguchi's classification for diagnosis of peripheral non-small-cell lung cancer 2 cm or less in size.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Mixed Tumor, Malignant; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Reproducibility of Results | 2007 |
FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
Topics: Aged; Analysis of Variance; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glucose Transporter Type 1; Humans; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies | 2007 |
Chewing gum causing a very high FDG uptake of the tongue on PET scan.
Topics: Aged; Artifacts; Carcinoma, Non-Small-Cell Lung; Chewing Gum; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals; Tongue | 2007 |
[18F-FDG PET/CT in paraneoplastic osteoarthropathy].
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Osteoarthropathy, Secondary Hypertrophic; Palliative Care; Paraneoplastic Syndromes; Positron-Emission Tomography; Radiography, Thoracic; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2007 |
Author's correction. "Incidental findings on integrated PET/CT that do not accumulate 18F-FDG".
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Incidental Findings; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Tomography, Emission-Computed | 2007 |
Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Time Factors | 2007 |
FDG-PET and CT features of non-small cell lung cancer based on tumor type.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Observer Variation; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2007 |
Improved non-invasive T-Staging in non-small cell lung cancer by integrated 18F-FDG PET/CT.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed | 2007 |
Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Sensitivity and Specificity; Tuberculosis, Pulmonary | 2007 |
18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radionuclide Imaging | 2007 |
PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes.
Topics: Artificial Intelligence; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Imaging, Three-Dimensional; Lung Neoplasms; Male; Observer Variation; Pattern Recognition, Automated; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2007 |
Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2006 |
Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals | 2007 |
Dynamic threshold for radiation target volume by PET/CT.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Linear Models; Lung Neoplasms; Neoplasms; Positron-Emission Tomography; Radiation Oncology; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2007 |
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphoma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prognosis; Tomography, X-Ray Computed | 2007 |
The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Survival Analysis | 2007 |
Correlating metabolic and anatomic responses of primary lung cancers to radiotherapy by combined F-18 FDG PET-CT imaging.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Models, Theoretical; Positron-Emission Tomography; Radiotherapy; Reproducibility of Results; Small Cell Lung Carcinoma; Time Factors; Tomography, X-Ray Computed | 2007 |
Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic | 2007 |
Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Survival Analysis | 2007 |
[18F-FDG imaging by coincidence circuit SPECT with low-dose CT in preoperative assessment of pulmonary lesions].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pneumonia; Preoperative Care; Radiation Dosage; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2006 |
Prognostic significance of fluorodeoxyglucose uptake in non-small cell lung cancer. A blurry picture?
Topics: Adenosine Triphosphate; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multivariate Analysis; Prognosis; Radiopharmaceuticals | 2007 |
Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Time Factors | 2007 |
Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed | 2007 |
A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Probability; Radiotherapy, Conformal; Risk Factors; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2007 |
Comparison of CT and positron emission tomography/CT coregistered images in planning radical radiotherapy in patients with non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2007 |
Positron emission tomography staging of pleural deposits following Monaldi's procedure: an accurate reflection or a false staging?
Topics: Carcinoma, Non-Small-Cell Lung; Diagnostic Errors; Drainage; False Positive Reactions; Fluorodeoxyglucose F18; Granuloma, Foreign-Body; Humans; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Pleura; Pleurodesis; Pneumonectomy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Talc; Tomography, X-Ray Computed | 2007 |
Factors causing inaccurate staging of mediastinal nodal involvement in non-small cell lung cancer patients staged by positron emission tomography.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Logistic Models; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2007 |
Endoscopic ultrasound guided fine-needle aspiration and 18FDG-positron emission tomography in the evaluation of patients with non-small cell lung cancer.
Topics: Aged; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; Endosonography; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Ultrasonography, Interventional | 2007 |
18F-FDG PET in planning radiation treatment of non-small cell lung cancer: where exactly is the tumor?
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted | 2007 |
Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2007 |
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed | 2007 |
When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Radiotherapy, Adjuvant; Retrospective Studies; ROC Curve; Survival Analysis; Time Factors; Tomography, X-Ray Computed | 2007 |
Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2008 |
STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Reproducibility of Results; Tomography, X-Ray Computed | 2007 |
Positron emission tomography imaging in nonsmall-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Treatment Outcome | 2007 |
Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas.
Topics: Adult; Aerobiosis; Aged; Aged, 80 and over; Blood Glucose; Carcinoma, Non-Small-Cell Lung; Energy Metabolism; Female; Fluorodeoxyglucose F18; Glucose; Glycolysis; HCT116 Cells; Humans; Lung Neoplasms; Male; Middle Aged; Mitochondria; Mitochondrial Proton-Translocating ATPases; Oxidative Phosphorylation; Positron-Emission Tomography | 2007 |
Restaging of mediastinal nodes with transbronchial needle aspiration after induction chemoradiation for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Mediastinoscopy; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Dosage; Tomography, X-Ray Computed | 2007 |
Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2008 |
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed | 2008 |
18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2007 |
[Preliminary study of 18F-FDG PET-CT in defining lymph node radiation target volume for non-small-cell lung cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2007 |
Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate | 2007 |
[Staging of non-small cell lung cancer. Diagnosis efficacy of structural (CT) and functional (FDG-PET) imaging methods].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed | 2007 |
Clinical significance of (18)F-FDG uptake by N2 lymph nodes in patients with resected stage IIIA N2 non-small-cell lung cancer: a retrospective study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2008 |
FDG uptake by the bone marrow in NSCLC patients is related to TGF-beta but not to VEGF or G-CSF serum levels.
Topics: Aged; Aged, 80 and over; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Statistics as Topic; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2008 |
18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinal Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Solitary Pulmonary Nodule; Technology Assessment, Biomedical | 2007 |
Nonpalpable supraclavicular lymph nodes in lung cancer patients: preoperative characterization with 18F-FDG PET/CT.
Topics: Adult; Aged; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck; Positron-Emission Tomography; Predictive Value of Tests; Preoperative Care; Sensitivity and Specificity; Tomography, X-Ray Computed | 2008 |
Choroidal and extraocular muscle metastases from non-small-cell lung carcinoma: F-18 FDG PET/CT imaging.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Oculomotor Muscles; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2008 |
Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Tomography, X-Ray Computed | 2008 |
Mediastinal lymph node staging by means of positron emission tomography is less sensitive in elderly patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2008 |
18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Taiwan; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2008 |
Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Multivariate Analysis; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Recurrence; Risk Factors | 2008 |
The effect of FDG-PET on the stage distribution of non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Survival Rate; United States | 2008 |
Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose po
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Models, Biological; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate | 2008 |
High correlations between primary tumours and loco-regional metastatic lymph nodes in non-small-cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2-F18-fluoro-D-glucose uptake.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2008 |
Multimodal virtual bronchoscopy using PET/CT images.
Topics: Bronchoscopes; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Lung Neoplasms; Lymphatic Metastasis; Positron-Emission Tomography; Sensitivity and Specificity; Software; Tomography, X-Ray Computed; User-Computer Interface | 2008 |
Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study.
Topics: Adult; Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients.
Topics: Aged; Antigens, CD; Apoptosis Regulatory Proteins; Cadherins; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Non-Small-Cell Lung; Core Binding Factor Alpha 2 Subunit; Cyclin-Dependent Kinase Inhibitor p16; Death-Associated Protein Kinases; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Ether-A-Go-Go Potassium Channels; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Radiopharmaceuticals; Receptors, Retinoic Acid; Tomography, Emission-Computed; Tumor Suppressor Proteins | 2008 |
Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Survival Analysis | 2008 |
(18)F-fluorodeoxyglucose positron emission tomography-based assessment of local failure patterns in non-small-cell lung cancer treated with definitive radiotherapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Tomography, X-Ray Computed; Treatment Failure; Tumor Burden | 2008 |
Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2008 |
18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
[Lung neoplasms--ultrasonic endoscopy as a first diagnostic tool].
Topics: Aged; Aged, 80 and over; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Endosonography; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed | 2008 |
Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making.
Topics: Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Decision Making; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
Spinal cord metastases from lung cancer: detection with F-18 FDG PET/CT.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lumbar Vertebrae; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Spinal Cord Neoplasms; Thoracic Vertebrae; Tomography, X-Ray Computed | 2008 |
[Significance of 8F-FDG PET-CT standard uptake value in clinical target delineation for radiotherapy of the primary tumor of non-small cell lung carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden | 2007 |
Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glucose; Humans; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2008 |
Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2007 |
Detection of scalene lymph node metastases from lung cancer. Positron emission tomography.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Sensitivity and Specificity; Tomography, Emission-Computed | 1995 |
The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?
Topics: Blood Glucose; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Models, Biological; Time Factors; Tomography, Emission-Computed | 1994 |
Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1994 |
Lung tumor metastasis to breast detected by fluorine-18-fluorodeoxyglucose PET.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Tomography, Emission-Computed | 1993 |
Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
Topics: Adenocarcinoma; Aged; Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Deoxyglucose; Diagnosis, Differential; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Radiography, Thoracic; Tomography, Emission-Computed | 1996 |
The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Evaluation Studies as Topic; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Predictive Value of Tests; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1996 |
Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings.
Topics: Carcinoma in Situ; Carcinoma, Non-Small-Cell Lung; Cicatrix; Deoxyglucose; Fibrosis; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung; Lung Diseases; Lung Neoplasms; Neoplasm, Residual; Prospective Studies; Remission Induction; Survival Rate; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 1996 |
Simplified measurement of deoxyglucose utilization rate.
Topics: Blood Glucose; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Tomography, Emission-Computed | 1996 |
Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Deoxyglucose; False Negative Reactions; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung; Lung Neoplasms; Male; Middle Aged; Time Factors; Tomography, Emission-Computed | 1996 |
PET scanning said to save money and improve staging of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cost Savings; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hospital Costs; Humans; Lung Neoplasms; Mediastinal Neoplasms; Neoplasm Staging; Solitary Pulmonary Nodule; Tomography, Emission-Computed | 1995 |
[Positron emission tomography in the evaluation of intrathoracic lymphatic extension of non-small cell bronchial cancer. A preliminary study of 30 patients].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Male; Mediastinoscopy; Mediastinum; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Thoracotomy; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1996 |
Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Trees; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Life Expectancy; Lung Neoplasms; Male; Neoplasm Staging; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1996 |
Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography.
Topics: Aged; Bone and Bones; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; False Positive Reactions; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prospective Studies; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1996 |
Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinum; Neoplasm Staging; Predictive Value of Tests; Preoperative Care; Prospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1996 |
Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling.
Topics: Adult; Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1997 |
Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1997 |
Role of positron emission tomography in the staging of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 1997 |
Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Topics: Carcinoma, Non-Small-Cell Lung; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Tomography, Emission-Computed | 1997 |
Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1997 |
Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1997 |
[Positron-emission tomography in the evaluation of lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Radiopharmaceuticals; Solitary Pulmonary Nodule; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1997 |
Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Middle Aged; Neoplasm Staging; Odds Ratio; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1998 |
Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer.
Topics: Aged; Bone and Bones; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Technetium Tc 99m Medronate; Tomography, Emission-Computed | 1998 |
The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tomography, Emission-Computed | 1998 |
[Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma)].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Trees; Fluorodeoxyglucose F18; Hospitalization; Humans; Lung Neoplasms; Middle Aged; Radiopharmaceuticals; Sensitivity and Specificity; Thorax; Tomography, Emission-Computed | 1998 |
Detection of extrathoracic metastases by positron emission tomography in lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Tomography, Emission-Computed | 1998 |
Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions.
Topics: Adenocarcinoma; Adult; Aged; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diagnosis, Differential; Fluorodeoxyglucose F18; Follow-Up Studies; Granuloma; Humans; Lung Diseases; Lung Neoplasms; Mediastinal Diseases; Mediastinal Neoplasms; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 1998 |
Diagnosis of spine metastases by FDG imaging using a gamma camera in the coincidence mode.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Lung Neoplasms; Male; Radiopharmaceuticals; Spinal Neoplasms; Tomography, Emission-Computed | 1998 |
Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Trees; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Life Expectancy; Lung Neoplasms; Medicare; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed; United States | 1998 |
[Detection of unexpected extrathoracic metastases in preoperative staging of non-small-cell bronchial carcinoma (NSCLC) with positron emission tomography (PET)].
Topics: Blood Glucose; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Sensitivity and Specificity; Tomography, Emission-Computed | 1998 |
Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Immunoenzyme Techniques; Lung; Lung Neoplasms; Male; Monosaccharide Transport Proteins; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Pulmonary Atelectasis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Prospective Studies; Survival Analysis; Tomography, Emission-Computed | 1999 |
On the use of image-derived input functions in oncological fluorine-18 fluorodeoxyglucose positron emission tomography studies.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
FDG/PET and spiral CT image fusion for medistinal lymph node assessment of non-small cell lung cancer patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Observer Variation; Prognosis; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
FDG PET measurement of the proliferative potential of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Division; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Proliferating Cell Nuclear Antigen; Radiopharmaceuticals; Tomography, Emission-Computed | 2000 |
Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Trees; Female; Fluorodeoxyglucose F18; Humans; Japan; Life Expectancy; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Survival Analysis; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Tomography, Emission-Computed; Treatment Outcome | 2000 |
Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
[Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in diagnosis of recurrent bronchial carcinoma].
Topics: Aged; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Tomography, Emission-Computed | 2000 |
Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Radiography, Thoracic; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Prospective Studies; Radiation Dosage; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Reproducibility of Results; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
Metabolic staging of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinal Neoplasms; Neoplasm Staging; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
Utility evaluations for Markov states of lung cancer for PET-based disease management.
Topics: Aged; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Decision Making; Decision Support Techniques; Fluorodeoxyglucose F18; Health Status Indicators; Humans; Lung Neoplasms; Markov Chains; Mediastinoscopy; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Patient Participation; Quality of Life; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2000 |
Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET.
Topics: Adult; Aged; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Choline; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Phantoms, Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2000 |
How useful is positron emission tomography for lymphnode staging in non-small-cell lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Local Lymph Node Assay; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Palliative Care; Probability; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Care Planning; Prospective Studies; Radiopharmaceuticals; Tomography, Emission-Computed; Treatment Outcome; Victoria | 2001 |
Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Survival Analysis; Tomography, Emission-Computed | 2001 |
Staging of non-small-cell lung cancer with positron-emission tomography.
Topics: Carcinoid Tumor; Carcinoma, Non-Small-Cell Lung; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mediastinal Neoplasms; Neoplasm Staging; Sensitivity and Specificity; Tomography, Emission-Computed | 2000 |
Correlation of Glut-1 glucose transporter expression with.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Monosaccharide Transport Proteins; Paraffin Embedding; Radiopharmaceuticals; Tomography, Emission-Computed | 2000 |
[Contribution of PET using FDG in the diagnosis of lung cancer--first results].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Phantoms, Imaging; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy, Conformal; Reproducibility of Results; Sensitivity and Specificity; Technology, Radiologic; Tomography, X-Ray Computed | 2001 |
Staging and managing lung tumors using F-18 FDG coincidence detection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
Detection of cranial metastases by F-18 FDG positron emission tomography.
Topics: Adrenal Gland Neoplasms; Adult; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Pheochromocytoma; Radiopharmaceuticals; Skull Neoplasms; Tomography, Emission-Computed | 2001 |
L-3-[123I]iodo-alpha-methyl-tyrosine SPECT in non-small cell lung cancer: preliminary observations.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Methyltyrosines; Middle Aged; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2001 |
Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging.
Topics: Carcinoma, Non-Small-Cell Lung; False Negative Reactions; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasm Staging; Sensitivity and Specificity; Tomography, Emission-Computed | 2001 |
[Accuracy of positron emission tomography with fluorine-18-fluoro-deoxyglucose].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Survival Analysis; Tomography, Emission-Computed | 2001 |
Patterns of abnormal FDG uptake by various histological types of non-small cell lung cancer at initial staging by PET.
Topics: Adenocarcinoma; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Observer Variation; Prospective Studies; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: a retrospective review.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Predictive Value of Tests; Retrospective Studies; Tomography, Emission-Computed | 2001 |
Comparison of early pulmonary changes in 18FDG-PET and CT after combined radiochemotherapy for advanced non-small-cell lung cancer: a study in 15 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Radiation Pneumonitis; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2002 |
[Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Survival Analysis; Tomography, Emission-Computed | 2002 |
Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hospital Costs; Hospitals, Community; Humans; Lung Neoplasms; Male; Medical Futility; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Netherlands; Postoperative Care; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Treatment Outcome | 2002 |
Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pilot Projects; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, Emission-Computed | 2002 |
An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Neoplasm Staging; Neoplasm, Residual; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed | 2002 |
Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Retrospective Studies; Tomography, Emission-Computed | 2002 |
Value of positron emission tomography for lung cancer staging.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prospective Studies; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
Imaging with F-18 FDG PET is superior to Tl-201 SPECT in the staging of non-small cell lung cancer for radical radiation therapy.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Thallium Radioisotopes; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2001 |
[Value of 18FDG-CDET in the evaluation of operable bronchial cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Bilateral adrenal metastases revealed by F-18 FDG coincidence detection positron emission tomography in a patient with lung cancer.
Topics: Adrenal Gland Neoplasms; Aged; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Radionuclide Imaging; Radiopharmaceuticals; Tomography, X-Ray Computed | 2002 |
FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Histoplasmosis; Humans; Iowa; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prevalence; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
FDG-PET imaging in small cell lung cancer: any value?
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Fluorodeoxyglucose F18; Lung Neoplasms; Neoplasm Staging; Patient Care Planning; Patient Selection; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Tomography, Emission-Computed | 1990 |